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CHAPTER I 
 
INTRODUCTION 
 
As each cell cycles, it must faithfully replicate its DNA and ensure equal separation of 
the duplicated genetic information into the dividing daughter cells. In human cells, DNA 
replication requires accurately duplicating more than 6 billion base pairs of DNA in just a matter 
of hours. This already daunting task is even more challenging considering cells must overcome 
several obstacles to replication such as DNA lesions, common fragile sites, repetitive 
sequences, DNA secondary structure, and collisions with transcription machinery (Zeman and 
Cimprich, 2014). All of these impediments block DNA replication and can cause slowing or 
stopping of the replication fork, which is globally termed replication stress (RS). In addition to 
unavoidable endogenous threats, our DNA is under constant barrage from exogenous genotoxic 
sources such as ultraviolet radiation (UV light), ionizing radiation (IR), and chemical agents 
resulting in tens of thousands of DNA lesions per cell per day (Ciccia and Elledge, 2010). A 
failure to accurately complete DNA replication or repair damaged DNA results in loss of genetic 
information, which can lead to cell death or disease. 
Luckily, our genomes are under constant surveillance for DNA damage and our cells 
have an arsenal of repair proteins to maintain genome integrity. However, cellular responses to 
DNA damage and replication stress must be coordinated with cell cycle progression ensuring 
cells have enough time to complete DNA replication or repair before progressing to the next 
phase of the cell cycle. To prevent passage of compromised genetic information, cells activate a 
signal transduction pathway called the DNA damage response (DDR), which is regulated by 
three apical kinases: ATM (Ataxia Telangiectasia Mutated), ATR (ATM and Rad3-related) and 
DNA-PK (DNA Dependent Protein Kinase) (Ciccia and Elledge, 2010). After sensing genotoxic 
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stress, these kinases rapidly initiate the DDR through phosphorylation of substrates, recruiting 
repair proteins to sites of damage while arresting cell cycle progression through activation of cell 
cycle checkpoints. 
 Hundreds of proteins participate in the DDR with diverse enzymatic activities and 
biological functions. One of the ongoing goals of the Cortez lab is to identify and characterize 
new DDR proteins. One methodology developed by the Cortez lab that has proved especially 
powerful for identifying new replication and repair proteins is isolation of proteins on nascent 
DNA (iPOND) (Sirbu et al., 2011, 2013). By combining iPOND with stable isotope labeling of 
amino acids in cell culture (SILAC) and liquid chromatography-tandem mass spectrometry (LC-
MS/MS), Dr. Huzefa Dungrawala and other Cortez lab members were able to identify proteins 
located at a normal replication fork and stalled replication fork (Dungrawala et al., 2015).  
Utilizing this SILAC-iPOND-MS approach combined with other genetic and proteomic screens, 
our lab has identified and characterized five new DNA repair and RS proteins in the last nine 
years:  CDK2-interacting protein (CINP) SWI/SNF, matrix associated, actin dependent regulator 
of chromatin A-like 1 (SMARCAL1), RPA-related, RAD51-antagonist on X-chromosome 
(RADX), 5-Hydroxymethylcytosine Binding, ES Cell Specific (HEMCES), and Ewing Tumor 
Associated Antigen 1 (ETAA1) (Lovejoy et al., 2009; Bansbach et al., 2009; Bass et al., 2016; 
Dungrawala et al., 2017, Mohni et al., 2019).  
The work outlined in this dissertation focuses on a previously uncharacterized protein, 
ETAA1, that we identified as a potential RS protein by iPOND and another proteomic screen. In 
Chapter III, I will describe how we identified ETAA1 as a RS protein and subsequently 
characterized it as a novel activator of ATR. In Chapter IV, I will describe how I utilized 
quantitative phosphoproteomics to determine how the two ATR activators, ETAA1 and TOPBP1 
(Topoisomerase-IIβ binding protein 1) differentially regulate ATR signaling. Additionally, I will 
discuss the function of ETAA1 to activate ATR during mitosis at centromeric regions. Finally, in 
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Chapter V I will discuss the impact of these results and outline some future directions of study 
for ETAA1 and ATR activation. In this chapter, I will introduce the key concepts of the DDR, 
replication stress, and the functions of ATR throughout the cell cycle.   
 
The DNA damage response 
 
Our DNA is under constant barrage by environmental genotoxic agents such as UV light 
and reactive chemicals that result in tens of thousands of DNA lesions a day per cell 
(Hoeijmakers, 2009). Additionally, genomic instability can arise from unavoidable endogenous 
sources such as reactive byproducts of metabolism, and replication stress (RS) (Ciccia and 
Elledge, 2010). A failure to recognize and respond to DNA damage and RS can result in loss of 
genetic information causing disease and cancer.  
Genome maintenance requires constant surveillance for damaged DNA and after recognition of 
genotoxic stress, cells must recruit repair proteins with the appropriate enzymatic activity to the 
DNA lesion. Simultaneously, cell cycle checkpoints must preclude cell cycle progression until 
completion of DNA repair.  To coordinate these responses to DNA damage, cells have 
developed an elaborate signal transduction pathway called the DNA damage response (DDR) 
(Fig 1.1) (Ciccia and Elledge, 2010). Initialization of DDR signaling begins with recognition of 
aberrant DNA structures like double-stranded breaks (DSBs) or single-stranded DNA (ssDNA) 
by sensor proteins such as the Ku70/Ku80 complex, Mre11-Rad50-Nbs1 (MRN) complex, or 
Replication protein A (RPA).  Sensor proteins bind DNA lesions and recruit apical kinases that 
relay this signal to mediator proteins. Mediators are kinases which further propagate the signal 
to downstream effector proteins, promoting DNA repair. The DDR effector proteins are an 
enzymatically diverse group consisting of helicases, polymerases, nucleases, topoisomerases, 
and other DNA modifying enzymes. DDR effector proteins also consist of transcription factors 	
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ATR ATM DNA-PK
CHK1 CHK2
Response
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non-homologous 
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Figure 1.1 Overview of the DNA Damage response (DDR). The DDR is initiated by 
recognition of aberrant DNA structures like single-stranded DNA or double strand breaks by 
sensor proteins such as RPA, MRN, or Ku70/Ku80. Sensor proteins recruit the apical 
kinases ATR, ATM, and DNA-PK which relay the signal to mediators such as CHK1 and 
CHK2. Mediators propagate the signal to downstream effector proteins and help the apical 
kinases coordinate DNA repair and checkpoint activation.
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and other cell cycle regulators that arrest cell cycle progression, or if the extent of damage is too 
severe, they may induce apoptosis rather than pass on the compromised genetic material. 
 
Regulation of the DDR by PIKKs  
The apical regulators of the DDR pathway that transduce the signal from the DNA 
damage sensors to the DDR effectors are the phosphoinositide 3-kinase related protein kinases  
(PIKKs), ATR, ATM, and DNA-PK (DNA Dependent protein kinase) (Blackford and Jackson, 
2017). ATR, ATM, and DNA-PK share similar domain organization, structural features, and 
substrate specificity; each kinase preferentially phosphorylates a serine or threonine followed by 
glutamine (S/TQ) (Kim et al., 1999; Bennetzen et al., 2010). Highlighting their importance as 
master regulators of the DDR, mutations in all three kinases are associated with cancer and 
disease; ATM deficiency is associated with Ataxia Telangiectasia, mutations in ATR cause 
Seckel syndrome, and loss of DNA-PK increases risk of multiple cancer types (O’Driscoll et al., 
2003; Savitsky et al., 1995; Goodwin et al., 2015).  
The C-terminus of all PIKKs is highly conserved, harboring a kinase domain surrounded 
by FRAP, ATM, TRRAP (FAT), FAT C-terminus (FATC) domains, and PIKK regulatory domains 
(PRD) (Fig. 1.2A). The FAT domain surrounds and stabilizes the kinase domain while the FATC 
domain is required for activation and the PRD domain regulates kinase activity through 
interactions with activators (Fig. 1.2 B-D) (Mordes et al., 2008a; Banin et al., 1998; Priestley et 
al., 1998; Baretić and Williams, 2014).  The N-terminus of PIKKs are less well conserved but 
consist of large numbers of Huntingtin, Elongation factor 3, a subunit of protein phosphatase 2A 
and TOR1 (HEAT)-repeat domains that help mediate protein-protein interactions (Perry and 
Kleckner, 2003; Baretić and Williams, 2014). Additionally, all three kinases harbor S/TQ motifs,  
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4128
3056
2644
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1
1
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B C D
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Figure 1.2 Domain layout and structure similiarities of ATR, ATM, and DNA-PK.    (A) Diagram of   ATR, 
ATM, and DNA-PK domain structures showing location of the FAT, kinase, PRD, and FATC domains. (B-D) 
Cartoons of the three demensional structures of ATR/Mec1, ATM, and DNA-PK. Cartoons were produced 
from structures detailed in (Imseng et al., 2018). The inactive dimeric form of Mec1/ATR is shown in B and 
the inactive dimeric form of ATM is shown in C. The monomeric form of DNA-PK is shown in D. 
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which they can autophosphorylate (Fig. 1.2A) (Blackford and Jackson, 2017). These 
autophosphorylation marks are important indicators of kinase activation and may regulatekinase 
activity (Nam et al., 2011b; Bakkenist and Kastan, 2003; Chan et al., 2002). In addition to 
sequence similarities, all three kinases share three dimensional structural similarities, a C-
terminal head unit composed of the FAT-kinase-FATC domains and a N-terminal 
cradle/solenoid unit composed of the heat repeats.  (Fig. 1.2 B-D) (Wang et al., 2017, 2016; 
Sibanda et al., 2017; Sawicka et al., 2016; Imseng and Aylett, 2018).   
Ensuring proper activation of the DDR, all three kinases share common regulatory 
themes (Lovejoy and Cortez, 2009). DDR kinase activity is dependent on recruitment to specific 
DNA lesions by a DDR sensor protein. Additionally, the DDR kinases require an activating 
protein to simulate kinase activity. In mammalian cells, Ku70/Ku80 both recruits and activates 
DNA-PK at DNA ends (Gottlieb and Jackson, 1993). Similarly, the MRN complex serves dual 
functions to recruit and activate ATM (Lee and Paull, 2005).  RPA bound to ssDNA recruits ATR 
via its obligate interaction partner ATRIP (Cortez et al., 2001; Zou and Elledge, 2003), while the 
ATR-activating proteins TOPBP1 and ETAA1 stimulate its kinase activity (Kumagai et al., 2006; 
Haahr et al., 2016; Bass et al., 2016).   
 
DNA-PK and non-homologous end joining 
DSBs are one of the most threatening DNA lesions to a cell and are caused by 
exogenous sources such as ionizing radiation and endogenous sources such as reactive 
oxygen species derived as metabolic byproducts (Mehta and Haber, 2014).  DNA-PK primarily 
regulates a small group of proteins in response to DSBs to promote repair through a pathway 
called non-homologous end joining (NHEJ) (Fig 1.3).  NHEJ is the preferred DSB repair  
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pathway in mammalian cells and is utilized throughout the cell cycle. Within seconds of DSB 
formation, DNA ends are bound by the Ku70/Ku80 heterodimer which recruits DNA-PK 
stabilizing the break and preventing extensive end resection (Mahaney et al., 2009). Nucleases 
such as ARTEMIS and kinases such as PNK (polynucleotide 5'-hydroxyl-kinase) process 
incompatible DNA ends prior to ligation by XRCC4 (X-ray repair cross-complementing protein 
4)/XLF (XRCC4-like factor) /LIG4 (DNA Ligase 4) (Mahaney et al., 2009; Chiruvella et al., 
2013).   
 
ATR/ATM kinases 
 ATR and ATM are large (>300 kDa), evolutionarily conserved kinases that can 
phosphorylate hundreds of proteins in response to DNA damage or replication stress (Matsuoka 
et al., 2007). There is extensive overlap of the proteins phosphorylated by ATM and ATR and 
both signal through downstream checkpoint kinases, CHK1 (Checkpoint kinase 1) and CHK2 
(Checkpoint Kinase 2) although ATR preferentially phosphorylates CHK1 while ATM 
phosphorylates CHK2.  
Despites their similarities both kinases have distinctive cellular functions and 
mechanisms of regulation. ATM forms dimers in the absence of stress but takes on an active 
monomeric form following DNA damage (Bakkenist and Kastan, 2003). ATR forms a 
heterodimer with its obligate binding partner, ATRIP (ATR-Interacting Protein) (Cortez et al., 
2001). Furthermore, ATR and ATM respond to different types of DNA damage. DSBs activate 
ATM while a wide range of lesions including stalled replication forks, RNA-DNA loops (R-loops), 
and unprotected telomere ends activate ATR. 
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ATM and homologous recombination 
ATM promotes the repair of DSBs through homologous recombination (HR), a pathway 
that utilizes a homologous DNA sequence as a repair template promoting error-free repair (Fig 
1.4). The requirement for a homologous DNA template limits HR to S and G2 phases of the cell 
cycle when a sister chromatid is available. Following DSB formation, DNA ends are bound by  
the MRN complex which completes the initial steps of DNA resection and recruits and activates 
ATM (Williams et al., 2007; Lee and Paull, 2005). ATM regulation of DNA end resection is a 
determinate of DSB repair choice, promoting HR over NHEJ. ATM phosphorylation of CtIP 
(CTBP-Interacting Protein) and EXO1 (Exonuclease 1) stimulates DNA end resection 
generating ssDNA bound by RPA (Bolderson et al., 2010; You and Bailis, 2010).  BRCA2 with 
DSS1 mediates displacement of RPA on ssDNA and promotes assembly of RAD51 filaments 
leading to strand invasion of homologous DNA. Polymerases extend the invading strand using 
the homologous DNA as a template. Once replicated past the break, capture of the second end 
of the invading strand forms a double Holliday junction (dHJ).  Removal of dHJs occurs through 
dissolution by BLM (Bloom syndrome protein)/TOPOIII-α (DNA topoisomerase III-α) or 
resolution by structure specific nucleases, generating non-crossover or crossover recombination 
products respectively (Raynard et al., 2006; Wu et al., 2006; Bussen et al., 2007).   
 
ATR and the replication stress response 
In human cells, the process of DNA replication requires accurately replicating more than 
6 billion base pairs of DNA in just a matter of hours. This already daunting task is even more 
challenging considering cells must overcome several obstacles to replication such as DNA 
lesions, common fragile sites, repetitive sequences, DNA secondary structure, and collisions 
with transcription machinery (Fig. 1.5 A-F) (Zeman and Cimprich, 2014). All these impediments  
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block DNA replication and can cause slowing or stopping of the replication fork termed 
replication stress (RS).  A failure to manage RS can occlude completion of DNA replication 
resulting in genome instability.  
To counteract RS, cells utilize ATR to activate a component of the DDR called the 
replication stress response (RSR).  RS can arise from many sources but results in one common 
aberrant DNA structure, ssDNA. Replication stressors stall polymerase activity, resulting in 
uncoupling of helicase and polymerase activities at the replication fork generating ssDNA (Fig. 
1.5 G).  RPA binds ssDNA that accumulates at sites of RS and recruits the master regulator of 
the RSR, ATR. Following stimulation of kinase activity by an activating protein, ATR 
phosphorylates downstream effector proteins, such as CHK1 promoting replication fork 
stabilization, cell cycle arrest, and inhibition of new origin firing (Cimprich and Cortez, 2008). 
ATR activation and cellular responses to ATR signaling is closely examined in subsequent 
chapters. 
In conclusion, three PIKKs, DNA-PK, ATM, and ATR regulate the DDR, coordinating 
responses to genotoxic stress. DNA-PK and ATM primarily direct cellular responses to DSBs 
while ATR responds to various DNA lesions and replication stress. Of the three master DDR 
regulators, only ATR is required for life in human cells. This final difference emphasizes the 
essential nature of ATR to maintain genome integrity. The widespread functions of ATR to 
manage replication stress and regulate checkpoints throughout the cell cycle is detailed below.  
 
 Regulation of ATR activity 
Recruitment of ATR by RPA-ssDNA 
A wide range of genomic stressors recruit and activate ATR such as stalled replication 
forks, dsDNA breaks, and unprotected telomeres (Fig. 1.5 H-J). While diverse in their 
	 	
	
14	
	
composition and origin, these stressors have one common DNA structure that recruits ATR, 
single stranded DNA (ssDNA) coated by RPA. 
RPA is a heterotrimeric complex composed of RPA1 (70 kDa subunit), RPA2 (32 kDa 
subunit), and RPA3 (14 kDA subunit) (Zou et al., 2006). RPA is an indispensable component of 
all DNA metabolic pathways such as DNA replication, DNA repair, and cell cycle checkpoints. 
RPA binds ssDNA using four OB (oligonucleotide/oligosaccharide-binding) fold domains, three 
of which reside in RPA1 while the remaining OB fold is located in RPA2. RPA also contains two 
primary protein-protein interaction domains, the RPA70N domain of RPA1 and the RPA32C 
domain of RPA2, that facilitate recruitment of DNA replication and repair proteins.  Additionally, 
post-translational modifications (PTMs) of RPA, such as phosphorylation by ATR, ATM, and 
DNA-PK, minimalize ssDNA generation and stimulates DNA repair (Vassin et al., 2009; Anantha 
et al., 2007).   
During RS, RPA binds and protects ssDNA, functioning as a platform to recruit additional 
DNA repair proteins. Indeed, RPA coated ssDNA is the underlying signal that initiates the RSR 
by recruiting ATR/ATRIP (Zou and Elledge, 2003). RPA recruitment of ATR/ATRIP is mediated 
by a direct interaction between the basic cleft of the RPA70N domain of RPA1 and a conserved 
acidic domain in ATRIP (Ball et al., 2007). However, recruitment of ATR to sites of replication 
stress is not sufficient for its activation, an activating protein must also interact with ATR to 
stimulate its kinases activity. The requirement for two independently recruited proteins to 
localize to sites of RS is a regulatory mechanism that ensures appropriate activation of ATR 
only during RS.  In yeast, three activators regulate the ATR-orthologue, Mec1ATR (Mitosis entry 
checkpoint 1), while vertebrates have two known activators of ATR, TOPBP1 and ETAA1.  
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Mec1ATR activation 
The RSR is highly conserved throughout eukaryotes. As in mammalian cells, initiation of 
the RSR in Saccharomyces cerevisiae begins with recruitment of Mec1ATR to RPA coated 
ssDNA through an interaction with Ddc2ATRIP. Activation of Mec1ATR relies on three activating 
proteins, Dpb11TOPBP1 (DNA replication regulator DPB11), Ddc1Rad9 (DNA Damage Checkpoint 
1) and Dna2 (DNA synthesis defective 2) (Mordes et al., 2008b; Navadgi-Patil and Burgers, 
2009, 2008a; Kumar and Burgers, 2013). Dpb11TOPBP1 is an essential protein required for DNA 
initiation and is the yeast orthologue of TOPBP1.  Recruitment of Dpb11TOPBP1 to sites of 
replication stress is dependent on the interaction with Ddc1Rad9, a member of the heterotrimeric 
17-3-1 checkpoint clamp composed of Rad17Rad1, Mec3Hus1, and Ddc1Rad9. RPA directs loading 
of the 17-3-1 checkpoint clamp to 5’ ssDNA-dsDNA junctions through interactions with the 
Rad24-RFC (Replication factor C) clamp loading complex (Majka et al., 2006). After localization 
of both Mec1ATR and Dpb11TOPBP1 to sites of RS, Dpb11TOPBP1 interacts with Mec1ATR stimulating 
its kinase activity.  
Ddc1Rad9 has dual functions in Mec1ATR activation. In addition to recruiting  Dpb11TOPBP1, 
Ddc1Rad9 can also directly activate Mec1ATR.(Navadgi-Patil and Burgers, 2009)  This ability 
appears to be unique to Saccharomyces cerevisiae as Ddc1Rad9 orthologues in 
Schizosaccharomyces pombe and higher eukaryotes do not share this activity.  
Similarly, Dna2 is a multifunctional enzyme moonlighting as a Mec1ATR activator (Kumar 
and Burgers, 2013). Dna2 is a dual nuclease/helicase required for Okazaki fragment maturation. 
Mec1ATR activation does not require either enzymatic activity but instead utilizes the 
unstructured N-terminal tail of Dna2. Although human DNA2 is also a nuclease/helicase that 
processes Okazaki fragments, it has not been shown to activate ATR.  
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The three Mec1ATR activators function to regulate timing of Mec1 activation and direct 
what substrates get phosphorylated. The cell-cycle-specific utilization of each MEC1 activator 
allows for temporal regulation of Mec1 throughout the process of cell division (Navadgi-Patil and 
Burgers, 2011). Ddc1Rad9 activates Mec1ATR during G1, while both Ddc1Rad9 and Dpb11TOPBP1 
activate Mec1ATR during G2 (Navadgi-Patil et al., 2011; Navadgi-Patil and Burgers, 2009). During 
S-phase, all three Mec1ATR activators contribute to Mec1ATR activation with partial redundancy. 
Only after mutation of all three activators is Mec1ATR activity abolished. Additionally, Mec1ATR 
activators direct Mec1ATR to phosphorylate substrates proximal to the activator allowing their 
localization to dictate Mec1ATR signaling (Lanz et al., 2018).    
 
ATR activation by TOPBP1 
As previously mentioned, the RSR begins with ATR/ATRIP recruitment to RPA-coated 
ssDNA. However, localization of ATR to sites of RS is not sufficient to trigger ATR signaling, an 
activating protein is also required to stimulate ATR kinase activity.  In vertebrates, two activating 
proteins, TOPBP1 and ETAA1 can subsequently trigger ATR activity.  My graduate studies 
focused on identifying ETAA1 as a novel ATR activating protein and examining how ETAA1 or 
TOPBP1 activation of ATR influences ATR signaling.  
Originally identified in a yeast two-hybrid screen as a Topoisomerase II β-interacting 
protein (Yamane et al., 1997), TOPBP1 was the first identified ATR activator (Kumagai et al., 
2006). TOPBP1 is a large (173 kDa), conserved protein containing nine BRCA1 carboxyl-
terminal (BRCT) motifs. TOPBP1 orthologues in budding and fission yeast, Dpb11 and Cut5, 
have functions in both DNA replication and checkpoint activation (Saka and Yanagida, 1993; 
Araki et al., 1995). Likewise, TOPBP1 serves dual functions and is required for initiation of DNA 
replication (Garcia et al., 2005).  TOPBP1 is required for cell viability and even a single point 
mutation in the TOPBP1-ATR activation domain (AAD) results in embryonic lethality in mice 
(Zhou et al., 2013). 
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Figure 1.6 ATR and the replication stress response. DNA lesions stall polymerase activity resulting in 
uncoupling of helicase and polymerase activities generating ssDNA. RPA binds ssDNA, then recruits the 
ATR/ATRIP complex and directs loading of the 9-1-1 complex by RAD17-RFC. TOPBP1 is recruited to sites 
of replication stress and stimulates ATR through interactions with Rad9 of the 9-1-1 complex, MRN, and 
RHINO. ETAA1 is recruited to sites of replication stress by RPA and can activate ATR independent of 
TOPBP1/Rad9. Once activated, ATR can phosphorylate downstream effectors such as CHK1 which further 
propagates the signal promoting replication stress response.
CHK1
MRN
RHINO
ATR
ATRIP
TOPBP1
ATR is activated 
by ETAA1
Replication fork 
encouters a DNA lesion
	 	
	
18	
	
TOPBP1 activation of ATR is well conserved throughout eukaryotes and homologous to 
Dpb11 activation of Mec1. Recruitment of TOPBP1 to sites of RS occurs through contributions 
by multiple interaction partners (Fig 1.6). Rad9, a component of the heterotrimeric  9-1-1 
checkpoint clamp consisting of Rad9-Rad1-Hus1, recruits TOPBP1 to sites of replication stress 
through a direct interaction with its phosphorylated C-terminal tail and the first two BRCT 
domains of TOPBP1 (Delacroix et al., 2007a; Lee et al., 2007a). RPA stimulates the clamp 
loading activity of the Rad17-RFC clamp loading complex and directs loading of the 9-1-1 
checkpoint clamp to 5’ ssDNA-dsDNA junctions (Ellison and Stillman, 2003). RHINO (Rad9, 
Hus1, Rad1 interacting nuclear orphan) associates with the 9-1-1 complex and TOPBP1 
through independent domains and is required for full ATR activation, although it does not 
promote or stabilize the TOPBP1-911 interaction (Cotta-Ramusino et al., 2011; Lindsey-Boltz et 
al., 2015). In Xenopus egg extracts, the MRN complex can recruit TOPB1 to ss/dsDNA 
junctions independent of the 9-1-1 complex, however 9-1-1 is still required for TOPBP1-
dependent ATR activation (Duursma et al., 2013).  After recruitment, TOPBP1 interacts with 
ATR stimulating its kinase activity and activating the RSR. 
 
ATR activation by ETAA1 
ETAA1 was originally identified as a cell surface antigen in Ewing’s tumors and therein 
derived its name, Ewing tumor associated antigen 1(Borowski et al., 2006).  Subsequent 
studies, including my own work, have identified ETAA1 as a nuclear protein that can activate 
ATR (Bass et al., 2016; Haahr et al., 2016; Lee et al., 2016). ETAA1 is a large (103 kDA) protein 
conserved throughout vertebrates. In addition to interacting with ATR, ETAA1 interacts with the 
BLM/TOP IIIα/RMI1/RMI2 complex to promote genome stability (Bass et al., 2016). Unlike 
TOPBP1, cells deficient for ETAA1 are viable in human and mice, albeit ETAA1 knockout mice 
are born at less than Mendelian frequencies indicating a partial embryonic lethality (Bass et al., 
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2016; Haahr et al., 2016; Miosge et al., 2017). Genome-wide association studies (GWAS) found 
that single-nucleotide polymorphisms at the ETAA1 locus increase pancreatic cancer risk 
suggesting ETAA1 is a cancer gene (Childs et al., 2015b; Klein et al., 2018; Wu et al., 2012).  
Additionally, defective ETAA1 in Ewing’s tumors may explain why these tumor types have high 
replicative stress (Nieto-Soler et al., 2016).  
Localization of ETAA1 to sites of RS occurs through the same mechanism as 
ATR/ATRIP, RPA coated ssDNA (Fig. 1.6). ETAA1 directly binds the RPA70N domain of RPA1 
and RPA32C domain of RPA2 through two RPA-interaction motifs (Bass et al., 2016; Haahr et 
al., 2016; Lee et al., 2016; Feng et al., 2016). Both RPA-interaction motifs are sufficient for its 
localization to sites of RS, however the RPA32C interacting domain of ETAA1 appears to be the 
primarily localization determinant (Bass et al., 2016).  Once localized, ETAA1 can trigger ATR 
signaling using an AAD with microhomology to the TOPBP1-AAD.  
 
Requirements for ATR/Mec1 activation  
Identifying the attributes that constitute an ATR or Mec1 activating protein has been an 
important focus for examining RSR regulation and identifying novel ATR/Mec1 activating 
proteins. Although ATR and Mec1 activators share minimal homology there are many common 
structural themes of ATR/Mec1 activators. First, all ATR/Mec1 activators require a domain that 
promotes recruitment to sites of RS independent of ATR/Mec1. The interaction between 
ATR/Mec1 and their activators is inherently weak, preventing non-specific activation away from 
sites of RS. Therefore, checkpoint activation only occurs if the sustained local concentration of 
both kinase and activator is sufficiently high. Independent recruitment of ATR/Mec1 and their 
activators requires at least two different protein complexes to recognize the presence of RS or 
DNA damage, ensuring activation of ATR/Mec1 only when and where appropriate.  Although the 
means of recruitment to sites of RS is different, loss or mutation of RS localization domains in 
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ATR/Mec1 activating proteins results in compromised checkpoint signaling (Bass et al., 2016; 
Haahr et al., 2016; Lee et al., 2007a).  Conversely, overexpression of AAD/MADs (Mec1 
activation domain) results in aberrant RSR signaling bypassing the requirement for RS or DNA 
damage (Bass et al., 2016; Kumagai et al., 2006; Haahr et al., 2016; Lanz et al., 2018). 
In addition to containing a localization domain, all activators must contain an ATR/Mec1 
activation domain (AAD/MAD). While AADs and MADs have limited primary sequence 
homology all have two aromatic residues located inside an intrinsically disordered domain 
(Wanrooij et al., 2015). Mutation of just one of these aromatic residues can result in a complete 
loss of function to activate ATR/Mec1. For example, mutation of tryptophan (W) 107 located in 
the ETAA1-AAD prevents ETAA1 from activating ATR and phenocopies ETAA1 null cells (Bass 
et al., 2016).  Likewise, mutation of W1147 ablates TOPBP1 ability to activate ATR and results 
in embryonic lethality in mice (Kumagai et al., 2006; Zhou et al., 2013).  While the two aromatic 
residues are essential for ATR/Mec1 activation, surrounding sequences contribute by stabilizing 
the interaction between activator and kinase (Wanrooij et al., 2015). Additionally, ongoing work 
by Cortez lab member Vaughn Thada suggest that a predicted coiled-coil domain is also an 
essential component of the AADs in ETAA1 and TOPBP1.  
 
ATR regulation of cell cycle checkpoints 
 
ATR activation ensures completion of DNA replication and repair prior to progression to 
the next stage of the cell cycle. In this section I will outline the functions of ATR to regulate the 
intra-S-phase checkpoint, S/G2 checkpoint, G2/M checkpoint, and mitotic checkpoint and the 
biological responses of ATR signaling during each checkpoint (Fig. 1.7)  
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Figure 1.7 ATR regulates checkpoints throughout the cell cycle.  (A) ATR regulates the intra-S-phase checkpoint 
promoting fork stabilization, inhibition of origin firing, and blocks S-phase progression. ATR arrests cell cycle 
progression through CHK1-dependent inactivation of CDC25. CDC25 is a phosphatase that removes inhibitory 
phosphorylations on the CDK1/2 kinases that drive S-phase progression. (B) ATR-CHK1 controls the S/G2 transition 
by suppressing phosphorylation of the transcription factor, FOXM1 until completion of DNA replication. 
Phosphorylation of FOXM1 by CDKs promotes transcription of a mitotic gene network required for the transition to G2 
phase. (C) The CDK1/cyclinB complex drives entry into mitosis but is blocked by inhibitory phosphorylations from 
WEE1 and MYT1. Dephosphorylation of CDK1 by CDC25 promotes entry into mitosis. In the presence of DNA 
damage, ATR activates CHK1 which inhibits CDC25 activity via phosphorylation. Protracted G2 arrest is maintained 
through transcription factors p53 and p21 which regulate expression of CHK1-inhibiting proteins. (D) ATR and CHK1 
regulate the mitotic checkpoint through phosphorylation of the mitotic kinase Aurora B. Aurora B promotes 
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ATR regulation of the intra-S-phase checkpoint  
Replication stress occurs every S-phase as cells deal with unavoidable obstacles that 
impede DNA replication such as DNA damage, difficult to replicate sequences, and shortages of 
deoxynucleotide triphosphate (dNTP) pools. To ensure faithful duplication of the genome, ATR 
enforces the intra-S-phase checkpoint, activating the RSR and coordinating cell cycle 
progression with completion of DNA replication. While ATR primarily regulates proteins localized 
to chromatin and near sites of RS, downstream effector kinases such as CHK1 propagate 
signaling away from sites of RS and throughout the nucleus. Together this signaling cascade  
promotes a widespread response affecting almost every nuclear biological process including 
DNA metabolism, cell cycle regulation, protein metabolism, and gene expression (Matsuoka et 
al., 2007). Below, I highlight three specific functions of ATR during S-phase to promote genome 
stability: regulation of origin firing, stabilization of stalled replication forks, and induction of cell 
cycle arrest.  
Regulation of origin firing 
Eukaryotic cells prepare for DNA replication during G1 by loading the minichromosome 
maintenance complex 2-7(MCM2-7) at origins of replication through a processed called origin 
licensing (Cook, 2009). During S-phase, origins are activated after the MCM complex interacts 
with Cdc45 (cell division Cycle 45) and the GINS complex forming the CMG (Cdc45-MCM-
GINS) replicative helicase. Although several thousand origins are licensed, only about 10% fire 
during an unperturbed S-phase, the remainder lying dormant (McIntosh and Blow, 2012). 
Dormant origins are capable of initiating, but are not required for completion of DNA replication, 
and are therefore passively replicated by forks originating from neighboring origins.    
DNA replication is a temporally organized process with regulated staggering of origin 
firing ensuring specific chromosomal regions are replicated in early, mid, or late S-phase. 
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During an unperturbed S-phase, ATR and CHK1 negatively regulate origin firing, preventing 
premature initiation of late-replicating origins (Cook, 2009).  Furthermore, treatment with drugs 
that induce replication stress cause premature stalling of forks, activating the intra-S-phase 
checkpoint. ATR activation in response to RS suppresses global firing from late-replicating 
origins by regulating Cdc45 recruitment to chromatin (Costanzo et al., 2003). Preventing late-
firing origins from initiating replication limits widespread polymerase stalling and excessive 
formation of ssDNA which can result in RPA exhaustion (Couch and Bansbach, 2013; Toledo et 
al., 2013). While suppressing global origin firing, ATR promotes firing of dormant origins near 
sites of RS, ensuring completion of replication by neighboring replication forks (Ge and Blow, 
2010). 
Stabilization of stalled forks 
DNA lesions can impede replisome progression resulting in a stalled replication fork.  
ATR is essential for stabilizing stalled forks, ensuring the stalled polymerase can restart 
replication following repair or bypass of the lesion. Failure to rescue stalled forks can result in 
accumulation of ssDNA and depletion of pools of RPA, formation of DSBs by structure-specific 
nucleases, and replisome dissociation termed fork collapse (Carr et al., 2011; Muñoz et al., 
2009; Toledo et al., 2013). Inhibition of ATR during RS suggests that ATR does not regulate 
replisome stability but protects forks from collapsing by preventing RPA exhaustion through 
inhibition of origin firing and regulating the activity of fork remodeling enzymes (Fig. 1.8A) 
(Dungrawala et al., 2015; Couch and Bansbach, 2013).  
One replication fork stabilization mechanism regulated by ATR and mediated by 
helicases such as SMARCAL1 (SWI/SNF, matrix associated, actin dependent regulator of 
chromatin A-like 1), HLTF (Helicase Like Transcription Factor), and ZRANB3 (Zinc Finger 
RANBP2-Type Containing 3) is fork reversal (Bansbach et al., 2009; Ciccia et al., 2009, 2012; 
Yusufzai and Kadonaga, 2010; Kile et al., 2015). During fork reversal, fork remodeling enzymes  
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regress the replication fork, annealing and extruding the newly synthesized strands resulting in 
a four-way junction resembling a chicken foot (Fig. 1.8B). Once conditions are favorable, the 
reversed fork is rescued by conversion of the four-way chicken foot structure to a standard 
three-way replication fork and polymerization can resume.   
Fork reversal frequently occurs during RS and protects stalled forks by allowing bypass 
of DNA lesions, halting replication during periods of unsuitable conditions, and preventing 
ssDNA accumulation that could result in DSBs (Neelsen and Lopes, 2015). Highlighting the 
importance of fork reversal as an instrument of genome maintenance, many diseases are 
associated with deficiencies in fork remodeling enzymes. Loss or mutation of the fork 
remodeling enzymes SMARCAL1, BLM, and WRN (Werner syndrome ATP-dependent 
helicase), are associated with Schimke immunoosseous dysplasia (SIOD), Bloom’s syndrome, 
and Werner’s syndrome respectively (Boerkoel et al., 2002; Carroll et al., 2013; Ellis et al., 
1995; Yu et al., 1996). However, fork reversal is a double edged-sword, with excessive fork 
reversal generating substrates for site-specific nucleases such as MUS81, SLX1/SLX4, and 
XPF (Couch and Bansbach, 2013).  
ATR directly regulates fork reversal through phosphorylation of fork remodeling enzymes 
such as SMARCAL1 and WRN (Werner syndrome ATP-dependent helicase) (Couch and 
Bansbach, 2013; Ammazzalorso et al., 2010; Mutreja et al., 2018). ATR prevents excessive fork 
reversal through phosphorylation of S652 of SMARCAL1, inhibiting its fork remodeling activities 
(Couch and Bansbach, 2013). Loss of ATR-dependent regulation of SMARCAL1 increases DSB 
formation due to SLX4-dependent cleavage of reversed forks (Fig. 1.8C). Therefore, ATR 
regulation of fork reversal stabilizes stalled forks and helps maintain genome integrity.  
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Cell cycle arrest 
Another crucial function of ATR during the intra-S-phase checkpoint is to promote cell 
cycle arrest during RS. Cyclin dependent kinases (CDKs) form active protein complexes with 
cyclins to drive cell cycle progression via regulatory phosphorylation networks. The CDC25 
phosphatases CDC25A, CDC25B, and CDC26C remove inhibitory phosphates from CDK1 and 
CDK2 sustaining high CDK activity required for S-phase progression (Saldivar et al., 2017). 
ATR signaling induces cell cycle arrest by CHK1-dependent phosphorylation and inactivation of 
the CDC25 phosphatases (Karlsson-Rosenthal and Millar, 2006) (Fig. 1.7A). The mechanism of 
inhibition for each CDC25 family member varies. Phosphorylation of CDC25A results in its 
degradation by the proteasome while CDC25C is sequestered in the cytoplasm (Mailand et al., 
2000; Peng et al., 1997). 
  
ATR regulation of the S/G2 checkpoint  
In a collaboration with the Cimprich lab, I identified ATR as a regulator of the newly 
defined S/G2 checkpoint, ensuring completion of DNA replication before cells enter G2 (Saldivar 
et al., 2018). CDK phosphorylation of the transcription factor Forkhead Box M1 (FOXM1) on 
T600 is required for expression of a G2/M gene network promoting the transition from S-phase 
to G2. During S-phase, ATR and CHK1 repress early onset of G2 by suppressing 
phosphorylation of FOXM1 (Fig 1.7B). As S-phase ends, ATR activity declines allowing 
phosphorylation of FOXM1 and transition to G2. This ATR function is dependent on ETAA1-
acitvation and not a TOPBP1-activation of ATR.  
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ATR regulation of the G2/M checkpoint  
The G2/M checkpoint prevents entry into mitosis in the presence of DNA damage. ATR 
and ATM can both induce the G2/M checkpoint although the ATR-CHK1 pathway may be the 
primary regulator (Lin and Dutta, 2007). The CyclinB1/CDK1 complex drives entry into mitosis 
but phosphorylation on Tyrosine 14 and 15 by MYT1 (myelin transcription factor 1) and WEE1 
(WEE1 G2 Checkpoint Kinase) inactivates the complex (Nigg, 2001). Dephosphorylation of 
CDK1 by the CDC25 phosphatases activates the CyclinB1/CDK1 complex promoting entry into 
mitosis. In response to DNA damage, ATR/ATM promote stabilization of WEE1 and inhibition of 
CDC25 via phosphorylation by CHK1/2 resulting in a G2 arrest (Fig 1.7C). Additionally, 
ATR/ATM can promote protracted G2 arrest through a pathway dependent on the transcription 
factors p53 and p21 which regulate expression of CDK1-inhibiting proteins (Lukas et al., 2004).  
Counteracting the checkpoint signal, Wip1, PP2A, PP4, and PP6 remove inhibitory or 
stimulating phosphate groups on WEE1, CDC25, and p53. ATR/ATM signaling diminishes as 
DNA repair progresses, further reducing the checkpoint signal and coordinating release from G2 
arrest with completion of DNA repair (Deckbar et al., 2011). 
 
ATR regulation of the mitotic checkpoint  
Spindle Assembly Checkpoint (SAC) 
ATR and CHK1 are also active during mitosis and function to promote Aurora B kinase 
signaling, chromosome stability and alignment, and robust activation of the mitotic checkpoint 
also referred to as the spindle assembly checkpoint (SAC). The SAC maintains genome 
integrity by delaying anaphase onset until accurate bipolar attachment of all chromosomes to 
the mitotic spindle ensuring equal separation of genetic material into the dividing daughter cells 
(Fig. 1.9) (Lara-Gonzalez et al., 2012).  
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Following completion of DNA replication, cohesion proteins hold duplicated 
chromosomes together maintaining their identity as sister chromatids until separation at 
anaphase. The SAC ensures accurate chromosome segregation by preventing cohesion ring 
opening until correct alignment of all chromosomes on the mitotic spindle. This is achieved by 
formation of the mitotic checkpoint complex (MCC) composed of BUBR1, BUB3, MAD2 and 
CDC20 at unattached kinetochores. Kinetochores are complex structures composed of at least 
80 different proteins assembled at the centromere of each sister chromatid and serve as an 
attachment site for spindle microtubules. The kinase BUB1 mediates recruitment of the MCC 
components to unattached kinetochores catalyzing formation of the MCC (Meraldi and Sorger, 
2005). BUBR1 and MAD2 inhibit anaphase onset by directly binding CDC20 preventing it from 
activating the anaphase promoting complex (APC/C) (Lara-Gonzalez et al., 2012).   
The APC/C is an E3 ubiquitin ligase complex that targets proteins for degradation, such 
as mitotic cyclins and securin (Pines, 2011). Once all kinetochores are properly attached, the 
MCC complex releases CDC20 allowing activation of APC/C and promoting entry into 
anaphase. Anaphase onset is promoted by degradation of CyclinB1 inactivating CDK1 and 
degradation of securin, an inhibitor of the protease separase. Once released, separase cleaves 
a subunit of the cohesion ring structure allowing ring opening and separation of the sister 
chromatids.  
ATR and CHK1 function during mitosis 
CHK1 was first tied to the mitotic checkpoint in yeast and flies after loss of CHK1 
delayed the onset of anaphase in mitotic cells following induction of DNA damage (Collura et al., 
2005; Royou et al., 2005).  Subsequent studies found that both CHK1 and ATR regulate the 
mitotic checkpoint through CHK1-dependent phosphorylation of the mitotic kinase Aurora B 
(Fig. 1.7D) (Zachos et al., 2007; Peddibhotla et al., 2009; Petsalaki et al., 2011; Kabeche et al., 
2017).  Aurora B kinase contributes to a number of mitotic processes such as kinetochore 
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stabilization, kinetochore-microtubule attachment, and regulation of the SAC (Krenn and 
Musacchio, 2015).  During mitosis, ATR can localize to centromeres through an Aurora A-
regulated interaction with CENPF, allowing it to bind RPA-coated R-loops. Once activated, ATR 
promotes CHK1 phosphorylation of Aurora B preventing formation of lagging chromosomes. 
Additionally, loss of mitotic CHK1-Aurora B activity causes chromosome missegregation and 
reduced recruitment of SAC proteins such as BubR1 to kinetochores (Zachos et al., 2007; 
Petsalaki et al., 2011). Due to deficiencies in the SAC, cells treated with small molecular 
inhibitors of ATR and CHK1 are unable to sustain mitotic arrest in the presence of taxol (Zachos 
et al., 2007).  
My work described in Chapter IV expands the functions of ATR during mitosis and 
demonstrates that the ATR-activator ETAA1 is required for mitotic ATR activation at centromeric 
regions. Loss of ETAA1 results in reduced phosphorylation of SAC proteins such as BUB1 and 
BUBR1 and decreased histone 3 phosphorylation. Additionally, loss of ETAA1-dependent ATR 
signaling results in decreased Aurora B kinase activity, chromosomal misalignment, and 
decreased SAC activity. While TOPBP1 was not required for ATR activation at kinetochores, 
previous studies indicate that TOPBP1 does function during mitosis at sites of under-replication 
but that it is independent of ATR signaling (Pedersen et al., 2015). Additionally, TOPBP1 
localizes to ultra-fine anaphase bridges and promotes their resolution through direct recruitment 
of topoisomerase IIα. (Germann et al., 2014; Broderick et al., 2015). Therefore, while TOPBP1 
is active during mitosis, its functions do not appear tied to ATR activation.  
In conclusion, ATR is an essential protein required for proper cell cycle progression and 
genome maintenance. ATR phosphorylates hundreds of proteins regulating DNA metabolic 
processes throughout the cell cycle. As a result, defects in ATR signaling pathways make 
proliferating cells susceptible to genome instability. Therefore, small molecule inhibitors to ATR 
and other DDR proteins are currently being evaluated as potential cancer therapies.   
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Targeting ATR in cancer 
 
Cancer is a tremendous threat to human health, with an estimated 18 million people 
predicted to develop cancer this year (Bray et al., 2018).  Mutations in oncogenes or tumor 
suppressors drive cancer development, causing unrestrained growth of abnormal cells.  In 
cancer, the normally highly ordered process of cell division is deregulated, allowing cells to 
bypass cell cycle checkpoints without having met the criteria required to proceed to the next 
stage of the cell cycle. Although this gives cancer cells limitless replicative potential, they are ill 
prepared for the challenging task of DNA replication. Therefore, a hallmark of all cancers is 
increased replication stress (Macheret and Halazonetis, 2015). Replication stress in cancer cells 
can be traced to a number of sources such as deregulated origin licensing, shortages of 
doxynucleotides, and increased transcription during S-phase, causing increased collisions 
between replication and transcription machinery (Macheret and Halazonetis, 2015). Additionally, 
most cancers have deficiencies in one or more pathways of the DDR due to selective pressures 
occurring during tumor development (Jackson and Bartek, 2009).  
To exploit these disadvantages, the most prevalent non-invasive cancer treatments are 
radiotherapy and chemotherapies that generate DNA damage. Ionizing radiation therapy 
induces free radicals and reactive oxygen species which damage DNA forming single-stranded 
and double-stranded breaks. Common chemotherapeutic agents also induce DNA damage or 
RS, such as platinum salts which cause interstrand DNA crosslinks, topotecan which traps 
topoisomerase I on DNA, and gemcitabine which inhibits ribonucleotide reductase (RNR) 
depleting levels of deoxyribonucleotide triphosphates (dNTPs). DNA-damaging therapeutic 
agents are advantageous due to their higher toxicity in cancer cells than most normal cell types. 
Genotoxic agents are most lethal during S-phase, when cells are particularly vulnerable to DNA-
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damage. Therefore, rapidly proliferating cells, such as cancer cells, are more likely to be 
targeted by these agents than normal tissues, which are mostly composed of quiescent cells.   
 The efficacy of DNA-damaging agents can be further improved by inhibition of DDR 
signaling pathways. Currently, therapies targeting important DDR proteins such as ATR, ATM, 
and CHK1 are being developed as potential cancer treatments (O’Connor, 2015). Many of these 
inhibitors are currently in clinical trials in combination with other DNA-damaging therapeutic 
agents. For example, the ATR inhibitors (ATRi) VX970 and AZD6738 are being currently used 
with replication stress inducing agents such as gemcitabine, cisplatin, and topotecan (O’Connor, 
2015).  DDR inhibitors may also prove useful as monotherapies through induction of synthetic 
lethality. Two genes are synthetically lethal if mutation or inhibition of a gene/protein alone has 
no effect on cellular viability but defects in both genes/proteins results in cell death (Kaelin, 
2005). ATR inhibition is synthetically lethal with loss of ERCC1, XRCC1, CDC25A, and ARID1A 
(Mohni et al., 2014; Sultana et al., 2013; Ruiz et al., 2016; Williamson et al., 2016). As the ability 
to sequence tumor DNA and identify specific mutations in cancer becomes a standardized 
practice of care, synthetic lethal relationships will be more easily exploited. 	
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CHAPTER II 
 
MATERIALS AND METHODS 
Antibodies 
Table 2.1 Antibodies.  Provided are the antibodies used for western blotting (WB), 
immunofluorescence (IF) and flow cytometry (FC). Antibody concentrations, host, vendor, 
catalog number, molecular weight and location in the Cortez lab are provided. 
Table 2.1 Antibodies 
Antibody Dilution Species Company Catalog Number 
Location 
(Cortez 
Lab) 
Molecular 
Weight 
(kDA) 
Use 
Anti-
centromere 
antibodies 
(ACA) 
1:200 Human Antibodies Inc. 
15-234-
0001 
Box12-
A2  IF 
ATM 1:2,500 Rabbit Abcam Ab206-1000 Box1-A1 350 WB 
ATM 
pS1981 1:600 Rabbit 
Affinity Bio 
Reagents 
PA1-
21770 Box5-A3 350 WB 
ATR (N-19) 1:1,000 Goat Santa Cruz SC-1887 Box1-A3 301 WB 
ATR 
pS1989 1:1,000 Rabbit Epitomics VAN 7P Box7-F5 301 WB 
ATRIP 403 1:1,000 Rabbit Cortez  Box2-A3 86 WB ATRIP C 1:1,000 Rabbit Cortez  Box2-A1 86 WB ATRIP N 1:1,000 Rabbit Cortez  Box2-A2 86 WB 
Aurora B 1:200 Rabbit Bethyl A300-431A 
Box10-
F9 39 IF 
Aurora B 
pT232 1:200 Rabbit Roche 
600-401-
677 
Box12-
B1 39 IF 
BLM (C-18) WB=1:1,000 IF=1:200 Goat Santa Cruz sc-7790 
EFBox1-
G8 159 
WB, 
IF 
BLM (H-
300) 1:1,000 Rabbit Santa Cruz sc-14018 
EFBox1-
G9 159 WB 
BRCA1 1:1,000 Mouse Calbiochem OP-92 Box1-B1 220 WB 
BRCA2 1:1,000 Mouse Calbiochem OP-95 Box9-H8 384 WB 
BrdU 1:1,000 Mouse BD 555627 Box10-A4  IF 
BrdU 
(CldU) 1:100 Rat Abcam ab6326 4°  IF 
BrdU (IdU) 1:100 Mouse BD 347580 4°  IF 
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Bub1 WB=1:1,000 IF=1:200 Rabbit Bethyl 
A300-
373A-M 
Box10-
E7 122 
WB, 
IF 
CENPF WB=1:1,000 IF=1:200 Rabbit Abcam ab5 
Box12-
A4 330 
WB, 
IF 
Chk1 (G-4) 1:1,000 Mouse Santa Cruz sc-8408 Box3-D3 55 WB 
Chk1 
pS317 
WB=1:1,000 
IF=1:200 Rabbit 
Cell 
Signaling 2344S Box4-A1 55 
WB, 
IF 
Chk1 
pS345 
WB=1:1,000 
IF=1:200 Rabbit 
Cell 
Signaling 2341S Box4-A3 55 
WB, 
IF 
Chk2 1:,2000 Rabbit Cortez  Box2-H5 61 WB 
Chk2 pT68 1:1,000 Rabbit Cell Signaling 2661S Box 4-A5 61 WB 
Cyclin A 1:1,000 A300-373A-M Santa Cruz sc-751 Box1-C7 60 IF 
ETAA1 1:1,000* Rabbit Cortez (Covance)  
Box 7-
H7 103 
WB, 
IP 
ETAA1 
(VU446) 1:1,000* Rabbit 
Cortez 
(Covance)  
Box 10-
D9 103 
WB, 
IP 
FANCD2 
(Fi17) 1:1,000 Mouse Santa Cruz sc-20022 Box3-D5 166 WB 
Flag WB=1:1,000 IF=1:200 Rabbit Sigma F7425 Box3-F8  
WB, 
IF 
Flag (M2) WB=1:1,000 IF=1:200 mouse Sigma F-3165 
Aliquots 
in box -
20  
WB, 
IF, 
IP 
GAPDH 1:50,000 Mouse Millipore MAB374 Box1-F4 36 WB 
GFP WB=1:1,000 IF=1:200 Rabbit Abcam ab290 
Box12-
A1  
WB, 
IF 
H2A 1:1,000 Rabbit Abcam ab18255 Box4-G8 14 WB 
H2A pT120 WB=1:1,000 IF=1:200 Rabbit Active Motif 61195 
Box12-
B2 14 
WB, 
IF 
H2AX (not 
phospho) 1:5,000 Rabbit Bethyl 
A300-
082A Box3-H8 17 WB 
H2B 1:5,000 Rabbit Abcam ab1790 Box5-E7 15 WB 
H3 1:5,000 Rabbit Abcam ab46765 Box5-A7 15 WB 
HA 1:1,000 Rabbit Abcam ab9110 Box4-H4  WB 
HA WB=1:1,000 IF=1:200 Rat Roche 
11 867 
423 001 Box7-D9  
WB, 
IF 
HLTF 1:1,000 Rabbit Cimprich  
Box13-
B1 114 WB 
Ku70 1:1,000 Mouse Abcam ab3114 Box9-C1 70 WB 
Ku80 1:500 Rabbit Abcam ab33242 Box9-C2 80 WB 
MCM2 1:10,000 Mouse BD 39289  100 WB MCM2 
pS108 1:10,000 Mouse Bethyl IHC-00014 Box1-H9 100 WB 
MDC1 1:500 Rabbit Bethyl BL578 Box3-A6 220 WB 
MRE11 1:1,000 Mouse Gene Tex GTX30294 Box1-C3 81 WB 
MUS81 1:1,000 Mouse Novus NBP1-00609N 
Box 6-
D5 66 WB 
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ORC2 1:5,000 Rabbit BD 551178 Box4-G7 66 WB 
p53 (DO-1) 1:1,000 Mouse Santa Cruz SC-126 Box2 D6 44 WB 
p53 pS15 1:1,000 Rabbit Cell Signaling 9284 Box4-A7 44 WB 
PCNA 1:1,000 Rabbit Santa Cruz SC-7907 Box2-F4 29 WB 
pH3 S10 
WB=1:1,000 
IF=1:200 
FC=1:400 
Rabbit Cell Signaling 3377 Box9-G6 15 
WB, 
IF, 
FC 
pH3 S28 1:200 Rabbit Upstate 07-145 Box4-F2 15 IF 
RAD17 1:2,500 Goat Bethyl A300-151A Box6-G3 77 WB 
RAD17 
S645 1:1,000 Rabbit Bethyl  Box3-B7 77 WB 
RAD51 (H-
92) 1:200 Rabbit Santa Cruz sc-8349 Box7-A1 37 IF 
RAD9 1:2,000 Rabbit Bethyl A300-890A Box6-G2 50 WB 
RAD9 
pS387 1:500 Rabbit ABGENT AP3230a Box6-C4 50 WB 
RMI1 1:1,000 Rabbit Bethyl A300-631A-M 
Box 10-
B1 27 WB 
RMI2 1:1,000 Rabbit Abcam ab122685 Box 10-C2 16 WB 
RPA32 WB=1:1,000 IF=1:200 Mouse Abcam 2175 Box1 B9 32 
WB, 
IF, 
IP 
RPA32 
pS33 
WB=1:1,000 
IF=1:200 Rabbit Novus NB100-54 
Box10 
D4 32 
WB, 
IF 
RPA32 
pS33 
WB=1:1,000 
IF=1:200 Rabbit Bethyl 
A300-
246A 
Box10 
E9 32 
WB, 
IF 
RPA32 
pS4/8 
WB=1:1,000 
IF=1:200 Rabbit Bethyl 
A300-
245A 
EFBox1-
B8 32 
WB, 
IF 
RPA70 WB=1:1,000 IF=1:200 Rabbit 
Cell 
Signaling 2267 Box4-G5 70 
WB, 
IP, 
IF 
SGO2 1:200 Rabbit Bethyl A301-262A-M 
Box10-
E8 28 IF 
SLX4 1:1,000 Rabbit Bethyl A302-269A-1 Box7-D3 200 WB 
SMARCAL1 1:5,000 Rabbit Bethyl A301-616A Box2-I2 110 WB 
SMARCAL1 
(909) 1:1,000 Rabbit Cortez  Box6-A7 110 WB 
SMARCAL1 
pS652 1:1,000 Rabbit Cortez  Box6-C1 110 WB 
SMC1 1:1,000 Rabbit Novus NB100-204 
EFBox 
F7 150 WB 
SMC1 
pS957 1:1,000 Rabbit Novus 
NB100-
205 
EFBox 
F8 150 WB 
TOP3A (N- 1:1,000 Goat Santa Cruz sc-11257 Box7-I1 109 WB 
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20) 
TOPBP1 1:1,000 Rabbit Bethyl A300-111A-1 Box3-E3 185 
WB, 
IF 
tubulin (B-
7) 1:200 Rabbit Santa Cruz sc-5286 
EF-
Box2-c5 50 IF 
ZRANB3 1:1,000 Rabbit J. Chen  Box7-C8 123 WB 
γH2AX 1:1,000 Rabbit Cell Signaling 2577 Box4-F4 17 IF 
γH2AX 
(JBW301) 
WB=1:1,000 
IF= 1:500 Mouse Millipore 05-636 Box6-I7 17 
WB, 
IF 
All antibodies were blocked in 5% milk in TBS/t and diluted in 1% milk in TBS/t for western 
blotting unless denoted with an asterisk. Antibodies with asterisk were diluted and blocked in 
Odyssey blocking buffer. For IF experiments cells were blocked with 5% BSA in PBS and 
diluted in 1% PBS in PBS.  
Cell culture  
Table 2.2 Cell lines. Cell lines are given with optimal media and transfection reagents. 
Table 2.2 Cell lines 
Cell Line Media 
Plasmid 
transfection 
reagent 
siRNA 
transfection 
reagent 
U2OS DMEM+7.5% FBS PEI/Fugene Dharmafect1  
HCT116 McCoy's 5A +10%FBS PEI/Fugene RNAiMax 
HEK293T DMEM+7.5% FBS PEI RNAiMax  
HeLa DMEM+7.5% FBS Lipofectamie 2000 RNAiMax 
A549 RPMI+10% FBS PEI Dharmafect1  
BT549 RPMI+10% FBS PEI Dharmafect1  
H157 RPMI+10% FBS PEI Dharmafect1  
 
Cell growth assays 
Plated 5x104 HCT116 cells in a 35 mm dish and left untreated or treated with 500 μM IAA. Cells 
were counted every 24 hours for four days. Cell number and percent viable cells was measured 
after trypan blue staining using a Countess II automated cell counter.  
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Cell profiler  
Table 2.3 Cell profiler pipelines. Pipelines used for image analysis are provided with a 
description of their use. Pipelines are available for download on the Cortez lab server in the Cell 
Profiler folder. 
Table 2.3 Cell profiler pipelines 
Pipeline Name Description 
H2AX intensity.cppipe Measure intensity of a channel (i.e. γH2AX) using a DAPI mask 
RPA_foci.cpproj Count and measure intensity of foci in one channel using a DAPI mask 
ETAA1_RPA.cppipe Count and measure intensity of foci in two channels using a DAPI mask 
ETAA1_RPA_TOPBP1.cppipe Count and measure intensity of foci in three channels using a DAPI mask 
Mitotic PLA assay.cppipe 
Count and measure intensity of foci in one channel using DAPI and 
as a mask. Nuclei are hand selected allowing only a subset of cells 
to be analyzed (i.e. mitotic cells) 
Kinetochores.cppipe 
Count and measure intensity of foci in two channels using\ DAPI and 
another channel (kinetochores) as masks. Nuclei are hand selected 
allowing only a subset of cells to be analyzed (i.e. mitotic cells) 
 
Clonogenic survival assay 
U2OS cells were seeded onto 60-mm cell culture plates at 200–5,000 cells per plate in 
triplicate. The following day, cells were treated with drug, washed, and released into 
fresh growth medium for 14 days prior to staining with methylene blue. 
 
COMET Assay 
 Neutral COMET assays  
Three days after transfection, cells were left untreated or treated with 100 nM CPT for 3 
hrs. Cells were harvested by trypsinization and washed once with cold PBS. Cells were 
resuspended in 1 mL of cold PBS to get 2x105 cells/mL.  During this time, low melting 
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temperature agarose (Trevigen) was melted and held in a 42 °C water bath.  To prepare slides, 
10 µL of cell suspension was mixed with 100 µL of agarose and spread into one well of a 
COMET slide (Trevigen). (Best to keep agarose at 42 °C when adding cells and spread 
immediately) Two wells were prepared per treatment condition. Place samples to be compared 
on same slide.  Slides were allowed to gel for 15 minutes at 4°C.  Slides were then immersed in 
pre-chilled Lysis Buffer (Trevigen) for 1 hour at 4°C. Slides were rinsed once with pre-chilled 
TAE (40 mM Tris Base, 20 mM Acetic acid, 1 mM EDTA, pH 8.45), then washed for 30 minutes 
immersed in TAE at 4°C. Slides were then electrophoresed for 1 hour at 21V immersed to a 
depth of at least 0.5 cm in TAE. After electrophoresis, slides were immersed in DNA 
Precipitation Solution (1M NH4Ac, 87% ethanol) for 30 minutes at room temperature. Next, 
slides were immersed in 70% ethanol for 30 minutes at room temperature then dried for 15 
minutes at 45°C and stored overnight at room temperature. Slides were stained with 50 mL of 
1X SYBR Green I (Trevigen) for 30 minutes at room temperature.  SYBR Green solution was 
decanted and slides allowed to dry at least 30 minutes before visualizing slides on the 20x 
objective. At least 20 images were taken per well and scored for tail moment using CometScore 
software (http://www.autocomet.com).  At least 100 comets were scored for each condition.  
Alkaline COMET assays  
Three days after transfection, cells were left untreated or treated with 100 nM CPT for 3 
hrs. Cells were harvested by trypsinization and washed once with cold PBS. Cells were 
resuspended in 1 mL of cold PBS to get 2x105 cells/mL. During this time, low melting 
temperature agarose (Trevigen) was melted and held in a 42°C water bath. To prepare slides, 
10 µL of cell suspension was mixed with 100 µL of agarose and spread into one well of a 
COMET slide (Trevigen). Two wells were prepared per treatment condition. Place samples to be 
compared on same slide.  Slides were allowed to gel for 15 minutes at 4°C. Slides were then 
immersed in pre-chilled Lysis Buffer (Trevigen) for 1 hour at 4°C. Slides were Immersed in 
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Alkaline electrophoresis solution (pH>13, 200 mM NaOH, 1 mM EDTA) for 20 min at room temp 
in the dark.  Slides were then electrophoresed for 1 hour at 21V immersed to a depth of at least 
0.5 cm in alkaline electrophoresis solution. Immersed slides twice in water for 5 min each, then 
in 70% ethanol for 5 min. Slides were dried for 15 minutes at 37°C. Slides were stained with 100 
µL of 1X SYBR Green I (Trevigen) for 30 minutes at room temperature. SYBR Green solution 
was decanted and slides allowed to dry at least 30 minutes before visualizing slides on the 20x 
objective. 
 
CRISPR knockout cell generation 
Table 2.4 gRNA sequences. The gRNA sequences and corresponding plasmid used 
for CRISPR genome editing are provided below. The PAM for each gRNA is shown in bold. 
Target Editing strategy gRNA Sequence Plasmid 
Name 
ZRANB3 knock out AGCTTTGCTCTTAGTCTGTCAGG pTB08 
ZRANB3 knock out TTTTTTATGTTATGAACCCTAGG pTB10 
SMARCAL1 knock out	 CATCCTCCGTGCGCTTCACCTGG pTB14 
SMARCAL1 knock out CTTTGACCTTCTTAGCAAGTTGG pTB16 
ETAA1 knock out ATTTGATAGATCAAAACTGTGG pTB54 
ETAA1 knock out GAAGAAGAACTTATGAAACTGG   pTB56 
ETAA1 Tag C-terminus TTCTTTAATGAAATATTAGTTGG pTB75 
ETAA1 Remove exon 2 GTTCTCCTAATGATCCAGA TGG pTB58 
ETAA1 Remove exon 2 CTAGTCAGATAATAGCATCGGG pTB60 
TOPBP1 Tag C-terminus GGACTGGATTATCACAAAAGAGG pTB111 
 
gRNA design 
Identify high scoring gRNAs targeting gene of interest using CRISPR design tool. For 
knockout generation I recommend ordering at least 2-3 gRNAs per gene that are 50-150 bp 
apart and target the N terminal of the gene. CRISPR design tool can be found at 
http://crispr.mit.edu/. 
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Design forward and reverse overhangs flanking gRNAs according to the following page. Use the 
pX330 overhangs: http://www.genome-engineering.org/crispr/wp-
content/uploads/2014/05/CRISPR-Reagent-Description-Rev20140509.pdf  
gRNA plasmid construction  
Insert gRNAs into pSPCas9(BB)-2A-GFP or pSPCas9(BB)-2A-Puro using the following 
protocol: 
1. Phosphorylate and anneal each pair of oligos: (forward and reverse gRNAs for gene of 
interest) 
1 ul oligo 1 (100µM) 
1 ul oligo 2 (100µM) 
1 ul 10X T4 Ligation Buffer (NEB) 
6.5 ul ddH2O 
0.5 ul T4 PNK (NEB) 
10 ul total 
Anneal in a thermocycler using the following parameters: 
37°C 30 min 
95°C 5 min and then ramp down to 25°C at 5°C/min 
 
Dilute the annealed oligo 1:250 (250-fold). 
 
2. Set up digestion-ligation reaction: 
X μL pSpCas9-GFP or pSpCas9-PURO (100ng) 
2 μL phosphorylated and annealed oligo duplex from step 1 (1:250 dilution) 
2 μL 10X Tango buffer (or FastDigest Buffer) 
1 μL DTT (10mM to a final concentration of 1mM) 
1 μL ATP (10mM to a final concentration of 1mM) 
1 μL FastDigest BbsI (Thermo Fisher Fermentas) 
0.5 μL T7 DNA ligase 
Y μL ddH2O 
20 μL total 
Incubate the ligation reaction in a thermocycler: 
37°C 5 min 
23°C 5 min 
Cycle the previous two steps for 6 cycles (total run time 1h) 
4 °C hold until ready to proceed 
4. Transformation with 1-2 μL of the final product into competent cells 
5. Pick colony and sequence verify the clones 
1. Miniprep 
Performed miniprep from 3mL overnight cultures using Sigma miniprep kit according to 
standard protocol.  
2. AgeI/BbsI Digest 
Component Amount (µL) 
DNA (from miniprep) 3 
FastDigest Buffer 2 
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Water 14.6 
AgeI 0.2 
BbsI 0.2 
  Run out samples on a 0.8% agarose gel. If linear then insert of gRNA was successful. If 
you have 7.5 and 1 kb fragments then gRNA insertion was unsuccessful. (Should work ~90% of 
the time. If all clones are incorrect then check for AgeI or BbsI restriction site in gRNA) 
 
Primer design and optimization for amplifying genomic DNA 
Primers that flank the targeted region are required for screening. I design 2-3 primer 
pairs that produce products 250-600 bp with the targeted region contained within the middle of 
the primer pairs.  
Test primer combinations using the PCR conditions given below:   
 
 
Run out samples on a 1.3 % agarose gel. Best primer combination can be improved by 
changing annealing temperature. If no primer pairs produced a product, ordering new primers 
may be faster and cheaper than several rounds of optimization 
gRNA optimization 
Determine best gRNA combination by transfecting 293T cells with pairs of puro-Cas9-
gRNA plasmids. Begin selection 24 hours after transfection by adding 1-2 µg puromycin. Select 
cells for 48 hours then harvest cells for gDNA purification. Screen for genomic editing using 
Component Amount Added Final Concentration Cycling 
H2O 31 µL  98 °C 3 min 
5x Phusion HF 10 µL 1x 98 °C 10 s 
10 mM DNTPs 1 µL 200 µM 55 °C 15 s 
10 µM Forward Primer 1 µL 0.5 µM 72 °C 15 s 
10 µM Reverse Primer 1 µL 0.5 µM 72 °C 2 min 
Template gDNA 5 µL 50 ng Hold 4 °C 
DMSO 1.5 µL 3%  
Phusion polymerase 0.5 µL 1 unit/ PCR reaction Total 35 cycles 
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optimized PCR combination. Edited clones should have a PCR product that smaller is by the 
distance between the gRNAs used. The most effective gRNA pair will have the brightest 
intensity of the smaller band compared to untransfected cells.  
Transfection and selection of 293T cells with gRNAs 
   Day 1 
1. Plate 5 x 105 293T cells per well in each well of a 6-well dish 
   Day 2 
2. Dilute 1 µg of each gRNA into 20 µL of OptiMEM 
3. Add 4.8 µL of PEI at 1 mg/mL and mix by flicking gently 
4. Incubate for 15 min at room temperature 
5. Overlay cells with 2 mL media 
6. Next day begin selection by adding 1-2 µg of puromycin. 
7. Continue selection for 48 hrs until control plate is all dead 
 
Plate surviving cells at a clonal density in either 10 cm plates or 96 well dish. Should take 2-
3 weeks for cells to form colonies.  
 
Genomic DNA purification and PCR 
Pick colonies from 10-cm dish to 24-well dish and continue to expand. Once cells are 
confluent in a 24-well dish I passage 10% of the cells and pellet the remaining 90% for gDNA 
purification using the Wizard gDNA purification kit. Use kit according to manufacturer’s 
instructions.  Screen clones by PCR using your optimized primers. Genome editing will be 
evident by the presence of a smaller band. Validate knockout cells by western and DNA 
sequencing.  
 
CRISPR knock-in cell generation (auxin-inducible cell lines) 
I produced TOPBP1 and ETAA1 cells tagged with an auxin inducible degron (AID) using 
the protocol described in (Natsume et al., 2016). First, I produced vectors containing gRNAs 
located near the desired site of editing using the protocol described above. Knocking in tags or 
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mutations requires homology arms of at least 150 bp to the region surrounding the targeted 
editing site. Additionally, the PAM site of the gRNA must also be edited in the homology donor 
to prevent cleavage by Cas9. To produce a homology vector, I order a geneblock containing 
homology arms separated by a BamH1 restriction site and HindIII and Not1 sites on either end 
of the gene block. The geneblock was then cloned into pBSK using HindIII/Not1 digest.  The 
AID degron with neomycin (Neo) and hygromycin (Hygro) selectable markers was removed 
from pMK289 (AID-mClover-NeoR, Addgene plasmid:72827) and pMK290 (AID-mClover-Hygro, 
Addgene plasmid:72828) by BamH1 digest and inserted between the homology arms in pBSK. 
Both neomycin and hygromycin –encoding template plasmids were cotransfected with 
pSpCas9(BB)-2A-Puro (Addgene plasmid #48139) containing a guide RNA proximal to the 
desired site of editing. Cells with homozygous editing were selected by 700 µg/ml G418, and 
100 µg/ml HygroGold and confirmed by DNA sequencing and SDS-PAGE immunoblotting. 
 
Fiber Labeling  
Plated 1.5x 105 siRNA transfected U2OS cells in a 35 mm dish. Plated a few extra 
dishes that contained unlabled U2OS cells for dilution. Place 1x HBSS and DMEM in incubator 
to equilibrate overnight. Next day cells were treated with 20 µM IdU for 20 minutes. Cells were 
then washed twice with equilibrated HBSS and then treated with 100 µM CldU for 20 minutes or 
left untreated. For CPT treated cells, added 100 µM CldU and 2.5 µM CPT onto cells and let 
incubate for 45 min. Cells were then washed twice with HBSS, collected by trypsinization, and 
pelleted at 2,000 xg for 3 min. Cells were resuspended in about 200 µL ice cold PBS to get a 
concentration of 1x106 cells/mL.  Labeled cells were diluted 1:2 with non-labeled cells before 
adding 2 µL of cell suspension near the white frosted end of a slide. Cells were lysed in 
spreading buffer (0.5% SDS, 200 mM Tris-HCl pH 7.4, 50 mM EDTA) for 6 min before 
spreading fibers by tilting slide 15°. Slides were air dried for 40 min before fixation in 3:1 
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methanol: acetic acid for 2 min. Air dry the slides for 20 min. Slides can be stored for up to 5 
days at 4°C.  
 Denature the DNA with 2.5 M HCl for 30 min. Rinse slides three times in PBS. Block in 
10% goat serum in PBS with 0.1% Triton X-100. Incubate 1 hour in rat monoclonal anti-BrdU 
(anti-CldU (Abcam, ab6326; 1:00 dilution) and mouse anti-BrdU (anti-IdU Becton Dickinson, 
347580; 1:100 dilution) diluted in PBS containing 10% goat serum and 0.1% Triton X-100. Rinse 
three times in PBS following incubation with primary antibodies. Stain with secondary antibodies 
(Alexa-594 goat anti-rat IgG and Alexa-488 goat anti-mouse (Invitrogen); 1:350 dilutions) diluted 
in PBS containing 10% goat serum and 0.1% Triton X-100 for 30 min in dark. Slides were then 
mounted with 100 µL Prolong Gold. At least 100 fibers were imaged and measured per 
condition.  
 
Flow Cytometry 
BrdU/PI incorporation 
Cells were labeled for 20-40 minutes with 10 µM BrdU prior to drug treatment, 
harvested, washed once in phosphate buffered saline (PBS), resuspended in 70% ethanol and 
incubated at -20°C. Following a wash with 0.5% BSA in PBS, cells were permeabilized and 
DNA denatured by resuspending in 2N HCl in PBS with 0.5% Triton X-100 for 30 minutes. The 
Triton/HCl solution was removed and the cells resuspended for two minutes in 0.1 M sodium 
borate prior to washing once with 0.5% BSA/PBS and incubation in 0.5% BSA/PBS containing 
0.5% Tween-20 and Alexa-488 conjugated mouse mAb to BrdU (Invitrogen, MObu1 antibody 
1:50 in 200ul for 1million cells -- best to count them before harvesting so all samples have same 
numbers) for 30 minutes. Cells were washed once with 0.5% BSA/PBS then resuspended in 
PBS containing 5 mg/mL propidium iodide and 10mg/ml RNase A. Cells were incubated for 2 
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hours at 37 °C or overnight at room temperature before collecting flow cytometry data on a BD 
FACScalibur. Data was analyzed and graphs produced with FlowJo. 
Mitotic index by pH3 S10  
Harvest cells collecting both floating and adherent cells. Resuspend cells in 300 µL of 
cold PBS.  Add 700 µL of cold 100% ethanol and mix immediately to fix cells.  Fix cells for 60 
min or overnight at –20 °C. Following fixation, wash cells twice with cold PBS.  Cells were then 
permeabilized in 1.0 mL of ice cold 0.25% tritionX-100 in PBS for 15 min on ice.  Centrifuge 
cells at 2 min then rinse cells (without pipetting) in PBS/1%BSA. Centrifuge again and 
resuspend cells in 100 µL of room temp PBS/1%BSA with pH3 S10 antibody at 1:400 
dilution.  Incubate for 1 hr at room temperature resuspending cells every 15 minutes by flicking 
tube. Following incubation with antibodies wash twice with PBS/1%BSA.  Next, resuspend cells 
in 100 µL of PBS/1%BSA + anti-rabbit FITC antibody at 1:50 dilution and incubate 30 min at 
room temperature in the dark. Secondary antibodies were removed, and cells washed once with 
PBS/1%BSA and once with PBS. Cells were stained with 25 µg/mL propidium iodide+0.1mg/mL 
RNase in 750 µL of PBS for 30 min at room temperature. Cells were filtered and measured on 
flow cytometer.   
 
Gel filtration 
HEK293T nuclear extract was loaded onto a Superdex 200 column equilibrated with gel 
filtration buffer (150 mM NaCl, 25 mM HEPES pH 7.5, 10% glycerol, 1 mM DTT) and eluted at 
0.20 mL/ min with collection of 0.5 mL fractions. Equal volumes of each fraction were 
immunoblotted directly or immunoprecipitated with anti-ETAA1 antibodies prior to the ETAA1 
immunoblot. 
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 Gene ontology analysis 
ETAA1 and TOPBP1 proteins were analyzed using the ClueGO plugin for Cytoscape 
(Bindea et al., 2009; Shannon et al., 2003). For grouping of GO terms the kappa score was set 
to 0.4 and the number of overlapping genes to combine groups was set to 50%. 
 
Kinase assays 
Kinase assays were performed by Jessica Luzwick as described in (Mordes et al., 
2008a). Assays measuring the basal ATR activity were performed by immunoprecipitating Flag-
ATR protein using anti-Flag M2 agarose beads (Sigma) from TGN buffer (50 mM Tris, 150 mM 
NaCl, 10% glycerol, 1% Tween 20, 5 µg/mL aprotinin, 5 µg/mL leupeptin, 1 mM NaF, 50 mM β-
glycerol phosphate, 1 mM sodium vanadate, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl 
fluoride) cell lysates. Immunoprecipitates were washed three times in TGN buffer, once in TGN 
+ 500 mM LiCl, and twice in kinase buffer (10 mM HEPES at pH 7.5, 50 mM NaCl, 50 mM β-
glycerol phosphate, 10 mM MgCl2, 1 mM diothiothreitol) prior to performing kinase reactions. 
Assays measuring ETAA1 or TopBP1 stimulation of ATR activity were performed by 
immunoprecipitating Flag-ATR/HA-ATRIP complexes using anti-HA agarose beads (Sigma). 
Immunoprecipitates were washed three times in TGN buffer, once in TGN + 500 mM LiCl, and 
twice in kinase buffer prior to performing kinase reactions. GST-TopBP1 AAD or GST-ETAA1 
AAD was added to the reactions prior to adding ATP and substrate. All reactions were stopped 
within the linear range of the assay and analyzed by SDS-PAGE and autoradiography. 
 
Immunofluorescence  
U2OS, HCT116, HeLa, H157, or BT549 cells were washed once with PBS and then 
fixed in 3% paraformaldehyde for 10 min at room temperature. For examining proteins localized 
	 	
	
47	
	
on chromatin, cells were pre-extracted using 0.5% triton X extraction buffer (0.5% triton X, 20 
mM HEPES, pH 7.4, 50 mM NaCl, 3 mM MgCl2, 300 mM sucrose) at 4 °C for 5 min before 
fixation. After fixation, slides were washed three times with PBS and treated with 0.5% Triton X 
in PBS for 5 min at room temperature. Slides were washed three times with PBS then blocked 
with 5% BSA in PBS for 15 min to 1 hour. After blocking, cells were incubated with antibody 
diluted in 1% BSA in PBS for 1 hr to overnight. Slides were removed from primary, washed 
three times with PBS, and then incubated with secondary Alexa fluor antibodies.  Secondary 
antibodies were removed, cells washed three times in PBS, and slides mounted on glass 
coverslips using Prolong Gold mounting media with DAPI. Immunofluorescent images were 
obtained with a Zeiss Axioplan or Nikon microscope with fixed camera exposure times.   
 
Immunoprecipitation 
Most immunoprecipitations (IPs) were completed using nuclear extracts although I have also 
used cells lysates after NP40 lysis. I use 1.5-8 mg of nuclear extract/cell lysate per 
immunoprecipitation. Extract was mixed with 3 μg of antibody and rotated at 4 °C for 1-4 hrs. 
The antibody-extract mixture was combined with 50-80 μL protein A or protein G dynabeads 
after beads were washed three times with dialysis buffer or lysis buffer and rotated at 4 °C for 1 
hr. Beads were magnetically separated from IP mixture using a magnetic rack and flow through 
removed. Beads were washed three times with dialysis buffer or lysis buffer. After last wash 
bound proteins were eluted by addition of 30 μL 2X SDS sample buffer and boiling for 5 min. 
For FLAG IPs proteins were eluted by adding 35 µL of Flag peptide (0.25 mg/mL) and 
incubating on ice for 1.5 hours, flicking tube every 15 min. After elution, beads were 
magnetically separated, and eluate removed and combined with 2X SDS buffer. 
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iPOND (isolation of Proteins on Nascent DNA) 
iPOND protocol is adapted from (Dungrawala and Cortez, 2015).  Plated 9 plates of both 
heavy and light cells at 25 x 106 the day before the experiment. Add 23 µl of the 10 mM EdU 
stock into 23 ml of cell culture medium in each dish to achieve a final EdU concentration of 10 
µM. Pulsed cells for 7.5 minutes. After 7.5 minutes of EdU added 100 µM CPT (15, 30 and 60 
min) and left for indicated time points. After designated CPT treatment time, immediately fix the 
cells on a dish by adding 10 mL of 1% (wt/vol) formaldehyde in PBS and incubating for 10 min 
at room temperature. Quench cross-linking by adding 1 mL of 1.25 M glycine. Collect the 
sample by scraping with a cell lifter and transfer it to a 50-mL conical tube. Note the volume. 
Centrifuge for 5 min at 900xg, 4 °C. Decant the supernatant. Wash pellets three times with PBS 
and centrifuge for 5 min at 900xg, 4 °C. Vortex to resuspend pellets in PBS. Resuspend the 
cells in permeabilization buffer at a concentration of 1 × 107 cells per mL. Incubate the cells at 
RT for 30 min. Spin down for 5 min at 900xg, 4 °C. Wash the cells once with cold 0.5% (wt/vol) 
BSA in PBS, then in PBS. Centrifuge the cells for 5 min at 900xg, 4 °C to pellet after washes. 
Combine the click reaction cocktail reagents on ice to contain a final concentration of 10 mM 
sodium ascorbate, 2 mM CuSO4, 10 µM biotin-azide, in PBS. Resuspend the cell pellets from in 
the click reaction cocktail by vortexing. Combine the heavy and light samples with each other at 
this step. Rotate the reactions at room temperature for 2 hr in the dark. Centrifuge the samples 
for 5 min at 900xg, 4 °C, and decant the supernatants. Wash the cells once with cold 0.5% 
(wt/vol) BSA in PBS, using the same volume as used in click reaction for one sample. Pellet by 
centrifugation for 5 min at 900xg, 4°C, then wash with PBS. Prepare the lysis buffer (1% SDS in 
50 mM Tris-HCl, pH 8.0) by adding aprotinin and leupeptin before use and place on ice. 
Resuspend the samples from at a concentration of 1.5 × 107 cells per 100 µL of lysis buffer and 
transfer them to 1.5-ml centrifuge tubes on ice. – resuspend very slowly with p1000 – NO 
VORTEXING- minimum bubbles. 
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Sonicate the cells by using a microtip sonicator and the following settings: pulse: 20 s 
constant pulse, 40 s pause; power: 13–16 Watts; repeat pulse 1× for every 200 µL of cell lysate; 
total pulse time: 4–5 min per sample. Centrifuge the samples for 10 min at 16,100xg, room 
temperature in a tabletop centrifuge. Filter the supernatant through a 90-µm nylon mesh into a 
new tube. Place the tube on ice. Note the lysate volume. Dilute the lysate 1:1 (vol/vol) with cold 
PBS containing 1 µg/mL of aprotinin and leupeptin. To capture biotin-tagged nascent DNA, 
each sample is incubated with streptavidin MyOne C1 beads using 100 µL for every 10 x 107 
cells. First, gently vortex the vial of dynabeads for 30 sec. Pipette the required volume of beads. 
Note the volume.  Resuspend the beads for all samples together in a total volume of 1 mL lysis 
buffer containing aprotinin and leupeptin. Wash the beads again with 1 mL of lysis buffer 
containing aprotinin and leupeptin. Wash the beads once with 1 mL of PBS containing aprotinin 
and leupeptin; carefully aspirate the supernatant. Resuspend the beads in volume of bead used 
with PBS containing protease inhibitors. Add an equal volume of beads to each sample. Rotate 
the biotin captures at room temperature for 1 hr (in the dark if photocleavable biotin azide is 
used). Separate the dynabeads with the captured DNA and associated proteins for 2 min using 
the magnetic stand. Split into 4 eppendorf tubes. Resuspend in 1 mL of lysis buffer to wash the 
beads. Rotate at room temperature for 5 min. Separate the beads using the magnetic stand and 
aspirate the supernatant. Repeat each wash with Low salt wash buffer, High salt wash buffer 
and LiCl salt wash buffer. Repeat lysis buffer washes 2 more times. Note: second time – use 1 
ml to pool all samples. To elute proteins bound to nascent DNA, add 25 µL of 2X sample buffer 
and resuspend the beads. Incubate the capture sample for 30 min at 95 °C to reverse cross-
links (At intervals of ten minutes, centrifuge the tube at 1000rpm for 1 min and place the tubes 
back in the heat block. Centrifuge the boiled samples for 1 min at 1,000 rpm, room temperature. 
Place the tubes on the magnetic stand. Collect the supernatant. The supernatant is the ‘eluted 
capture’ sample and is ready to use in immunoblotting and Mass spec procedures.  
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NMR analysis 
Two-dimensional 15N-1H HSQC NMR spectra were used to monitor titrations of RPA32C 
and RPA70N with peptides corresponding to ETAA1888-909 and ETAA1594-609. Peptides were 
resuspended in 25 mM Tris, 75 mM NaCl, pH 7.0 and titrated in increments into a sample of 60 
µM, 15N-enriched RPA32C or 100 µM RPA70N in 25 mM Tris, 75 mM NaCl, pH 7.0. Data were 
collected on a 600 MHz Bruker Avance III spectrometer equipped with a 5 mm single-axis z 
gradient inverse cryoprobe. Ten titration points were collected at molar ratios of peptide to 
protein of approximately 1:6, 1:3, 1:1.5, 1:1, 3:1, 5:1, 11:1, 21:1, and 80:1. 
 
NP40 lysis 
For most western blotting experiments, I lysed cells using a NP40 lysis buffer (150 mM 
NaCl, 50 mM Tris-Cl, pH 7.5, 10% glycerol, 0.5% NP40). After trypsinization cells were washed 
once with PBS and pelleted at 1,000 xg for 3 min. Pelleted cells were resuspended in a volume 
of NP40 approximately four-times the pellet size and incubated on ice for 20-30 min. Lysates 
were then cleared by centrifugation at 16,000xg for 15 min at 4 °C. Lysate concentration was 
determined by Bradford assay. Lysates were prepared for SDS-PAGE by addition of SDS-
PAGE buffer and incubation at 95 °C for 5 min.  
 
Nuclear extract preparation 
Wash cells 1x with cold PBS then add 2 mLs of cold PBS and scrape cells into a 50 mL 
conical. Spin cells at 2553 x g for 10 min at 4°C. Record the packed cell volume (pcv) and 
rapidly resuspend the cells in five times the packed cell volume of hypotonic buffer (10 mM 
HEPES pH 7.9, 1.5 mM MgCl2,10 mM KCl, 0.2 mM PMSF, 0.5 mM DTT). Centrifuge cells for 5 
min at 2,553 x g at 4°C.  Resuspend the cells to a volume 3 times the pcv and allow to swell on 
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ice for 10 min. Transfer the cells to a glass Dounce homogenizer. Homogenize cells with 10 
slow strokes. (keep dounce on ice and make sure it has a B type pestle). Transfer cells to 
Eppendorf tubes and centrifuged at 3,300 x g for 15 min at 4 °C. Measure the packed nuclear 
volume (pnv) and resuspend the nuclei in a volume of low-salt buffer (20 mM HEPES pH 7.9, 
25% glycerol, 1.5 mM MgCl2,20 mM KCl, 0.2 mM EDTA, 0.2 mM PMSF, 0.5 mM DTT) equal to 
½ pnv. Add ½ pnv of high-salt buffer (same as low salt buffer but with 1.2 mM KCl) dropwise to 
cells under with gentle mixing (slow vortex or invert tube after every few drops). Allow the nuclei 
to extract for 30 min on rotator in cold room. Pellet the nuclei by centrifuging for 30 min at 
16,000 xg at 4 °C. Remove supernatant as nuclear extract. Dialyze the extract in a 3,500 MW 
dialysis tubing for 1 hour against dialysis buffer (20 mM HEPES, pH 7.9, 10% glycerol, 100 mM 
KCl, 0.2 mM EDTA, 0.2 mM PMSF, 0.5 mM DTT). Remove the extract from the dialysis 
cassette and centrifuge for 20 min at 16,000 x g at 4 °C. After pelleting nuclear debris, collect 
supernatant. This is nuclear extract and can be used for downstream functions such as 
immunoprecipitation.   
 
Packaging Lentiviral Particles 
	
Protocol 1 
	
Day 1: Plate 4-5 x 106 293T cells in a 100mm dish. Cells should be about 80% confluent on the 
day of transfection (Day 2). 
Day 2: Transfect cells with 4 µg lentiviral vector, 3µg psPAX2, and 1µg pMD2.G in 100 µL 
DMEM and add 24µL of 1mg/mL PEI. Incubate for 10-15 minutes at room temperature and add 
to 10 mL of complete media on cells. Also transfected with empty viral vector for empty vector 
control.  
Day 3: Aspirate media, wash cells once in PBS, and add 7 mL DMEM + 10% FBS + Pen/Strep. 
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Day 4: Collect media in a 15 mL tube and place at 4°C. Add another 7 mL media to the 
transfected cells. 
Day 5: Collect media and pool with the media from the day before in the 15 mL tube. Spin the 
collected media at low speed to pellet any cellular debris. Move supernatant to a new 15 mL 
tube and aliquot. Freeze aliquots at -80°C. I suggest making 1mL aliquots. 
Protocol 2 
Day 1: Plate 3-4 x 106 GP2-293 cells in a 100 mm dish. Cells should be about 60% confluent on 
the day of transfection. 
Day 2: Transfect cells with 4 µg pLPCX or appropriate lentiviral vector and 2 µg pVSV-G using 
PEI based transfection method. Dilute DNA in 100mL DMEM or Optimem and add 24mL of 
1mg/mL PEI. Incubate for 10-15 minutes at room temperature and add to 10mL of complete 
media on cells. 
Day 3: Aspirate media, wash cells once in PBS, and add 5-6mL complete media. 
Day 6: Collect media and pass through 0.2 µM filter. Freeze aliquots at -80°C. Make 1mL 
aliquots. 
 
Note: I have used both protocols above successfully although I believe I get better results with 
protocol 2.  
 
Phosphatase treatment of cell lysates 
Took 60 µg of lysate from CPT-treated and untreated cells and added 1.1 µL of 10x 
(Protein MetalloPhosphatases) PMP buffer, 1.1 µL of 10x MnCl, and 1 µL Lambda Protein 
phosphatase. Mixture was incubated for 10, 20, 30, or 60 minutes at 30 °C before reaction was 
stopped by addition of 11 µL 2x SDS Sample buffer and boiling for 5 min. Proteins were 
examined for gel mobility shifts or phospho-specific antibodies by SDS-PAGE. 
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Phosphoproteomics 
Preparation of samples 
For each condition 4.5 x107 HCT116-WT and HCT116-ETAA1ΔAAD or TOPBP1-AID 
cells were grown in heavy (13C) and light (12C) SILAC DMEM with 10% dialyzed FBS. The 
following day, cells were treated with 100 nM CPT following a two-hour pretreatment with 500 
μM IAA. Approximately 7 x 107 cells were harvested for each labeling condition, counted, and 
combined in a 1:1 ratio. Cells were resuspended in hypotonic buffer (10 mM HEPES pH 7.9, 1.5 
mM MgCl2,10 mM KCl, 0.2 mM PMSF, 0.5 mM DTT) for 10 min at 4° C and lysed via dounce 
homogenization. Nuclei were pelleted at 3,300xg for 15 min at 4° C and then resuspended in 
low salt buffer (20 mM HEPES pH 7.9, 25% glycerol, 1.5 mM MgCl2,20 mM KCl, 0.2 mM EDTA, 
0.2 mM PMSF, 0.5 mM DTT) followed by mixing with an equal amount of high salt buffer (same 
as low salt buffer but with 1.6 mM KCl). Following a 30 min incubation at 4 °C nuclear extracts 
were centrifuged for 20 min at 16,000xg.  
The supernatant contained nuclear soluble proteins which were dialyzed (20 mM 
HEPES, pH 7.9, 10% glycerol, 100 mM KCl, 0.2 mM EDTA, 0.2 mM PMSF, 0.5 mM DTT) for 1 
hour at 4° C. Following dialysis, DTT was added to 20 mM and nuclear extract was incubated for 
30 min at room temperature. Denatured proteins were alkylated by addition of 50 mM 
chloroacetamide and incubated for 40 min at room temperature. Phosphoproteins were 
subsequently proteolyzed by treatment with trypsin. The chromatin pellet was resuspended in 
denaturation buffer (8 M Urea, 100 mM Tris pH 8.0, 20 mM DTT) and incubated for 30 min at 
room temperature. Denatured proteins were alkylated by addition of 50 mM chloroacetamide 
and incubated for 40 min at room temperature. Proteins were then proteolyzed by LysC (1:100 
(mg:mg)) and incubated overnight at 30° C. Phosphopeptides were then diluted 1:4 with 
ammonium bicarbonate and then trypsinized.  
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SILAC-labeled samples were combined such that equal protein per light or heavy SILAC 
state were combined for each experimental replicate. To the combined SILAC protein lysates, 
128 uL of trifluoroethanol (TFE) was added to make each sample contain 50% TFE. Proteins 
were reduced by addition of 2uL of 0.5M TCEP for 1h at room temperature, and 
carbamidomethylation was completed by treatment with 4uL of 500mM iodoacetamide for 30 
min in the dark at room temperature. Samples were diluted 10-fold with 100mM Tris HCl, pH 8.0 
to reduce the solution to 5% TFE, and proteins were digested overnight at 37 °C with 
proteomics-grade trypsin (Sigma Chemical Co., St. Louis, MO) at a ratio of 1:25 enzyme to 
protein. The resulting peptides were then desalted by solid-phase extraction (Sep-pak Light C18 
cartridges, WAT023501 Waters corporation, Milford, MA). Digested samples were first acidified 
with TFA, diluted 2-fold with 0.1% TFA, and loaded via syringe onto the Sep-pak SPE material. 
After sample loading, the cartridges were washed with 0.1% TFA, and peptides were eluted with 
60% acetonitrile, 0.1% TFA and 80% acetonitrile.   Three sequential 0.5mL elutions were 
performed, and eluates were reduced to dryness via vacuum centrifugation. 
TiO2 enrichment of phosphopeptides  
Phosphopeptides were enriched as previously described (Chaturvedi et al., 2014). 
Purified tryptic peptides were resuspended in 0.05% heptafluorbutyric acid/ 2% ACN containing 
300 mg/ml lactic acid. Thirty mg of Titanosphere TiO2 5 μm beads (GL Sciences, Japan) were 
used per 1 mg of digested protein. The beads were first washed with 0.05% HFBA/ 80% ACN, 
and then added to the resuspended tryptic peptides. The mixtures were rotated at room 
temperature for 30 min at room temperature, centrifuged for 30 sec at 5,000xg, and the 
supernatant was discarded.  The phosphopeptide-bound beads were washed with 500 µL of 
0.05% HFBA/ 80% ACN containing 300 mg/mL lactic acid and then twice with 500 µL of 0.05% 
HFBA/ 80% ACN. Phosphopeptides were eluted from the TiO2 beads using 500 µL of 0.5M 
ammonia and then twice with 500 µl of 5M ammonia prior to drying by vacuum centrifugation. 
Each eluate was reconstituted in 0.1% formic acid. 
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LC-MS/MS analysis of enriched phosphorylated peptides 
Peptides were loaded onto a self-packed biphasic C18/SCX MudPIT column using a 
Helium-pressurized cell (pressure bomb). The MudPIT column consisted of 360 x 150 μm i.d. 
fused silica, which was fitted with a filter-end fitting (IDEX Health & Science) and packed with 
6cm of Luna SCX material (5μm, 100Å) followed by 4cm of Jupiter C18 material (5μm, 300Å, 
Phenomenex).  Once the sample was loaded, the MudPIT column was connected using an M-
520 microfilter union (IDEX Health & Science) to an analytical column (360 μm x 100 μm i.d.), 
equipped with a laser-pulled emitter tip and packed with 20cm of C18 reverse phase material 
(Jupiter, 3μm beads, 300Å, Phenomenex).  Using a Dionex Ultimate 3000 nanoLC and 
Autosampler, MudPIT analysis was performed with an 11-step salt pulse gradient (25, 50, 75, 
100, 150, 200, 250, 300, 500, 750, and 1M ammonium acetate). Following each salt pulse, 
peptides were gradient-eluted from the reverse analytical column at a flow rate of 350nL/min, 
and the mobile phase solvents consisted of 0.1% formic acid, 99.9% water (solvent A) and 0.1% 
formic acid, 99.9% acetonitrile (solvent B). For the peptides from the first 10 SCX fractions, the 
reverse phase gradient consisted of the following: 1-6min, 2 %B (salt loading from 
autosampler); 6-83 min, 2-50 %B; 83-84 min, 50 %B, 84-84.5 min, 50-2 %B; 84.5-95min, 2 %B 
(column equilibration). For the last SCX-eluted peptide fraction, the peptides were eluted from 
the reverse phase analytical column using a gradient of 1-6min, 2 %B (salt loading from 
autosampler); 6-83 min, 2-98 %B; 83-84 min, 98 %B, 84-84.5 min, 98-2 %B; 84.5-95min, 2 %B 
(column requilibration). Peptides were introduced via nano-electrospray into a Q Exactive Plus 
or Q Exactive HF spectrometer (Thermo Scientific). For each sample analyzed, the Q Exactive 
instrument was operated in data-dependent mode acquiring HCD MS/MS scans after each MS1 
scan on the 15 most abundant ions using an MS1 ion target of 3 × 106 ions and an MS2 target 
of 1 × 105 ions.  The HCD-normalized collision energy was set to 27, dynamic exclusion was 
set to 30 s, and peptide match and isotope exclusion were enabled. 
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For peptide and protein identification, data were analyzed using the Maxquant software 
package, version 1.3.0.5 (Cox and Mann, 2008; Cox et al., 2011). MS/MS spectra were 
searched again the human subset of the UniprotKB protein database. Precursor mass tolerance 
was set to 20ppm for the first search, and for the main search, a 6ppm precursor mass 
tolerance was used. The maximum precursor charge state was set to 6. Modifications included 
oxidation of methionine, carbamidomethylation of cysteine, N-terminal acetylation, and 
phosphorylation of serine, threonine, and tyrosine. Enzyme specificity was set to trypsin, and a 
maximum of 2 missed cleavages were allowed. The false discovery rate (FDR) for peptide and 
protein identifications was set to 1%. SILAC peptide ratios were obtained from the MaxQuant 
Evidence table. 
Phosphoproteomics Analysis 
Prior to analysis, the outputs from MaxQuant were filtered to remove reverse sequences 
and known contaminants. The SILAC ratios for each experiment were log2 transformed using 
Perseus. The median value for each phosphosite was calculated for the nuclear extract (NE) 
and chromatin pellet (CP) fractions. Phosphosites that were observed at least twice with a 
median change in abundance in activator-deficient cells of at least 1.5 fold in either the nuclear 
soluble or chromatin fractions are reported as dependent on that activator. ATR and CHK1 
phosphorylation motifs were analyzed using Icelogo (Colaert et al., 2009). Comparison of 
ETAA1 and TOPBP1 phosphorylation sites at kinetochores was performed using Phosphopath, 
a Cytoscape application (Raaijmakers et al., 2015; Shannon et al., 2003).  
 
Protein purification 
Induction of protein 
Transformed Artic express cells with GST expression vector. Following day pick colonies 
from Artic Express Cell transformation plate to test for induction. Inoculated 1mL LB + 20 µg/ml 
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gentamycin + kanamycin using a single colony and incubated overnight at 37°C. Removed 60 
μL overnight culture and inoculated 3 mLs LB (NO ANTIBOTICS) for each sample. Incubated 
cultures for 3 hrs at 30°C at 250 rpm. Removed 100 µL from each culture to save as uninduced 
sample. Transferred cultures to 13°C at 250 rpm for 10 minutes. Added 1mM IPTG to each 
culture and incubated at 13°C at 250 rpm for 24 hours.  Removed 100 µL from each culture for 
induced sample. Ran samples on a 10% SDS-PAGE gel to check for induction.  
Took two of the 1 mL overnight cultures and inoculated 200 mL of LB without antibiotics 
at 37 °C, periodically checking OD600. Once OD600 reaches ~0.6 (about 2 hours), induce 
bacteria with 200µl of 1M IPTG to give a final concentration of 1mM IPTG. Note: make 1M IPTG 
fresh each time. Incubate cultures at 12 °C for 24 hrs. After induction, pellet bacteria at 5,000xg 
for 15 min at 4°C. Remove supernatant and store pellet at -20°C until ready to purify protein. 
Purification of protein 
Resuspend bacterial pellet in 15 mL (7.5mL/100mL bacterial culture) pre-chilled NET 
buffer (25mM Tris pH 8.0, 50mM NaCl, 0.1mM EDTA, 5% Glycerol, 1mM DTT, 0.1mM PMSF, 
Aprotinin, Leupeptin). Transfer to round bottom 40mL tube and sonicate suspension 3 times in 
cold room. (Setting 4, Duty cycle 90, 15 seconds). After 3 sonications removed half of culture 
and sonicated 3 more times. Incubate suspension on ice for 1 minute between sonications. After 
sonication, add 780 μL of 20% Triton X-100 to 15 mLs of bacteria to get a 1% final 
concentration. Incubate on ice for 30 minutes and then centrifuge at 5,000 x g for 10 min at 4°C. 
Meanwhile, aliquot 200 µL glutathione sepharose bead slurry in microcentrifuge tube. Wash 
beads twice with 1 mL of NET buffer. For washes, centrifuge beads at 500 x g for 1 minute. 
Transfer supernatant (cleared lysate) to new tube. Save 20 µL sample of cleared lysate and 
20µL sample of pellet to run on gel. Pellet can be stored at -20 C 
Incubate cleared lysate with washed glutathione beads on rotator for 2.5 hrs. Wash 
beads three times with 10 mL NET buffer and 1% Triton-X. 
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Meanwhile, prepare Elution buffer (75mM Tris pH 8.0, 15 mM Glutathione, 0.1 µg/µL Leupeptin) 
Note: For 1mL of buffer: 75µL of 1M Tris pH 8.0, 4.61mg Glutathione, 1µL Leupeptin stock 
After washes, transfer beads to microfuge tube, spin down beads (30sec, 1,000xg) and remove 
supernatant. Add 200µL elution buffer to 200µL bead slurry (equal volumes). For each elution, 
incubate on rotator for 5 min at room temp, then centrifuge beads at 500xg for 30-60 s. Remove 
supernatant and store on ice. Repeat for a total of four elutions, keeping each elution separate. 
Take 20µL sample of each elution and 10µL sample of beads. Examine purification strategy by 
running the following samples on gel: Cleared lysate, pellet, beads before elution, each elution 
sample (4), beads after elution. Coomassie stain gel. Combine desired elutions and proceed 
with dialysis. 
 
Proximity ligation assay 
Cells were plated and fixed as described for other immunofluorescence experiments. 
After fixation, cells were blocked with Duolink Blocking solution in PBS for 1 hour at 37 °C. Cells 
were incubated in primary antibodies diluted 1:200 in Duolink antibody diluent for 1 hour at 
37°C.  Slides were removed from primary and washed twice for five minutes in 1x Wash Buffer 
A at room temperature. Slides were incubated with Secondary PLUS and MINUS antibodies 
diluted 1:5 in Duolink Antibody Diluent for 1 hour at 37 °C. Slides were removed from secondary 
antibodies and washed twice for five minutes in 1x Wash Buffer A. Diluted ligase 1:40 in 1x 
ligation buffer incubate for 30 min at 37 °C. Removed slides from ligation mixture and washed 
twice for five minutes in 1x Wash Buffer A. Diluted polymerase 1:80 in 1x amplification solution. 
Added polymerase to slides and incubate for 100 min at 37 °C. Removed amplification buffer 
and washed twice for 10 min in 1x Wash buffer B. Then washed slides in 0.01x Wash Buffer B 
for one minute.  Slides were mounted with 12µL Duolink In Situ Mounting Medium containing 
DAPI and sealed with clear nail polish. Slides were imaged on a Nikon Eclipse scope.   
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Sister chromatid exchange assay 
Protocol was adapted from (German and Alhadeff, 2001). The next morning after siRNA 
transfection, added BrdU to final concentration of 10 µM to cells. Covered plates with aluminum 
foil and left in incubator for 48 hours (2 cell cycles). After 48 hours added colcemid to a final 
concentration of 150 ng/mL (60 µL of 10 µg/mL stock for 4 mLs in 6 well dish). Enriched for 
mitotic cells for 2-4 hours. Transferred medium (floating cells) and trypsinized cells to new tube. 
Spin cells at 180 xg for 5 min. Aspirate supernatant leaving 0.2 mL media and resuspend cells 
gently tapping bottom of the tube. Add 6 mLs of prewarmed (37 °C) 75 mM KCL dropwise for 
first 1 mL while gently vortexing. Incubate for 16 min at 37 °C. Add four drops of fixative (3:1 
solution of methanol: glacial acetic acid), gently invert and spin down cells at 180 x g for 5 min. 
Aspirate supernatant leaving 0.2 mL of 75 mM KCl solution. Resuspend pellet by gently tapping 
and add 5 mL of freshly prepared fixative dropwise for the first 1 mL while gently vortexing. 
Incubate for 20 min at 4 °C. Spin down cells at 180 xg for 5 min. Repeat washes in fixative three 
times. Resuspend the pellet in small volume of fixative (200 µL) until the cell suspension looks 
slightly cloudy. Slides should be prechilled in freezer before use. Draw cells into plastic transfer 
pipet (or cut off bottom of yellow pipet tip). Hold 6 in (15 cm) above the slide and place 2 drops 
onto the slide with enough room for the drops not to touch. Stand slides on a slant to dry (use 
tilted racks for fiber labeling) covering with foil. After a few hours move slides to dark drawer to 
let dry for 2-3 days. Stain slides with 0.1 mg/mL acridine orange in dH2O for 5 min at room 
temperature. Wash slides extensively for 2 min under running dH2O tap water. Put them in 
coplin jar and let water pour over them. Incubate slides for 1 min in Sorenson Buffer, pH 6.8 (0.1 
M Na2HPO4, 0.1 M NaH2PO4) and then mount in Sorenson buffer. To mount place two 75 µL 
drops on slide and then place rectangular slide on top View immediately on scope at 100 x 
using YFP filter. Count the number of SCEs per spread. 
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Viability assay using alamar blue 
Trypsinize U2OS cells and plate in 96-well plate at a density of 4,000 (4x103) cells per 
well in a volume of 100 µL. For a full 96 wells prepare 15 mL of DMEM + 7.5% FBS with 6x105 
cells to give 4x103 cells/100 µL. Prepare drug dilutions at 10X higher than the desired 
concentration and add 10µL of drug per well. Drug ranges are given below: 
Range of drug dilutions:  
Camptothecin     0.01 µM-1 µM  
Olaparib (Parp inhibitor)    1 µM- 100 µM 
BMN673      10 nM-1 µM 
Etoposide      1-100 µM  
Cisplatin      0.1 µM-10 µM 
MMS      0.0005%-0.05% 
Mitomycin C     2.5-250 ng/mL 
Formaldehyde     0.1 µM-1 mM 
Bleomycin      5-500 nM  
HU       0.1-10 mM 
 
After 24 hours of drug treatment, cells were washed once with DMEM then replace with 
fresh full media. Olaparib and BMN763 were not washed out. Three to four days after drug 
treatment, media was removed and replaced with DMEM+7.5% FBS supplemented with alamar 
Blue. The alamar blue stock is 10X, so dilute alamar blue 1:10 in media. Return cells to 
incubator for 4-5 hours. Read on plate reader.  
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CHAPTER III 
 
ETAA1 ACTS AT STALLED REPLICATION FORKS TO MAINTAIN GENOME INTEGRITY 
 
Introduction 
DNA replication is challenged by difficult to replicate sequences, DNA damage, and 
collisions with transcriptional machinery. DNA damage response (DDR) pathways respond to 
replication stress to maintain genome stability, and DDR defects cause developmental disorders 
and cancer (Ciccia and Elledge, 2010) (Zeman and Cimprich, 2014).  
Replication protein A (RPA) binds and protects single-stranded DNA (ssDNA) at stalled 
replication forks (Fanning et al., 2006). It also recruits DDR proteins such as ATRIP which is 
part of the ATR/ATRIP checkpoint kinase complex (Zou and Elledge, 2003; Ball et al., 2005; 
Cortez et al., 2001). ATR is then activated by a direct interaction with TOPBP1 (Kumagai et al., 
2006), which requires RHINO, and the RAD9/RAD1/HUS1 (9-1-1) and MRE11/RAD50/NBS1 
(MRN) complexes for its ATR-activating function (Lindsey-Boltz et al., 2015; Cotta-Ramusino et 
al., 2011; Duursma et al., 2013). In budding yeast, there are at least three Mec1ATR-activating 
proteins including Dpb11 (a TOPBP1 orthologue), Ddc1, and Dna2 (Mordes et al., 2008b; 
Navadgi-Patil and Burgers, 2009, 2008a; Kumar and Burgers, 2013). As yet, TOPBP1 is the 
only known ATR activator in mammals. 
A second RPA interacting protein at stalled forks is the BLM helicase (Brosh et al., 
2000). Mutations in BLM cause Bloom syndrome (Ellis et al., 1995), and BLM-deficient cells 
suffer from chromosomal abnormalities such as an increase in sister chromatid exchanges 
(SCEs) (Chaganti et al., 1974; Croteau et al., 2014). BLM functions with Topoisomerase IIIα, 
RMI1, and RMI2 (BTR complex) to generate non-cross over products during recombination 
(Plan
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2006; Xu et al., 2008a). TOPBP1 interacts with BLM and regulates its ability to prevent SCEs 
through a mechanism reported to be independent of its ATR activating function (Blackford et al., 
2015; Wang et al., 2013).  
ETAA1 is an uncharacterized protein that derives its name from a study of Ewing tumor 
antigens (Borowski et al., 2006). Additionally, ETAA1 was identified as an ATM/ATR substrate 
(Matsuoka et al., 2007), and genome wide association studies found single nucleotide 
polymorphisms at the ETAA1 locus increase pancreatic cancer risk (Childs et al., 2015a; Wu et 
al., 2012). We find that ETAA1 is a replication stress response protein that localizes to stalled 
forks via a direct interaction with RPA. It also interacts with several other DDR proteins including 
ATR/ATRIP and the BTR complexes. ETAA1 maintains genome integrity by activating ATR 
using a motif that has sequence similarity to the TOPBP1 ATR-activation domain (AAD). 
Furthermore, ETAA1 acts in a distinct pathway from TOPBP1.  
 
Results 
 
ETAA1 is an RPA-interacting protein that localizes to stalled forks 
 We recently conducted a proteomic screen utilizing iPOND (isolation of Proteins On 
Nascent DNA) combined with quantitative mass spectrometry to identify proteins enriched at 
stalled replication forks (Dungrawala et al., 2015). Samples treated with hydroxyurea (HU) for 
15 minutes or two hours were compared to untreated cells (Fig. 3.1A). 72 proteins are 
significantly enriched at the HU-stalled forks compared to elongating forks at these times 
(Dungrawala et al., 2015). These include known DDR proteins like ATR, RPA, BLM, 
SMARCAL1, BRCA1, FANCJ, MMS22L, and TONSL as well as ETAA1 (Fig. 3.1B).   
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Figure 3.1 ETAA1 is enriched at stalled replication forks and interacts with RPA. (A) HEK293T cells 
grown in heavy isotope media and incubated with EdU and HU were compared to EdU-labeled cells grown 
in light isotope media. Replication fork proteins were isolated and detected by iPOND and mass 
spectrometry. (B) The log2 of the average abundance ratio for selected proteins or complexes is depicted. 
(C) Flag-RPA1 was immunopurified from HEK293T nuclear extracts and interacting proteins were identified 
by mass spectrometry. The table indicates the number of peptides identified for each protein. The control 
sample was an immunopurification from untransfected cells.  (D) HEK293T cells were transfected with a 
Flag-ETAA1 or empty expression vector (EV), and nuclear extracts used for immunoprecipitation with Flag 
antibodies. Immunoprecipitates were immunoblotted with the indicated antibodies after separation by 
SDS-PAGE. Representative blots from one of five independent experiments are shown. (E) Nuclear 
extracts from HEK293T cells were used for immunoprecipitation with RPA2 or control IgG antibodies 
followed by immunoblotting. Representative blots from one of two independent experiments are shown. 
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A proteomic screen to identify RPA-interacting proteins also identified ETAA1 (Fig. 3.1C). We 
validated the interaction by co-immunoprecipitation of RPA with Flag-ETAA1 (Fig. 3.1D). 
Additionally, RPA2 co-immunoprecipitates with endogenous ETAA1 (Fig. 3.1E).  
While a previous study identified ETAA1 on the cell surface or in the cytoplasm 
(Borowski et al., 2006), we found ETAA1 is localized exclusively in the nucleus. Overexpressed 
Flag-ETAA1 localizes to intranuclear foci in approximately 25% of cells and is diffusely pan-
nuclear in others (Fig. 3.2A). When it is localized to foci, ETAA1 co-localizes with RPA (Fig. 
3.2A). Overexpressed ETAA1 is also localized in foci when cells are treated with agents that 
cause replication stress including camptothecin (CPT), cisplatin (CISP), and hydroxyurea (HU) 
(Fig. 3.2B). These ETAA1 foci also co-localize with RPA and partially co-localize with γH2AX.   
The untreated cells overexpressing ETAA1 with focal localization almost invariably 
contained elevated γH2AX levels, and many of the cells with pan-nuclear ETAA1 also contain 
elevated γH2AX suggesting that ETAA1 overexpression stimulates DNA damage signaling (Fig. 
3.2C). To better assess how ETAA1 localizes without overexpression, we generated stable cell 
lines by lentiviral infection and used fluorescence activated cell sorting to select for the 10% of 
cells with the lowest GFP-ETAA1 levels. In over 95% of these cells, ETAA1 is localized diffusely 
throughout the nucleoplasm, but after treatment with CPT, it localizes to nuclear foci that also 
contain RPA and γH2AX (Fig. 3.2D, E). Most cells with ETAA1 foci also contained cyclin A 
indicating they are in S or G2 phase (Fig. 3.2F). We conclude that ETAA1 overexpression 
induces DNA damage signaling and ETAA1 focal accumulation, but that when it is expressed at 
lower levels it is primarily recruited to replication foci in response to stress. 
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Figure 3.2 ETAA1 colocalizes with RPA at sites of replication stress.  (A-C)  U2OS cells were 
transiently transfected with a Flag-ETAA1 expression vector and stained and imaged for Flag-ETAA1, RPA, 
and γH2AX. Scale bars are 5 µm. In (B) cells were treated with HU, cisplatin, or camptothecin (CPT) for 3 
hrs.  (D-F) Stable cell lines expressing GFP-Flag-ETAA1 were sorted by flow cytometry to select the 10% 
of cells expressing the lowest levels, stained for Flag-ETAA1, RPA, γH2AX, and cyclin A as indicated, and 
scored for focal co-localization before and after treatment with 100 nM CPT. Error bars are SEM from n=3 
experiments; student’s, two-tailed, unpaired t-test. 
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ETAA1 binds two RPA domains to recruit it to damaged forks 
To test whether the interaction with RPA recruits ETAA1 to stalled forks, we first examined a 
series of ETAA1 fragments for their ability to co-immunoprecipitate RPA. RPA binding is largely 
restricted to an ETAA1 fragment containing amino acids 571-926 (Fig. 3.3 A,B). Sequence 
alignments identified an evolutionarily conserved motif within this fragment consisting of amino 
acids 900-912 that closely resembles the RPA32C binding motif of other RPA32C-interacting 
proteins including SMARCAL1 and TIPIN (Bansbach et al., 2009; Mer et al., 2000) (Fig. 3.4A). 
An NMR chemical shift perturbation approach demonstrated that this ETAA1 motif binds directly 
to the same surface of RPA32C as previously observed for other RPA32C-interacting proteins 
(Mer et al., 2000; Feldkamp et al., 2014) (Fig. 3.4B,C) 
Deletion of the ETAA1 RPA32C interaction motif (ETAA1Δ32) greatly reduced but did 
not eliminate its ability to associate with RPA and localize to foci (Fig. 3.3 E, and Fig. 3.4 D-F). 
Knockdown of RPA70 in cells expressing ETAA1Δ32 abrogated this residual localization 
suggesting an additional RPA-interaction surface (Fig. 3.3F). Indeed, fragments of ETAA1 
containing either residues 600-678 or 574-724 co-immunoprecipitate RPA; whereas ETAA1 
fragments containing residues 2-569, 623-885 or 623-724 do not (Fig. 3.3A,C, D), thereby 
narrowing the interacting motif to amino acids 600-623. This region has sequence homology to 
the RPA70N-interacting peptides of ATRIP, MRE11, RAD9, and p53(Xu et al., 2008b) (Fig. 
3.4G). NMR chemical shift mapping with this ETAA1 peptide indicates that it directly binds the 
basic cleft in RPA70N (Fig. 3.4H). Deletion of this motif in ETAA1 (ETAA1Δ70) caused a slight 
reduction in RPA co-immunoprecipitation, and modest impairment in localization to RPA foci 
(Fig. 3.3 E, and Fig. 3.4 E,F). Deletion or mutation of both RPA binding motifs largely abolished 
RPA co-immunoprecipitation and eliminated focal accumulation (Fig. 3.3E,G, and Fig. 3.4E,F). 
Thus, ETAA1 interacts with both the 70N and 32C domains of RPA, and these interactions 
recruit ETAA1 to stalled replication forks.  
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Figure 3.3 RPA recruits ETAA1 to damaged replication forks.  (A) Schematic of ETAA1 fragments tested for their 
ability to bind RPA. (B-D) Nuclear extracts were prepared from HEK293T cells after transfection with the indicated 
GFP-Flag-NLS-ETAA1 expression vectors. Flag immunoprecipitates were separated by SDS-PAGE and examined 
by immunoblotting. Mock, mock-transfected. Cells were treated with 100 nM CPT for 3 hrs prior to lysis where 
indicated. The interaction between ETAA1 and RPA was not changed substantially in cells treated with CPT. 
Representative blots from one of two independent experiments are shown. (E) Quantitation of cells containing 
ETAA1 foci after transfection with the indicated ETAA1 expression vectors. Mean and SEM from n=3 experiments 
is shown. (F) U2OS cells were transfected with an ETAA1 expression vector missing the C-terminal RPA32 
interaction motif (ETAA1Δ32) in combination with non-targeting or RPA siRNA and imaged for ETAA1 and RPA 
localization after a challenge with 100 mM CPT. (G) ETAA1Δ cells were transduced with lentivirus to express empty 
vector (GFP-Flag), GFP-Flag-ETAA1 (WT), or GFP-Flag-ETAA1 with point mutations (residues 606-611 mutated 
from DVDDDL to NAAIRS) in the RPA70N motif and deletion of the ETAA1-RPA32C (deletion of residues 885-926) 
interaction motif (ETAA1∆RPA).  Cells were treated with 100 nM CPT for 3 hrs. RPA, and Flag-GPF-ETAA1 were 
visualized by immunofluorescence. Representative images from one of two independent experiments in F and G 
are shown. Scale bars are 5 µm. 
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Figure 3.4 ETAA1 interacts with RPA through the RPA32C and RPA70N domains. (A) Sequence alignment of 
ETAA1 900-912 with the RPA32C binding motif of other RPA32C-interacting proteins. (B) Plot of RPA32C chemical 
shift perturbations induced by the binding of the ETAA1 peptide calculated from 15N-1H HSQC NMR spectra of 
15N-labeled RPA32C obtained in the absence and presence of peptide. (C) Map of RPA32C residues with chemical 
shift perturbations greater than one standard deviation (SD) above the mean (red) on the structure of RPA32C (PDBID 
4OU0). (D) Schematic diagram of ETAA1 mutants examined in E and F. (E) Nuclear extract from HEK293T cells mock 
transfected or transfected with ETAA1 expression constructs were used for immunoprecipitation with Flag antibodies; 
FL, full length. Immunoprecipitates were immunoblotted with Flag or RPA2 antibodies. (F) U2OS cells were transfected 
with the indicated ETAA1 expression vectors and treated with 100 nM CPT for 3 hrs prior to examining ETAA1 and RPA 
localization. Scale bars are 5 µm. (G) Sequence alignment of ETAA1599-611 with the RPA70N-interaction motif of 
other RPA70N-interacting proteins. (H) Map of RPA70N residues with chemical shift perturbations greater than one SD 
above the mean (red) on the structure of RPA70N (PDBID 2B29) calculated from NMR 15N-1H HSQC spectra of 
15N-labeled RPA70N obtained in the absence and presence of ETAA1 peptide. All panels are representative of two 
experiments.
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ETAA1 is a replication stress response protein  
To determine if ETAA1 has an essential function in the replication stress response, we 
examined the consequences of ETAA1 gene silencing. Even in untreated U2OS cells, ETAA1 
knockdown caused an increase in the appearance of DNA damage markers including increased 
γH2AX and chromatin-associated RPA (Fig. 3.5A, B). These differences were more pronounced 
in cells challenged with either HU or CPT, and happened in multiple cancer cell lines including 
HeLa, H157, and BT549 (Fig. 3.6 A, B). The increase in chromatin-associated RPA suggested 
that there may be additional ssDNA in ETAA1-deficient cells. Indeed, staining with BrdU 
antibodies in non-denaturing conditions confirmed this ssDNA increase (Fig. 3.5C).  
ETAA1 knockdown resulted in hypersensitivity to CPT as well as etoposide (Fig. 3.5D-
G). This phenotype is not due to off-target effects since multiple siRNAs cause hypersensitivity 
(Fig. 3.6C). Furthermore, we generated ETAA1Δ cells using CRISPR-Cas9 and again found that 
two independent knockout cell lines were hypersensitive to CPT and contain elevated ssDNA 
levels (Fig. 3.5 C,D,H). Additionally, expression of a wild-type ETAA1 cDNA in ETAA1Δ cells 
was able to complement this defect (Fig. 3.5I). ETAA1-deficient cells are also hypersensitive to 
HU (Fig. 3.5J). Hypersensitivity is not limited to ETAA1-deficient U2OS cells as knockdown of 
ETAA1 in most other cell types also caused hypersensitivity to both CPT and HU (Fig. 3.6 D-K). 
However, we did not observe increased sensitivity to ionizing radiation, cisplatin, or the PARP 
inhibitors Olaparib or BMN673 in ETAA1-deficient cells (Fig. 3.7 A-D).  
In the absence of added genotoxic stress, ETAA1-deficient cell populations exhibited 
slightly higher percentages of cells with greater than 2n DNA content compared to controls (Fig. 
3.8A) consistent with some difficulty in DNA replication. After HU challenge, control cells rapidly 
resume DNA synthesis and complete the cell division cycle by 16 hrs. ETAA1 knockdown 
resulted in a slightly slower recovery with fewer cells able to complete the cell division cycle 
(Fig. 3.8B). The differences between control and ETAA1-deficient cells were even  
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Figure 3.5. Loss of ETAA1 results in increased DNA damage and sensitivity to DNA damaging agents. (A,B) 
U2OS cells transfected with non-targeting (NT) or ETAA1 siRNAs were left untreated (Unt), or treated with 2 mM HU 
or 100 nM CPT for 3 hrs. Soluble proteins were extracted with detergent prior to fixation. γH2AX and RPA intensity 
were quantified by immunofluorescence imaging. (C) U2OS cells transfected with siRNA or ETAA1Δ U2OS cells were 
labeled with BrdU for 24 hrs and then treated with CPT for 3 hrs as indicated. Cells were fixed and stained with BrdU 
antibodies in non-denaturing conditions to measure ssDNA levels. In A-C the intensity of each nucleus and mean 
intensity from a representative experiment of at least two independent experiments is shown. Significance was 
determined by the Mann-Whitney test. ***p<0.001 The numbers avove each sample indicates the n value, which 
represents the number of nuclei imaged. (D) Immunoblot to confirm ETAA1 siRNA knockdown and gene deletion. A 
cross-reacting protein that migrates at a similar position as ETAA1 is observed in some ETAA1 immunoblots. (E) 
Nuclear extracts were prepared from U2OS cells transfected with pooled ETAA1 siRNAs and ETAA1 was detected by 
immunoblotting after SDS-PAGE. Star denotes cross-reacting protein. (F-G) U2OS cells were transfected with NT, 
ETAA1, or ATR siRNAs and treated with CPT or etoposide for 24 hrs. Viability compared to untreated cells was 
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expressing wild type ETAA1 were also examined. In all viability assays, the mean viability from three technical 
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Figure 3.6. ETAA1 knockdown causes hypersensitivity to replication stress. (A,B) HeLa, H157, and BT549 cells 
transfected with non-targeting (NT) or ETAA1 siRNAs were left untreated or treated with 100 nM CPT for 3 hrs. Cells 
were fixed and RPA foci and γH2AX intensity were quantified by immunofluorescence imaging. The intensity of each 
nucleus, mean intensity, and number of nuclei imaged is depicted. (C) U2OS cells were transfected with non-targeting 
or ETAA1 siRNAs. All siRNAs target different regions of the ETAA1 coding sequence or 3’ UTR. siE1, siE3, and siE3 
are different from the four ETAA1 siRNAs in the pool. Viability was measured 48 hrs after challenging the cells with 0.5 
µM CPT for 24 hrs. Data show the mean of three independent experiments for siNT and siETAA1 pool and two for the 
other siRNAs. (D-K) HeLa, HCT116, H157, and BT549 cells were transfected with non-targeting or ETAA1 siRNAs and 
viability was measured 72 hrs after challenge with CPT or HU. Data show the mean from three technical replicates.
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Figure 3.7 ETAA1 knockdown does not cause sensitivity to all DNA damaging agents (A) U2OS cells were 
transfected with non-targeting or ETAA1 siRNAs and exposed to 0, 3, or 5 Gy ionizing radiation. Cell viability was 
determined by clonogenic assay. (B-D) U2OS cells were transfected with non-targeting or ETAA1 siRNAs and viability 
was measured 72 hrs after challenge with cisplatin, olaparib, or BMN673. ATR siRNA was used as a positive control. 
In A-D the mean viability from from three replicates. One representative experiment is shown and the experiments 
were completed twice independently. 
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more pronounced upon treatment with CPT. These cells accumulated in early to mid S-phase 
and were largely unable to complete DNA synthesis after removing CPT (Fig. 3.8C).  
To confirm that ETAA1-deficient cells have difficulty in DNA replication in response to 
replication stress, we performed DNA fiber labeling experiments. Elongation rates in 
unchallenged ETAA1Δ and control U2OS cells are similar (0.21±0.01 µm/min and 0.20±0.01 
µm/min respectively).	ETAA1Δ cells treated with CPT exhibit significant shortening of replication 
track lengths compared to controls consistent with increased fork collapse (Fig. 3.9A, B). We 
also observed an increase in origin firing in ETAA1Δ cells (Fig. 3.9C). Furthermore, neutral 
comet assays indicate that ETAA1-deficient cells contain elevated levels of double-strand 
breaks with and without added replication stress (Fig. 3.9D). Thus, we conclude that ETAA1 is 
needed to maintain replication fork stability. 
 
ETAA1 interacts with multiple DDR proteins including ATR and BLM 
ETAA1 lacks any predicted domain structure other than a potential coiled-coil motif. To 
determine if it exerts its genome maintenance functions through protein-protein interactions we 
immunopurified Flag-ETAA1 and identified ETAA1-interacting proteins by mass spectrometry. 
As expected, all three subunits of RPA were observed in the ETAA1 immunopurifications (Fig. 
3.10A). In addition, ETAA1 complexes contain many proteins that act at damaged replication 
forks including all four subunits of the BTR complex, both subunits of the ATR/ATRIP 
checkpoint kinase complex, BRCA1, BRCA2, HLTF, FANCM and FANCJ.  
We validated that overexpressed ETAA1 interacts with BLM, HLTF, BRCA1, BRCA2 and 
ATR/ATRIP in co-immunoprecipitation experiments (Fig. 3.10B, C). In contrast, we did not 
observe FANCD2 in the ETAA1 immunoprecipitates. ETAA1 co-fractionates with BLM, TOP3α, 
and RMI1 over a size exclusion column (Fig. 3.10D). Some ATR, RPA2 and HLTF also co- 
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Figure 3.9 ETAA1 promotes fork stability. (A-B) Wild-type or ETAA1 knockout cells were labeled with 
CldU and IdU and treated with 100 nM CPT as indicated during the second labeling period. DNA fibers 
stretched on a microscope slide were stained with IdU and CldU antibodies, imaged, and the lengths of 
fiber tracks measured. n=107 and 116 fibers for WT and ETAA1∆ respectively. One of two biological 
replicates is shown. (C) The percent of new origins (red only fibers) were also quantitated. n=500 fibers for 
WT and 508 fibers for ETAA1Δ. (D) U2OS cells transfected with non-targeting or ETAA1 siRNAs and left 
untreated or treated with 1 µM CPT for 1 hr were subjected to a neutral comet assay to measure 
double-strand breaks. The box depicts 25-75%, whiskers are 5-95%, and the line is the median value. The 
numbers of comets measured (n values) from one of two independent experiments are indicated.
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Figure 3.10 ETAA1 interacts with multiple DNA damage response proteins. (A) Flag-ETAA1 was 
immunoprecipitated from nuclear extracts of HEK293T cells, and immunoprecipitated proteins were 
identified by mass spectrometry. Extracts in the second replicate were treated with benzonase and RNAse 
prior to the immunopurification. Shown are peptide counts from two experiments including untransfected 
cell populations (Ctl). (B,C) HEK293T cells were mock transfected (lanes 1 and 3) or transfected with a 
Flag-GFP-ETAA1 expression vector (lanes 2 and 4) and ETAA1 was immunoprecipitated using Flag 
antibodies. Co-precipitating proteins were separated by SDS-PAGE and detected by immunoblotting. (D) 
HEK293T nuclear extracts were fractionated on a Superdex 200 column. Protein fractions were then 
separated using SDS-PAGE and immunoblotted with the indicated antibodies. To detect ETAA1, it was 
immunoprecipitated from the fractions prior to immunoblotting. The reason ETAA1 migrates as a doublet in 
some gel conditions is not known but may represent post-translational modifications. 
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fractionate in these high molecular weight complexes. Thus, ETAA1 likely participates in one or 
more large DDR protein complexes.  
 
ETAA1 activates ATR 
 Since ETAA1 interacts with ATR and ATRIP we next asked whether it participates in the 
ATR signaling pathway by examining ATR substrate phosphorylation. We observe a modest 
decrease in RPA phosphorylation in U2OS cells transfected with ETAA1 siRNA (Fig. 3.11A). 
This difference cannot be explained by decreased RPA association with damaged replication 
forks in ETAA1-deficient cells since there is actually an increase in chromatin-associated RPA 
(Fig. 3.5B). Quantitation of multiple experiments confirmed the differences in RPA 
phosphorylation in two clones of ETAA1Δ HEK293T cells (Fig. 3.11B, C). Decreased RPA 
phosphorylation following ETAA1 knockdown was also observed in HeLa, HCT116, H157, 
BT549, and A549 cells (Fig. 3.11E). In contrast to RPA, ATR-dependent CHK1 phosphorylation 
was largely unaffected by ETAA1 inactivation (Fig. 3.11A,D,E). There is a change in ETAA1 
protein migration and detection on immunoblots following treatment with CPT consistent with it 
being an ATM/ATR substrate (Fig. 3.11E) (Matsuoka et al., 2007). 
 To understand whether the defective RPA phosphorylation in ETAA1-deficient cells is 
due to a defect in ATR regulation, we mapped the ATR-binding motif in ETAA1 to an N-terminal 
region (Fig. 3.12A). Sequence analysis identified a highly evolutionarily conserved tryptophan 
(residue 107) accompanied by a short region of sequence similarity to the ATR-activation 
domain (AAD) of TOPBP1 within this region (Fig. 3.12B). In TOPBP1 this tryptophan is essential 
to bind and activate ATR (Kumagai et al., 2006). Mutation of ETAA1 W107 to alanine reduced 
the ability of ETAA1 to co-immunoprecipitate ATR (Fig. 3.12A).  
 Based on the similarity to TOPBP1 and the reduction in RPA phosphorylation in ETAA1-
deficient cells, we considered the possibility that ETAA1 acts as a direct ATR activator. Indeed, 
like the TOPBP1 AAD, an ETAA1 fragment containing amino acids 75-250 purified from E. coli  
	 	
	
78	
	
   
RPA2 pS4/S8
RPA2
CHK1 pS317
RPA2 pS33
CHK1
GAPDH
siETAA1siNT
CPT (hrs): 0 2 4 8 0 2 4 8
A
0 4 8
pR
PA
32
(p
S4
/8)
/R
PA
32
0 4 8 0 4 8
WT Δ #1
+CPT
(hrs)
B
Δ #2C
pR
PA
32
(p
S3
3)
/R
PA
32
0 4 8 0 4 8 0 4 8
WT Δ #1 Δ #2
D
pC
HK
1(
pS
31
7)
/C
HK
1
0 4 8 0 4 8 0 4 8
WT Δ #1 Δ #2
+CPT
(hrs)
+CPT
(hrs)
Mr (K)
37
37
37
50
50
37
0
5
10
15
0
2
4
6
8
0
2
4
6
8
Figure 3.11. ETAA1 is required for RPA phosphorylation in multiple cell types. (A) U2OS cells transfected with 
non-targeting or ETAA1 siRNAs or (B-D) wild-type and two ETAA1Δ HEK293T cell clones were treated with 100 nM 
CPT for 2, 4, or 8 hrs. Cell lysates were separated by SDS-PAGE and immunoblotted with the indicated antibodies. 
The blots in a are representative of two experiments. (B-D) The amount of phosphorylated versus total RPA and 
CHK1 from n=4, 3, and 5 experiments in b, c, and d respectively is shown. Black bars are the mean. (E)  U2OS, HeLa, 
HCT116, H157, BT549, and A549 cells transfected with non-targeting or ETAA1 siRNAs were left untreated or treated 
with 100 nM CPT for 8 hrs. Proteins were separated by SDS-PAGE and detected by immunoblotting. 
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Figure 3.12 ETAA1 activates ATR. (A) Immunoprecipitates of GFP-Flag-NLS-tagged ETAA1 fragments 
expressed in HEK293T cells were immunoblotted for Flag and ATR. Representative blots from one of two 
independent experiments are shown. (B) Schematic diagram of the ETAA1 protein indicating the 
ATR-interacting domain and evolutionarily conserved sequence similarity with the TOPBP1-AAD. (C) 
Purified ATR/ATRIP complexes were incubated with GST-TOPBP1 or ETAA1 proteins purified from E. coli, 
substrate, and γ-32P-ATP. The kinase reactions were separated by SDS-PAGE prior to immunoblotting or 
quantitating substrate phosphorylation by phosphorimaging. ATRi, ATR inhibitor. (D) ATR kinase activity 
relative to the control reaction of n=4 independent experiments is graphed. Significance was calculated with 
the Mann-Whitney test. 
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activates ATR in vitro (Fig. 3.12 C,D). This activation requires W107, other fragments of ETAA1 
do not stimulate ATR, and an ATR inhibitor eliminates the kinase activity indicating specificity. 
Thus, ETAA1 contains an AAD within amino acids 75-250, and ETAA1 is a direct ATR activator 
like TOPBP1. 
 We hypothesized that the increased DNA damage signaling that we observed in cells 
overexpressing ETAA1 (Fig. 3.1) could be due to ectopic activation of ATR like what happens 
upon TOPBP1-AAD overexpression (Kumagai et al., 2006; Toledo et al., 2008; Ball et al., 
2007). It is also possible that ETAA1 overexpression could cause damage by interfering with 
RPA function yielding an RPA-exhaustion-like phenotype (Toledo et al., 2013). To test these 
ideas, we overexpressed various ETAA1 proteins and measured γH2AX. The high level of 
γH2AX induced by wild-type ETAA1 is reduced but not eliminated by mutation of the RPA-
interacting motifs (Fig. 3.13A,C,E). These proteins are expressed at least 10-fold higher than 
the stable ETAA1 expressing cell lines that lack spontaneous ETAA1 foci (Fig. 3.13F). A 
fragment of ETAA1 missing the ETAA1 AAD (aa251-926) does not cause γH2AX despite its 
ability to localize to RPA-foci (Fig. 3.13B-D).   
The ETAA1 AAD by itself is sufficient to induce γH2AX when highly overexpressed and 
the level of γH2AX induced is correlated with its expression level (Fig. 3.13B,C,E,G). In contrast, 
the ETAA1 AAD containing the W107A mutation largely does not induce damage signaling (Fig. 
3.13B,C,H). Thus, we conclude that overexpression of ETAA1 promotes DNA damage signaling 
by binding both RPA and ATR, and high levels of expression of just the ETAA1 AAD is sufficient 
to activate ATR.  
  
ETAA1 requires its RPA-interaction and ATR-activation domains to maintain genome stability 
 We next tested whether the ETAA1 replication stress response functions are dependent 
on its ability to bind RPA and activate ATR. First, we complemented the ETAA1Δ cells with wild- 
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Figure 3.13. ETAA1 over-expression causes DNA damage signaling.
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Figure 3.13. ETAA1 over-expression causes DNA damage signaling (continued). (A-H) U2OS cells 
were transfected with the indicated GFP-Flag-NLS-ETAA1 protein expression vectors, and GFP and γH2AX 
were visualized by immunofluorescence imaging. (A,B) Cell Profiler was used to quantitate γH2AX intensity 
in ETAA1 expressing cells. The intensity of each nucleus, mean intensity, and number of nuclei imaged  is 
depicted. Data represent one out of three experiments in a and one out of two experiments in B. (C,D) The 
percentage of cells with γH2AX or ETAA1 foci were scored manually in blinded samples. Mean and SEM 
from n=4 experiments is graphed. (E) Immunoblot of proteins to examine expression levels. (F) Immunoblot 
of untransfected (lane 1), transiently transfected (lane 3), and stable ETAA1 expressing cell lines after sorting 
(lane 2). (G,H) GFP-Flag-ETAA1-2-250 or 2-250-W107A intensity versus γH2AX intensity is plotted. Pearson 
correlation coefficient is shown. Data in E-H are representative of two experiments. 
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type or RPA binding mutant GFP-ETAA1 cDNA. Cells were sorted to select for the 10% of cells 
with the lowest expression of GFP-ETAA1 proteins (Fig. 3.14A, B). While wild-type ETAA1 fully 
complements the CPT hypersensitivity of ETAA1Δ cells, the ETAA1-ΔRPA expressing cells 
remain modestly hyper-sensitive (Fig. 3.14C). Furthermore, ETAA1Δ cells also exhibited 
significantly higher levels of genome instability as measured by micronuclei formation, which 
could be rescued by wild-type but not RPA-binding defective ETAA1 (Fig. 3.14D). Thus, we 
conclude that RPA binding is needed for ETAA1 to maintain genome stability. 
To examine the cellular functions of the ETAA1 AAD and avoid problems caused by 
ETAA1 overexpression we devised a strategy to delete the AAD in the endogenous ETAA1 
gene locus. A portion of the AAD including W107 is encoded by ETAA1 exon 2. Cas9-mediated 
deletion of exon 2 using two guide RNAs spanning the 5’ intron-exon boundary results in the 
production of an ETAA1 mRNA in which exon 1 splices to exon 3. This mutation maintains the 
open reading frame and results in the expression of an ETAA1Δexon2 protein missing residues 
76-118 that remains capable of binding RPA (Fig. 3.15A,B).  
ETAA1Δexon2 cells show a very similar reduction in DNA replication track lengths as the 
ETAA1Δ cells in response to a CPT challenge (Fig. 3.15C,D). They also exhibit a reduction in 
RPA phosphorylation (Fig. 3.16A,B,C), although there is no obvious defect in CHK1 or MCM2 
phosphorylation (Fig. 3.16A,D).  
  
ETAA1-deficient cells exhibit elevated levels of SCEs 
Many of the other proteins that ETAA1 associates with are involved in recombination-
based repair mechanisms. However, we did not observe a significant hypersensitivity of ETAA1-
deficient cells to ionizing radiation (Fig. 3.7A) or PARP inhibition (Fig. 3.7C,D). The interaction of 
ETAA1 with both HLTF and the BTR complex was of interest since the budding yeast 
orthologue of HLTF (RAD5) promotes template switching, while the BLM orthologue (SGS1)  
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Figure 3.14. An interaction with RPA is needed for ETAA1 to maintain genome integrity. (A,B) ETAA1Δ 
cells were infected with wild-type or RPA binding-deficient ETAA1 lentiviruses. After antibiotic selection, the cell 
populations were sorted to select for the 10% of cells expressing the lowest amount of ETAA1 protein. (b) 
Immunoblot shows that the complemented cells overexpress approximately equal amounts of wild-type (WT) 
and ETAA1ΔRPA proteins. (C) Cell populations were challenged with the indicated concentrations of CPT and 
cell viability measured after 72 hrs. The mean viability from three technical replicates from one of two 
independent experiments is shown. (D) The percentage of cells with micronuclei was scored in the indicated cell 
populations. Data from two independent complemented ETAA1Δ clones are shown. The mean percentage of 
cells with micronuclei and total number of nuclei scored from five technical replicates of one of two biological 
replicates is shown. 
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Figure 3.15 The ETAA1 ATR activation domain is needed to maintain fork stability  (A) Schematic of 
the ETAA1Δexon2 gene and protein. (B) ETAA1 immunoprecipitates from wild-type, ETAA1Δ, and ETAA1
Δexon2 cells were immunoblotted for ETAA1 and RPA. Data are representative of two experiments.  (C, D) 
Cells were labeled with CldU and IdU and treated with 100 nM CPT during the second labeling period. DNA 
fibers stretched on a microscope slide were stained with IdU and CldU antibodies, imaged, and the lengths 
of fiber tracks measured. n=107, 116, and 105 fibers for WT, ETAA1∆, and ETAA1∆exon2 respectively. One 
of two biological replicates is shown. 
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Figure 3.16 The ETAA1 ATR activation domain is needed for ATR signaling  (A-D) Wild-type, ETAA1Δ, 
and ETAA1Δexon2 HEK293T cells were treated with 100 nM CPT for 0, 4, or 8 hrs. Cell lysates were 
immunoblotted for phosphorylated and total RPA and CHK1. Black bars are the mean from n=3, 4, and 5 
experiments in B, C, and D respectively. 
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helps to dissolve these repair intermediates to prevent crossovers (Putnam et al., 2010). The 
human BTR complex also promotes non-crossover repair outcomes during replication fork 
repair (Wu et al., 2006; Bussen et al., 2007; Raynard et al., 2006). Thus, a defining 
characteristic of BLM-deficient cells is a striking increase in SCEs. Indeed, BLM silencing 
increases SCEs by approximately 10-fold while silencing ETAA1 resulted in a 2.5-fold increase 
(Fig. 3.17A,B). ETAA1Δ cells also exhibited an increased frequency of SCEs compared to 
controls (Fig. 3.17C). The frequency of SCEs in ETAA1Δ and wild-type cells transfected with 
BLM siRNA were not different suggesting an epistatic relationship (Fig. 3.17C). Both ETAA1 
and BLM-deficiency also yield increased levels of micronuclei, and again ETAA1 and BLM are 
epistatic for this phenotype (Fig. 3.17D,E). ETAA1Δexon2 cell lines also exhibit elevated levels 
of micronuclei and SCEs similar to the ETAA1Δ cells indicating that ETAA1 must be able to 
activate ATR to prevent genetic instability (Fig. 3.17F, G).   
 
ETAA1 and TOPBP1 function in distinct pathways 
ETAA1 is similar to TOPBP1 in that both activate ATR, complex with BLM, and prevent 
SCEs. Thus, we considered whether they function in the same or distinct pathways. Unlike 
ETAA1 deficiency, TOPBP1 knockdown has a strong affect on ATR-dependent CHK1 
phosphorylation (Fig. 3.18A). However, we consistently observe that RPA phosphorylation is 
primarily dependent on ETAA1 and only modestly affected by TOPBP1 knockdown. We also did 
not observe TOPBP1 in our ETAA1 purifications suggesting they function in distinct pathways.  
TOPBP1 binding and ATR activation requires ATR amino acids between the kinase and 
FATC domains called the PIKK regulatory domain (PRD) (Mordes et al., 2008a). Mutations in 
the PRD do not interfere with the basal activity of ATR, but they greatly reduce the ability of 
TOPBP1 to activate ATR (Mordes et al., 2008a). Like TOPBP1, ETAA1-dependent ATR 
activation is greatly diminished by ATR PRD mutations (Fig. 3.18B).  This result and the  
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Figure 3.17 ETAA1 deficient cells have elevated sister chromatid exchanges and genetic instability. (A,B) 
SCEs were imaged and scored after ETAA1 knockdown. Scale bars are 5 µm. Four eperiments were performed 
for siNT and siEpool and one experiment was completed for the other siRNAs. Mean and SEM from a 
representative experiment is shown and significance calculated by ANOVA with a Dunnett multiple comparison 
post-test. The number of metaphases analyzed (n value) is indicated. (C) SCEs were scored in wild-type or 
ETAA1Δ U2OS cells transfected with non-targeting or BLM siRNAs. Data are representative from three 
independent experiments and significance was calculated with a Mann-Whitney test. The number of metaphases 
(n value) is indicated. (D,E) Micronuclei were imaged and scored in U2OS cells transfected with non-targeting, 
ETAA1, or BLM siRNAs as indicated. Data are mean and SD of n=3 independent experiments. Scale bar is 5 μm. 
(F) Micronuclei and (G) SCEs were scored in wild-type, ETAA1Δ, and two independent ETAA1Δexon2 U2OS cell 
clones. Mean, SEM, and number of metaphases analyzed (n value) is presented. Significance in e, f and g was 
determined by ANOVA with a Dunnett multiple comparison post-test. (H) WT and ETAA1Δ U2OS cells were 
transfected with non-targeting or two siRNAs targeting TOPBP1. Cell lysates were immunoblotted with the 
indicated antibodies.  
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Figure 3.18 ETAA1 and TOPBP1 act in separate pathways to regulate ATR and maintain genome 
stability. (A) Wild-type or ETAA1Δ U2OS cells were transfected with non-targeting or TOPBP1 siRNAs, 
treated with 100 nM CPT for the indicated times, lysed, and immunoblotted with the indicated antibodies. 
Blots are representative of two experiments.    
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Figure 3.18 ETAA1 and TOPBP1 act in separate pathways to regulate ATR and maintain 
genome stability (continued).  (B) Purified wild-type or mutant ATR/ATRIP complexes were 
incubated with GST or the AAD domains of TOPBP1 or ETAA1 in the presence of substrate and 
γ-32P-ATP. The kinase reactions were separated by SDS-PAGE prior to immunoblotting or 
quantitating substrate phosphorylation by phosphorimaging. Two independent replicates of the mutant 
ATR kinase reactions are shown. (C) SCEs in wild-type or ETAA1Δ U2OS cells transfected with 
non-targeting or TOPBP1 siRNAs were quantitated. Error bars are SEM and significance was 
calculated with a Mann-Whitney test. The number of metaphases scored (n value) is indicated. (D) 
Cells transfected with non-targeting, TOPBP1, RAD9, or ATR siRNAs were challenged with 10 nM 
CPT for 24 hrs and viability was determined by clonogenic assay. Untreated viability was set at 100%. 
Bars indicate the mean of three technical replicates from a representative experiment of two 
independent experiments  (E) Simplified model of ATR activation by ETAA1 and TOPBP1. The 911 
complex stabilizes TOPBP1 at stalled forks and assists in the TOPBP1-dependent activation pathway. 
ETAA1 is recruited directly by RPA and functions independently of 911 and TOPBP1 to activate ATR. 
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similarity of the AAD motifs suggest that ETAA1 and TOPBP1 utilize a similar mechanism to 
activate ATR. 
ETAA1 requires its AAD to prevent SCEs (Fig. 3.17G), while TOPBP1 is reported to 
regulate SCEs independently of its AAD (Wang et al., 2013; Blackford et al., 2015). TOPBP1 
knockdown yields a similar increase in SCEs as ETAA1-deficiency and TOPBP1 knockdown in 
ETAA1Δ cells further increases SCE frequency above that of either TOPBP1 or ETAA1-
deficiency alone again consistent with operation in distinct pathways (Fig. 3.18C).  Previous 
studies have made conflicting conclusions about whether TOPBP1 regulation of BLM is through 
changing its stability (Wang et al., 2013; Blackford et al., 2015). We did not observe large 
changes in BLM protein levels when we knocked down TOPBP1, and ETAA1 deficiency also 
does not alter BLM protein levels (Fig 3.17H).  
Finally, if ETAA1 and TOPBP1 pathways are distinct we would expect loss of ETAA1 to 
be synthetically lethal with TOPBP1 or 911 deficiency. Indeed, knockdown of TOPBP1 or RAD9 
resulted in decreased survival of ETAA1Δ cells following a challenge with CPT (Fig. 3.18D). 
Taken together, these data indicate that ETAA1 and TOPBP1 function in distinct pathways to 
activate ATR signaling and maintain genome stability. 
 
Discussion 
 
Previous studies identified three ATR (Mec1) activators in budding yeast (Dpb11, Ddc1, 
and Dna2) (Navadgi-Patil and Burgers, 2009, 2008a; Kumar and Burgers, 2013). We now report 
that human cells contain at least two ATR activators, TOPBP1 and ETAA1. This conclusion is 
consistent with that of the accompanying paper that independently identified ETAA1 as an ATR 
activator (Haahr et al., 2016). TOPBP1 is the Dpb11 functional orthologue; however, ETAA1 
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does not resemble any of the yeast ATR activating proteins outside of the key residues needed 
to activate ATR.    
 TOPBP1 and ETAA1 act in separate pathways to maintain genome integrity and 
regulate ATR. The ability of ETAA1 to bind directly to RPA distinguishes it from TOPBP1, which 
requires the MRN and 911 complexes for its recruitment and ATR activating function (Duursma 
et al., 2013; Delacroix et al., 2007a). 911 is only loaded on DNA gaps when a free 5’ end is 
available at the ssDNA-dsDNA junction. Thus, extensive ssDNA generation may not generate 
more 911-TOPBP1-ATR signaling complexes. We propose that ETAA1 helps to propagate ATR 
activation along stretches of ssDNA since it can bind RPA and function independently of 911 
(Fig. 3.18E). 
  RPA is particularly dependent on ETAA1 for phosphorylation; whereas other ATR 
substrates like CHK1 and MCM2 are more dependent on TOPBP1. CHK1 phosphorylation 
requires the replisome component CLASPIN (Kumagai and Dunphy, 2000), and MCM2 is part 
of the replicative helicase. Thus, it is possible that the proximity to the replisome where it may 
be more likely to have a 5’ DNA junction to load 911/TOPBP1 could determine ETAA1 vs. 
TOPBP1 dependency. The ability of TOPBP1 and ETAA1 to interact with DDR proteins or their 
relative level of expression, which differs considerably across cell types, may be additional 
levels of substrate selection.   
In conclusion, ETAA1 is a replication stress response protein needed to maintain 
genome stability. ETAA1 complexes with multiple DDR proteins and one mechanism of ETAA1 
action in the replication stress response is as a direct ATR activator. The requirement for 
ETAA1 to maintain genome stability could be why polymorphisms in the ETAA1 locus increase 
the risk of pancreatic cancer (Childs et al., 2015a; Wu et al., 2012).  
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Conclusions 
 
The replication stress response is well conserved throughout eukaryotes; however, 
yeast have three proteins that can activate Mec1, while eukaryotes had only one known ATR 
activator, TOPBP1. Our data identified the previously uncharacterized protein ETAA1 as a 
potential replication stress response protein in two proteomic screens. We validated its function 
during replication stress and discovered that like TOPBP1, ETAA1 can stimulate ATR kinase 
activity, identifying it as a second activator of ATR. Furthermore, we found that ETAA1 contains 
two RPA-interacting motifs that are necessary for its localization to sites of RS.   Loss of ETAA1 
or deletion of its AAD sensitizes cells to replication stress and DNA damage. Lastly, found that 
ETAA1 and TOPBP1 regulate ATR through separate pathways.  
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CHAPTER IV 
 
QUANTITATIVE PHOSPHOPROTOMICS REVEALS MITOTIC FUNCTION OF THE 
ATR-ACTIVATOR ETAA1 
 
Introduction 
ATR is an apical DNA damage response (DDR) kinase that promotes genome stability 
by regulating the cell division cycle and cellular stress responses (Saldivar et al., 2017). ATR 
signaling coordinates the DNA replication stress response, controls the S/G2 and G2/M 
transitions to ensure completion of DNA replication before mitosis, and ensures proper 
chromosome separation during mitosis (Cimprich and Cortez, 2008; Saldivar et al., 2018; 
Kabeche et al., 2017; Zachos et al., 2007).  
In budding yeast there are at least three activators of the ATR-orthologue, Mec1 that 
regulate timing of Mec1 activation and direct what substrates are phosphorylated (Kumar and 
Burgers, 2013; Mordes et al., 2008b; Navadgi-Patil and Burgers, 2008b, 2009; 
Bastos de Oliveira et al., 2015). The cell-cycle-specific utilization of each Mec1 activator allows 
for temporal regulation of Mec1 throughout the process of cell division (Navadgi-Patil and 
Burgers, 2011). Additionally, Mec1 activators direct Mec1 to phosphorylate substrates proximal 
to the activator promoting localization-dependent Mec1 signaling (Lanz et al., 2018).    
In mammalian cells, ATR kinase activity is regulated by at least two ATR-activating 
proteins ETAA1 and TOPBP1 (Bass et al., 2016; Haahr et al., 2016; Lee et al., 2016; Kumagai 
et al., 2006).  Although ETAA1 and TOPBP1 share similar ATR activation domains and may 
interact with ATR similarly (Bass et al., 2016), they are recruited to DNA via different 
mechanisms. ETAA1 is recruited by a direct interaction with RPA bound to single stranded DNA 
(ssDNA) (Bass et al., 2016; Haahr et al., 2016; Feng et al., 2016; Lee et al., 2016); whereas 
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TOPBP1 is recruited to the 5’ junction of single and double-stranded DNA by the 
RAD9/RAD1/HUS1 (9-1-1) complex with assistance from RHINO and the MRE11/RAD50/NBS1 
(MRN) complex (Delacroix et al., 2007b; Lee et al., 2007b; Cotta-Ramusino et al., 2011; 
Lindsey-Boltz et al., 2015; Duursma et al., 2013). 
 Loss of ETAA1 or TOPBP1 differentially effect phosphorylation of ATR substrates such 
as CHK1 and RPA in cells exposed to replication stress (Bass et al., 2016). ETAA1 also 
appears especially important for the newly described function of ATR in controlling the S/G2 
transition in unstressed cells (Saldivar et al., 2018).  To more globally determine how ETAA1 
and TOPBP1 influence ATR signaling, we utilized quantitative phosphoproteomics to identify 
changes in protein phosphorylation in cells deficient for each ATR-activator. These data 
indicated that ETAA1 may be particularly important for the mitotic functions of ATR.  Indeed, 
ETAA1-dependent activation of ATR during mitosis promotes Aurora B kinase signaling, 
prevents chromosomal misalignment during metaphase and maintains the spindle assembly 
checkpoint.  Thus, ETAA1 may be the primary ATR activator to control cell division in 
unstressed cells while TOPBP1 has a dominant function in response to replication stress. 
 
Results 
 
Generation of cell lines deficient for ATR activators 
To interrogate the unique functions of ETAA1 and TOPBP1, we utilized CRISPR/Cas9 
genome editing to generate HCT116 cells deficient for each ATR activator. ETAA1 function was 
disrupted by targeting the 5’ splice junction of exon 2, resulting in an in-frame deletion of ETAA1 
that removes part of the ATR activation domain (AAD) containing a tryptophan residue required 
to activate ATR (Fig. 4.1A, B). These ETAA1ΔAAD cells express a mutant ETAA1 protein   
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Figure 4.1 Production of ETAA1 and TOPBP1-deficient cell lines. (A) Schematic of the ETAA1ΔAAD 
gene and protein. (B) HCT116 and HCT116 ETAA1ΔAAD cells were lysed and immunoblotted with ETAA1 
antibodies. Upper band is full length ETAA1 and lower band is mutated ETAA1. ETAA1 electrophoretic 
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TOPBP1-AID gene and protein. (D) HCT116 WT and TOPBP1-AID cells were treated with 500 μM IAA for 
the indicated times. Cells were lysed and immunoblotted with the indicated antibodies. Upper band is full 
length TOPBP1-AID and lower band is TOPBP1.  (E) Schematic of TOPBP1 degradation by the auxin 
inducible degron system.
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which can bind RPA and localize to sites of DNA damage but is incapable of binding and 
activating ATR (Bass et al., 2016). 
 Unlike ETAA1, TOPBP1 is required for cell viability and has essential functions during 
the initiation of DNA replication (Garcia et al., 2005). We attempted to mutate the TOPBP1-AAD 
in HCT116 cells using CRISPR-Cas9 but were unsuccessful, consistent with the observation 
that inactivation of the TOPBP1-AAD results in cell death in mice (Zhou et al., 2013). To 
circumvent these obstacles, we tagged endogenous TOPBP1 with an auxin inducible degron 
(AID) (Fig. 4.1C-E). The tag itself reduced TOPBP1 expression significantly but yielded viable 
cell lines that retained proliferative capacity (Fig. 4.1D, Fig. 4.2A and C). Addition of the auxin 
indole-3-acetic acid (IAA) resulted in specific and rapid degradation of TOPBP1, cell death, and 
block to proliferation (Fig. 4.1D, Fig. 4.2B,D). Thus, this approach provides a rapid method of 
inactivating TOPBP1.  
In addition to producing cell lines defective for ETAA1 or TOPBP1, we generated 
ETAA1ΔAAD/TOPBP1-AID cells that are conditionally deficient for both ATR activating proteins. 
Prolonged IAA treatment in wild type (WT) or ETAA1ΔAAD cells did not increase γH2AX levels, 
a biomarker for DNA damage (Fig. 4.2E).  However, cells containing the TOPBP1-degron 
stopped growing and began to accumulate DNA damage as indicated by induction of γH2AX 
and phosphorylated RPA (Fig. 4.1D, Fig. 4.2B, E). Cells deficient for both ETAA1 and TOPBP1-
AID exhibited much more severe genomic instability evident by fragmented nuclei and high 
levels of γH2AX consistent with the conclusion that these ATR activators function in separate 
pathways (Fig. 4.2E).  
 To examine replication stress signaling in cells defective for ETAA1 or TOPBP1, cells 
were treated with 100 nM camptothecin (CPT) for four hours following a two-hour pretreatment 
with IAA. As previously observed in other cell types (Bass et al., 2016), loss of ETAA1-
dependent ATR activation resulted in a reduction in RPA phosphorylation but did not strongly 
affect CHK1 phosphorylation (Fig. 4.2F). While addition of the AID tag lowered endogenous   
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Figure 4.2 Characterization of ETAA1 and TOPBP1-deficient cell lines (continued). (A, B) HCT116 WT, ETAA1Δ
AAD, TOPBP1-AID, and ETAA1ΔAAD/TOPBP1-AID cells were left untreated (A) or treated (B) with 500 μM IAA. Cells 
numbers were counted every 24 hours. (C and D) Same as in A and B but viability was measured by trypan blue. (E) 
HCT116 (WT), ETAA1ΔAAD, TOPBP1-AID, and ETAA1ΔAAD/TOPBP1-AID cells were treated with DMSO or IAA for 
2 or 24 hours and γH2AX induction measured by immunofluorescence imaging. Representative images and 
quantification are shown. Scale bar is 10 μM. (F) Cells were treated with 100 nM CPT for four hours following a 
two-hour pretreatment with IAA or DMSO as indicated, then lysed and immunoblotted with the indicated antibodies.
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TOPBP1 levels, these cells remained capable of activating ATR and only showed reduced ATR 
signaling after treatment with IAA to degrade TOPBP1 (Fig. 4.2F). Cells deficient for both 
ETAA1 and TOPBP1 exhibited more severe defects in RPA and ATR phosphorylation than the 
single mutants further demonstrating that ETAA1 and TOPBP1 function in separate pathways to 
activate ATR (Fig. 4.2F).  
 
Quantitative phosphoproteomics identifies ETAA1 and TOPBP1-dependent phosphosites 
To examine how each ATR activator differentially regulates ATR signaling responses, 
we compared the nuclear phosphoproteomes of wild type cells to cells deficient for each ATR 
activator using SILAC-mass spectrometry (Fig 4.3A). WT, ETAA1ΔADD and TOPBP1-AID cells 
labeled with heavy (13C) or light (12C) arginine and lysine were treated for four hours with 100 
nM CPT following a two-hour pretreatment with IAA. Cells were harvested, combined in a 1:1 
ratio, nuclei isolated, lysed, and fractionated into soluble nuclear extract and 
insoluble/chromatin-bound proteins. The nuclear soluble proteins were proteolyzed by treatment 
with trypsin while chromatin bound proteins were denatured in 8 M urea and subsequently 
proteolyzed by LysC and trypsin. Phosphopeptides from each fraction were enriched using TiO2 
beads and identified and quantified by liquid chromatography-tandem mass spectrometry (LC-
MS/MS). The abundance of each phosphopeptide in wild type compared to the ATR-activator 
deficient cell line was measured.  Three replicates of TOPBP1-AID cells and four replicates of 
ETAA1ΔAAD cells were analyzed. 
 Using this approach, we identified a total of 20,674 unique phosphosites on 4,045 
proteins. Phosphosites that were observed at least twice with a median decrease in abundance 
in activator-deficient cells of at least 1.5 fold in either the nuclear soluble or chromatin fractions 
were considered as dependent on that activator (Fig. 4.3B). Using these criteria, 285 
phosphosites were ETAA1-dependent, 724 phosphosites TOPBP1-dependent, and 118 
phosphosites were dependent on both ATR activators (Fig. 4.3C). These phosphorylation sites   
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Figure 4.3 Quantitative phosphoproteomics identifies ETAA1 and TOPBP1-dependent 
phosphorylation sites.  (A) Schematic of SILAC-phosphoproteomics approach. (B) Scatter plot of 
phosphoproteomic data. Each point represents a phosphosite and the X and Y value corresponds to the 
log2 transformed ratios of ETAA1 and TOPBP1 dependent phosphorylation events. Higher ratio values 
correspond to more phosphorylation in wild type (WT) cells than in ETAA1ΔAAD or TOPBP1-AID cells. (C) 
Number of phosphosites and (D) phosphoproteins dependent on ETAA1, TOPBP1, or both ATR activators. 
(E) Diagram of ATR signaling pathway with preferred phosphorylation motifs of ATR and CHK1. (F,G) 
Abundance of ATR and CHK1 motifs in ETAA1 and TOPBP1-dependent phosphorylation sites. 
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were located on 162 proteins unique to ETAA1, 383 proteins unique to TOPBP1, and 120 
proteins regulated by both ETAA1 and TOPBP1 (Fig. 4.3D). Tables 4.1, 4.2 and 4.3 contain a 
complete list of all ETAA1, TOPBP1, and dual-dependent phosphosites and are provided at the 
end of this chapter.  
While ATR has been found to phosphorylate a variety of sequences, it preferentially 
phosphorylates serine or threonines followed by a glutamine (S/T-Q) (Kim et al., 1999). CHK1 
preferentially phosphorylates serine with an arginine in the -3 position (R-X-X-S) (O’Neill et al., 
2002) (Fig. 4.3E).  Of the 403 ETAA1-dependent phosphorylation sites only 7 corresponded to 
the preferred ATR motif, while 87 had a CHK1 phosphorylation motif. Of the 842 TOPBP1-
dependent phosphorylation sites 24 contained an ATR motif, while 177 had a CHK1 
phosphorylation motif (Fig. 4.3F, G). Thus, most of these phosphorylation events are likely to be 
indirectly targeted downstream of ATR by CHK1 or other ATR-regulated kinases. 
 
Gene ontology analysis of ETAA1 and TOPBP1-dependent phosphorylation 
To determine if ETAA1 or TOPBP1 regulate specific biological processes we performed 
a gene ontology (GO) enrichment analysis on the phosphoproteins regulated by each ATR-
activator.  To consolidate similar GO terms and easily visualize the relationship between terms, 
ClueGO was utilized to generate a functionally organized GO term network (Bindea et al., 
2009). Phosphoproteins and their corresponding GO terms were assigned functional groups 
based on a kappa score that compares the observed events with those expected by random 
chance and iterative merging of groups containing 50% of the same proteins. The complete GO 
analysis is provided in Table 4.4 while Figures 4.4A and 4.5A display the resulting GO networks 
for TOPBP1 and ETAA1-dependent phosphoproteins, respectively.  
Listed in Figures 4.4B and 4.5B are the ten most significantly enriched functional GO 
groups for TOPBP1 and ETAA1 along with the GO term with the highest percentage of 
associated genes from each group. The most highly enriched functional group for TOPBP1 
	 	
	
103	
	
 
	 	
	
104	
	
  
Figure 4.4 TOPBP1-dependent phosphorylation gene ontology analysis (continued) (A) Functional 
GO network displaying grouping of GO terms enriched in TOPBP1-dependent phosphoproteins. 
Phosphoproteins and their corresponding GO terms were assigned functional groups after iterative 
merging of groups containing 50% of the same proteins. Each node in the network represents a GO term 
with a p value <0.05. A larger node size corresponds to more significant enrichment.  Functional groups are 
indicated by color and represented in colored text by the most significant term in that group.  Nodes with 
multiple colors belong to multiple groups. (B) Table displaying the ten most highly enriched GO groups. The 
first term for each group represents the GO term with the highest significant enrichment. The second term 
for each group had the highest percentage of associated proteins for that GO group.  
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(colored yellow) contained the GO terms: regulation of cell cycle, mitotic cell cycle, and DNA 
integrity checkpoint.  
The GO term from this group with the highest percentage of represented proteins is 
response to ionizing radiation. Other functional GO groups that TOPBP1 regulated include 
chromosome organization, cellular macromolecule metabolic process, and nucleic acid 
metabolic process. GO terms found in GO Group 1 (yellow), Group 6 (green), and Group 9 
(blue) such as DNA integrity checkpoint, response to ionizing radiation, DNA repair, DNA 
replication, and cellular response to DNA damage stimulus are all consistent with the known 
functions for TOPBP1-dependent activation of ATR in response to DNA damage and replication 
stress. These terms were not highly enriched in ETAA1-dependent phosphorylation events 
suggesting TOPBP1 is the primary activator of ATR during DNA damage and replication stress 
signaling.  
In contrast to TOPBP1, the most enriched functional GO group for ETAA1 contained the 
GO terms mitotic cell cycle, nuclear chromosome segregation, cell cycle process, and cell cycle 
checkpoint. The GO term with the highest percentage of represented genes from this group was 
spindle checkpoint. Other ETAA1-dependent GO groups were chromosome organization, 
negative regulation of mRNA metabolic process, cytoskeleton organization, and DNA metabolic 
process. 
 
ETAA1 regulates and interacts with mitotic proteins 
The significant enrichment of multiple mitotic GO terms in the phosphoproteome of 
ETAA1ΔAAD cells was striking since the experiment was not designed to identify mitotic ATR 
targets. Supporting a role in mitosis, our mass spectrometry analysis of ETAA1 protein 
complexes indicates that multiple mitotic proteins co-purify with ETAA1 including kinetochore 
and spindle-localized proteins such as BUB1, SGO2, KNL1 and NDC80 (Fig. 4.6A).   
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Furthermore, we confirmed that ETAA1 co-localizes with Bub1 in cells trapped in mitosis with 
taxol using a proximity ligation assay (Fig. 4.6B).  
Although both ETAA1 and TOPBP1 regulated phosphoproteins were enriched for the 
GO term mitotic cell cycle, only 21 (19.6%) of the 107 mitotic proteins identified were dependent 
on both activators suggesting they might regulate different subpathways during mitosis (Fig. 
4.7A). Further analysis of these mitotic proteins revealed ETAA1-dependent phosphoproteins 
had a significant enrichment for proteins localizing to the kinetochore-centromere attachment 
site and mitotic spindle (Fig 4.7B-D), some of which are also ETAA1-interactors such as BUB1 
and CLASP1. Notably, most of the kinetochore and spindle-localized proteins were 
phosphorylated in an ETAA1-dependent but not TOPBP1-dependent manner (Fig. 4.6C).  
 
ETAA1 regulates Aurora B Kinase activity through an ATR pathway 
ATR, via its downstream effector CHK1, regulates the mitotic kinase Aurora B to control 
cell division (Zachos et al., 2007; Peddibhotla et al., 2009; Petsalaki et al., 2011). To examine if 
ETAA1 or TOPBP1 regulates ATR activation of this pathway, Aurora B kinase activity was 
measured by Aurora B autophosphorylation on threonine 232 and by phosphorylation of its 
downstream substrate, histone 3 (H3) on serine 10 (Fig. 4.8A).  Comparable to inhibition of ATR 
or CHK1, ETAA1ΔAAD cells had reduced autophosphorylation of Aurora B at T232 in mitotic 
cells whereas cells lacking TOPBP1 exhibited wild-type phosphorylation levels (Fig. 4.8B). 
Furthermore, complete knockout of ETAA1 resulted in decreased H3 S10 phosphorylation, 
which could be rescued by restoring expression of ETAA1 from a cDNA expression vector in 
ΔETAA1 cells indicating that the regulation of Aurora B is dependent on ETAA1 (Fig. 4.8C). 
 
Loss of mitotic ETAA1-ATR signaling results in chromosome alignment defects 
 To examine the functional effects of mitotic ETAA1- and TOPBP1-dependent ATR 
signaling, we used live cell imaging to monitor progression of cells deficient for each ATR-   
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Figure 4.8 ETAA1-dependent ATR activation regulates Aurora B kinase activity. (A) Diagram of mitotic 
ATR signaling to Aurora B (AURKB). (B). Aurora B kinase activity measured by autophosphorylation on 
T232. HCT116 (WT), and two clones of ETAA1ΔAAD and TOPBP1-AID cells were arrested in G2 by 
addition of a CDK2 inhibitor, (RO-3306, 10 μM) for 16 hours to avoid replication stress induced by ATRi or 
TOPBP1 degradation. Cells were treated with IAA or ATRi for two hours then released into fresh media 
containing taxol, IAA or ATRi. Cells were fixed one hour after release.  Shown are representative 
immunofluorescent images and quantification of Aurora B kinase pT232. Anti-centromere antibodies (ACA) 
were used to confirm kinetochore localization of Aurora B. Error bars represent standard deviation. (C) 
U2OS WT, ETAA1 null (ΔETAA1), and ΔETAA1 cells stably complemented with an ETAA1 expression 
vector were treated with 10 μM CDK2i for 16 hours, released for 1 hour into media with or without 1 μM ATRi 
and then fixed. Shown are representative immunofluorescent images and quantification of pH3 S10 in 
prometaphase cells. Scale bar is 5 μM.  Significance for B and C was determined by ANOVA with a Dunnett 
multiple comparison post-test.
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activator through mitosis.  Cells expressing GFP-tagged Histone 2B for chromatin visualization 
were synchronized using double thymidine block and released into fresh media. After seven 
hours, cells had completed DNA replication and IAA was added at that point to degrade 
TOPBP1. Alternatively, we utilize a selective ATR inhibitor (ATRi), VE822, to inactivate ATR in 
G2 phase cells. As cells progressed through mitosis each cell was scored for mitotic defects 
such as misaligned chromosomes during metaphase and the formation of lagging 
chromosomes or chromatin bridges during anaphase (Fig. 4.9A, B).  There was no significant 
difference between cell lines in the time from nuclear envelope breakdown (NEB) to the onset of 
anaphase (Fig. 4.10A). Loss of ETAA1, TOPBP1, or inhibition of ATR kinase activity all resulted 
in an approximately two-fold increase in the frequency of anaphase bridges, which can form due 
to incomplete DNA replication or failure to decatenate separating chromosomes. Interestingly, 
the number of metaphases with misaligned chromosomes more than doubled in ETAA1ΔAAD 
and ATR inhibited cells and the number of lagging chromosomes was more than ten-fold higher 
than in WT cells (Fig. 4.9A, B).  Many of the misaligned chromosomes in these cells became 
lagging chromosomes during anaphase and later formed micronuclei. TOPBP1-AID cells 
showed only a small increase in lagging chromosomes and did not display an increase in the 
number of metaphases with misaligned chromosomes (Fig. 4.9A, B).   
 To examine the severity of chromosome misalignment during metaphase, ETAA1ΔAAD, 
TOPBP1-AID and ATRi treated cells were stained with anti-centromere-antibodies (ACA) and 
scored for the number of chromosomes that were not aligned at the metaphase plate. There 
was a significant increase in both the frequency and severity of misalignment in ETAA1ΔAAD 
and ATRi treated cells but not in TOPBP1-AID cells (Fig. 4.9C, D). U2OS ETAA1 knockout cells 
also displayed an increase in the number of misaligned chromosomes and addition of an 
ETAA1 cDNA to the ΔETAA1 cells rescued the misalignment defect (Fig. 4.9E). These results 
suggest that ETAA1-ATR signaling is needed for proper attachment of the chromosomes to the 
spindle in unstressed cells.  
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Figure 4.9 ETAA1 activation of ATR is required for proper chromosome alignment and a fully functional 
SAC. (A, B) HCT116 WT, ETAA1ΔAAD, and TOPBP1-AID cells expressing GFP-H2B for chromatin visualization 
were examined by live cell imaging and scored for defects during mitosis. ATRi or IAA was added 1.5 hours before 
beginning imaging. Representative time-lapse images are shown in (A). White arrows indicate anaphase bridges 
and misaligned or lagging chromosomes.  Scale bar is 5 μM. (B) Quantification of mitotic defects from live-cell 
imaging experiments. Listed is the total number of cells examined for each cell type. (C) Representative 
immunofluorescence images of normal and misaligned chromosomes during metaphase. Scale bar is 5 μM. (D) 
HCT116 WT, ETAA1ΔAAD, and TOPBP1-AID cells were arrested for 16 hours with CDK2i, treated with IAA or ATRi 
for 2 hours, released from CDK2i and fixed. Metaphase cells were scored for the number of misaligned 
chromosomes. (E) U2OS WT, ΔETAA1, and ΔETAA1 cells stably expressing ETAA1 were examined for 
chromosome misalignment as in (D). (F) Synchronized HCT116 cells expressing H2B-GFP were released from a 
double thymidine block and taxol, ATRi, or CHK1i were added 1.5 hours before starting imaging. (G) Same as in (F) 
but HCT116 WT, and two clones of ETAA1ΔAAD and TOPBP1-AID cells were examined for ability to sustain mitotic 
arrest during taxol treatment. 
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Figure 4.10  Length of mitosis is unchanged by loss of ETAA1, TOPBP1, or ATR activity. (A) 
HCT116 WT, ETAA1ΔAAD, and TOPBP1-AID cells expressing GFP-H2B for chromatin visualization 
were examined by live cell imaging and time between nuclear envelope breakdown (NEB) and onset 
of anaphase was measured. Significance was determined by ANOVA with a Dunnett multiple 
comparison post-test. n.s.= not significant, p>0.05.
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Having observed that loss of ETAA1-dependent ATR signaling causes lower Aurora B 
kinase activity, decreased phosphorylation of kinetochore/spindle associated proteins, and 
defects in chromosome attachment we examined if ETAA1 and ATR are required for a fully 
functioning spindle assembly checkpoint (SAC). The SAC ensures genome stability by 
preventing the onset of anaphase until all chromosomes are properly attached via kinetochores 
to the spindle (Lara-Gonzalez et al., 2012). Cells expressing H2B-GFP were treated with ATRi 
and CHK1i and examined for ability to sustain mitotic arrest during treatment with taxol by live 
cell imaging. Entry into mitosis was determined by nuclear envelope breakdown (NEB) and 
plotted as time zero. Exit from mitosis was determined by chromosome decondensation. Ten 
hours after NEB only 22% of ATRi treated and 18% of CHK1i treated cells maintained mitotic 
arrest compared to 55% of untreated cells (Fig. 4.9F). To examine if ETAA1 or TOPBP1 
primarily contributes to ATR regulation of the SAC, two ETAA1ΔAAD and TOPBP1-AID cell 
lines were examined for ability to maintain taxol-induced mitotic arrest. Both ETAA1ΔAAD 
clones showed an inability to sustain mitotic arrest with only 33% and 20% of cells remaining in 
mitosis ten hours after NEB (Fig. 4.9G).  In contrast, mitotic arrest of TOPBP1-AID cells was 
comparable to those of control cells. Therefore, we conclude that ETAA1 is the primary 
regulator of ATR activation in mitosis to promote SAC activity.  
 
Discussion 
 
We utilized quantitative phosphoproteomics to define ETAA1 and TOPBP1-dependent 
signaling. These data identified ETAA1 as the primary regulator of ATR during mitosis at 
centromeric regions. ETAA1-dependent ATR signaling during mitosis promotes robust Aurora B 
kinase activity, proper separation of chromosomes, and a fully functioning SAC.  
These data also indicate that TOPBP1 regulates more of the ATR response to 
replication stress than ETAA1 since more than twice as many phosphosites depend on 
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TOPBP1 than ETAA1 and replication-related proteins were much more highly enriched in the 
TOPBP1-dependent versus the ETAA1 phosphoproteomes. Together these results suggest that 
TOPBP1 is a principle ATR-activator during replication stress, while ETAA1 has important 
functions during the unstressed cell division cycle (Fig. 4.11A).  
While we quantitated over 20,000 phosphosites, the phosphoproteomes lacked a large 
number of known direct ATR phosphorylation targets. Thus, further phosphorylation studies 
using additional strategies to enrich for direct targets are needed. Nonetheless, analysis of 
ETAA1-dependent phosphorylation events and interaction partners revealed ETAA1 functions at 
centromeric regions as a regulator of mitotic ATR activity (Fig. 4.11B). Loss of ETAA1 but not 
TOPBP1-dependent ATR activation phenocopies the mitotic defects caused by inhibiting ATR 
or CHK1 using small molecules.  CHK1 inactivation impairs the spindle assembly checkpoint 
through deregulation of Aurora B and Bub proteins (Zachos et al., 2007; Peddibhotla et al., 
2009; Petsalaki et al., 2011), both of which exhibit reduced phosphorylation in ETAA1ΔAAD 
cells. Additionally, ATR can localize to RPA-coated centromeric R-loops where it prevents the 
formation of lagging chromosomes (Kabeche et al., 2017), an anaphase defect observed in 
ETAA1ΔAAD cells.  
Previous studies indicate that TOPBP1 does function during mitosis at sites of under-
replication but that it is independent of ATR signaling (Pedersen et al., 2015). Additionally, 
TOPBP1 localizes to ultra-fine anaphase bridges and promotes their resolution through direct 
recruitment of topoisomerase IIα. (Germann et al., 2014; Broderick et al., 2015). Therefore, 
while TOPBP1 is active during mitosis, its functions do not appear tied to ATR activation.  
Utilizing cells deficient for each ATR activator we were able to separate the functions of 
ATR during replication stress and a normal cell cycle. These findings expand the requirement 
for ETAA1 to enforce normal cell cycle progression as ETAA1 was recently found to activate 
ATR during an unperturbed S-phase to control the S/G2 transition (Saldivar et al., 2018). This 
separation of function parallels how different Mec1ATR activators work in yeast where the   
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TOPBP1 orthologue Dpb11 activates Mec1-Rad53 signaling during replication stress while the 
other Mec1 activators, Dna2 and Ddc1, activate Mec1 during an unperturbed cell cycle 
(Bastos de Oliveira et al., 2015). In conclusion, ETAA1 and TOPBP1 promote genome stability 
through regulation of different ATR signaling pathways with ETAA1 having a dominant function 
in controlling chromosome segregation during mitosis. 
 
Conclusion 
We utilized quantitative phosphoproteomics to compare the phosphoproteomes of cells 
deficient for ETAA1 and TOPBP1. We found that while TOPBP1 is primarily utilized to activate 
ATR in response to replication stress, ETAA1 promotes mitotic ATR signaling at centromeric 
regions. ETAA1-activation of ATR is required for proper mitotic progression, ensuring accurate 
kinetochore-microtubule attachment and full activation of the spindle assembly checkpoint. 
These findings expand our models for how ATR activators regulate ATR signaling and direct 
ATR to specific substrates.  
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Table 4.1 ETAA1-dependent phosphosites. ETAA1-dependent phosphosites are given below 
along with the Uniprot ID, modified residue, presence of ATR or CHK1 motif, and the number of 
experiments in which that peptide was observed. The ratio value is the log2 transformed ratio of 
WT /ETAA1 or TOPBP1 cells. Therefore, a higher value (darker green) is more dependent on 
ETAA1 or TOPBP1.   
Table 4.1 ETAA1-dependent phosphosites.  
Phosphosite Uniprot ATR Motif (SQ/TQ) CHK1 Motif (R-X-X-S) 
Protein 
Name 
Amino 
acid 
ETAA1 
Ratio 
TOPBP1 
Ratio 
Count 
ETAA1∆AAD 
Count 
TOPBP1-AID 
ACSA S30 Q9NR19 R-X-X-S ACSA S 0.767824 -0.05229 3 4 
ADAM9 T761 Q13443  ADAM9 T 0.803227 0.4368 6 6 ADDG S677 Q9UEY8  ADDG S 1.59431 -0.16019 3 1 ADDG S681 Q9UEY8  ADDG S 0.596173 -0.1644 4 3 
AFAD S1779 P55196  AFAD S 0.608904 -0.47574 4 2 AHNK S210 Q09666 R-X-X-S AHNK S 0.794339 0.43499 7 6 
AHNK S332 Q09666  AHNK S 0.741872 0.58294 3 5 AKA12 S1390 Q02952  AKA12 S 0.719315 0.24948 2 3 AKA12 S286 Q02952  AKA12 S 0.645333 0.55139 5 6 
AKP13 S1565 Q12802 R-X-X-S AKP13 S 0.691911 -0.14167 2 1 
ALS2 S353 Q96Q42 R-X-X-S ALS2 S 0.866037 0.06185 2 1 
ALS2 S483 Q96Q42 R-X-X-S ALS2 S 1.38173 0.10178 7 5 
ALS2 S489 Q96Q42 SQ ALS2 S 1.22625 0.08849 4 3 
ALS2 S492 Q96Q42  ALS2 S 1.35095 0.20364 7 6 
ANLN S323 Q9NQW6  ANLN S 0.642964 -0.28007 6 5 APC S1371 P25054  APC S 2.38789 0.1513 5 5 
ARHG7 S694 Q14155 R-X-X-S ARHG7 S 0.724999 0.04963 3 2 
ARI1A S696 O14497 R-X-X-S ARI1A S 1.23695 0.24586 4 4 
BCL9L S750 Q86UU0  BCL9L S 0.607831 -0.04406 5 3 BCL9L S984 Q86UU0  BCL9L S 0.888149 -0.38204 2 2 BCL9L S991 Q86UU0  BCL9L S 0.898634 -0.38907 5 6 
BCL9L T989 Q86UU0 R-X-X-S BCL9L T 0.888149 -0.42146 2 3 
BPTF S1300 Q12830  BPTF S 1.22669 -0.13423 2 2 BRAT1 S582 Q6PJG6  BRAT1 S 2.57957 0.28053 2 2 BRAT1 T581 Q6PJG6  BRAT1 T 2.57957 0.5839 2 1 BRD7 S279 Q9NPI1 R-X-X-S BRD7 S 1.22138 0.45386 2 1 
BUB1 S593 O43683  BUB1 S 0.708009 0.03689 7 6 BUB1 S596 O43683  BUB1 S 0.653774 0.03689 7 6 
BUB1 S655 O43683  BUB1 S 0.795172 0.30314 3 3 BUB1 S661 O43683  BUB1 S 0.868553 -0.56957 2 1 BUB1 T601 O43683  BUB1 T 0.650029 0.16877 6 5 BUB1B S543 O60566  BUB1B S 0.624896 0.24086 5 6 BUB1B S670 O60566  BUB1B S 1.13635 0.06502 2 1 
C2D1A S455 Q6P1N0  C2D1A S 1.24957 -0.02912 4 4 CALD1 S789 Q05682  CALD1 S 0.970921 -0.36025 2 2 CBX8 S191 Q9HC52  CBX8 S 0.760519 -0.25828 3 4 CBY1 S9 Q9Y3M2  CBY1 S 0.920223 -0.25044 4 1 CCD14 S798 Q49A88  CCD14 S 0.799668 0.14718 3 5 
CDT1 S31 Q9H211 R-X-X-S CDT1 S 0.785843 -0.41665 3 5 
CDT1 T29 Q9H211  CDT1 T 0.785843 -0.36882 3 5 CENPF S3119 P49454  CENPF S 0.736125 0.53476 4 1 CENPF S3150 P49454  CENPF S 0.668113 0.04236 7 6 CEP55 S428 Q53EZ4  CEP55 S 0.615725 -0.23091 4 5 
CHMP7 S417 Q8WUX9  CHMP7 S 0.667937 0.32496 2 2 CLAP1 S1196 Q7Z460 SQ CLAP1 S 1.5365 -0.05412 2 2 
CLAP1 S646 Q7Z460 R-X-X-S CLAP1 S 0.683202 0.13764 4 6 
CLD12 S228 P56749  CLD12 S 0.626112 -0.3626 2 1 CLK1 S140 P49759 R-X-X-S CLK1 S 0.707463 0.25854 2 2 
CLK1 T138 P49759 R-X-X-S CLK1 T 0.786049 -0.26286 2 2 
CLMN S635 Q96JQ2  CLMN S 2.00328 -0.72588 3 2 
CN093 T283 Q9H972  CN093 T 0.797345 -0.30731 2 1 CP135 T1121 Q66GS9  CP135 T 0.943348 0.23687 5 5 CPSF2 S423 Q9P2I0  CPSF2 S 1.01861 0.17004 6 5 CROCC S488 Q5TZA2 R-X-X-S CROCC S 1.23702 0.01949 3 2 
CROCC S494 Q5TZA2 R-X-X-S CROCC S 1.23702 -0.18174 3 4 
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Table 4.1 ETAA1-dependent phosphosites.  
Phosphosite Uniprot ATR Motif (SQ/TQ) CHK1 Motif (R-X-X-S) 
Protein 
Name 
Amino 
acid 
ETAA1 
Ratio 
TOPBP1 
Ratio 
Count 
ETAA1∆AAD 
Count 
TOPBP1-AID 
CROCC S512 Q5TZA2 R-X-X-S CROCC S 0.757378 -0.29808 2 2 
CROCC T492 Q5TZA2  CROCC T 1.23702 -0.03781 3 4 CS021 T377 Q8IVT2 R-X-X-S CS021 T 0.600186 -0.59476 2 2 
CT2NL S557 Q9P2B4  CT2NL S 0.79693 -0.24398 5 3 CTF18 S225 Q8WVB6  CTF18 S 1.13849 -1.14976 3 1 CTR9 S1097 Q6PD62 R-X-X-S CTR9 S 0.608325 0.12062 2 3 
CTR9 S1099 Q6PD62  CTR9 S 0.686318 -0.09174 2 3 DAB2P S702 Q5VWQ8 R-X-X-S DAB2P S 1.51687 -0.71078 2 1 
DBF4A S103 Q9UBU7  DBF4A S 0.877823 0.04578 3 4 DDX54 S782 Q8TDD1  DDX54 S 0.946955 0.01164 4 4 DEN4C S1042 Q5VZ89 R-X-X-S DEN4C S 0.659285 -0.29488 3 2 
DEP1B S160 Q8WUY9  DEP1B S 0.726195 -0.52776 2 1 DHX16 S107 O60231  DHX16 S 1.26694 -0.28932 5 2 
DMWD S495 Q09019 R-X-X-S DMWD S 0.595217 0.47537 2 2 
DNJA1 S335 P31689  DNJA1 S 0.660777 0.07423 5 3 DPOA2 S141 Q14181  DPOA2 S 0.828144 -0.41758 5 6 DPOA2 S147 Q14181  DPOA2 S 0.654252 -0.46222 2 6 DPOA2 S152 Q14181  DPOA2 S 0.912037 -1.08281 5 5 
DTL S512 Q9NZJ0  DTL S 0.706995 -0.32366 3 1 DTL T516 Q9NZJ0  DTL T 0.706995 -0.52458 4 1 
DUS7 S369 Q16829  DUS7 S 0.671656 0.13973 2 2 DYRK2 S48 Q92630  DYRK2 S 1.16124 -0.35039 2 5 DYST S7510 Q03001 R-X-X-S DYST S 0.614945 0.15937 2 1 
E41L2 S715 O43491  E41L2 S 0.636636 0.29678 2 1 EDC4 S879 Q6P2E9  EDC4 S 0.797731 -0.06287 3 3 
ELAV1 S202 Q15717  ELAV1 S 0.602362 -0.17894 3 2 EMAL4 S94 Q9HC35 R-X-X-S EMAL4 S 1.55297 -0.7047 2 1 
ENL S411 Q03111  ENL S 0.747946 0.22639 2 2 ENL S414 Q03111  ENL S 0.747946 0.22639 2 2 ENL S419 Q03111  ENL S 0.747946 0.22639 2 2 
ENL S420 Q03111  ENL S 0.747946 0.22639 2 2 ENL S421 Q03111  ENL S 0.747946 0.22639 2 2 ERC6L S14 Q2NKX8  ERC6L S 0.643764 0.30661 7 5 ERCC5 S341 P28715  ERCC5 S 0.595313 -0.32834 5 5 ERCC5 S384 P28715  ERCC5 S 0.719048 -0.25357 3 4 
ERF S548 P50548  ERF S 0.785152 0.1744 2 2 ES8L1 S182 Q8TE68 R-X-X-S ES8L1 S 0.662205 0.06667 2 1 
ESYT1 S820 Q9BSJ8  ESYT1 S 0.801841 -0.21734 2 3 F134C S435 Q86VR2 R-X-X-S F134C S 1.0536 0.28712 2 3 
F134C S436 Q86VR2  F134C S 1.0536 0.28712 2 3 F208B S1172 Q5VWN6  F208B S 0.659454 0.48192 2 1 FA53C S232 Q9NYF3 R-X-X-S FA53C S 0.711367 0.40479 6 6 
FA53C S234 Q9NYF3  FA53C S 0.857511 0.40479 6 6 FA64A S131 Q9BSJ6  FA64A S 0.619178 -0.46883 4 5 FIP1 S259 Q6UN15  FIP1 S 0.59388 -0.90457 3 2 FLII S436 Q13045  FLII S 0.749835 -0.09866 2 2 FLII S856 Q13045  FLII S 0.606916 0.363 3 1 
FOXK1 T436 P85037  FOXK1 T 0.704939 -0.10315 2 3 GPBP1 S49 Q86WP2 R-X-X-S GPBP1 S 0.717561 0.47186 3 2 
GTSE1 S575 Q9NYZ3  GTSE1 S 0.796266 -0.34386 6 5 GTSE1 S580 Q9NYZ3  GTSE1 S 0.705498 -0.2206 5 5 H14 S2 P10412  H14 S 0.736821 0.22713 5 3 
H14 T4 P10412  H14 T 0.736821 0.16792 5 2 HDGR2 S633 Q7Z4V5 R-X-X-S HDGR2 S 6.1533 -0.16539 2 2 
HIRP3 S227 Q9BW71  HIRP3 S 1.09101 0.31398 6 5 HMGA2 S44 P52926  HMGA2 S 0.720541 0.20639 7 6 HNRPU S59 Q00839  HNRPU S 0.782744 -0.12069 4 3 IF2P S135 O60841  IF2P S 1.11801 0.29631 6 6 IF4B S93 P23588  IF4B S 0.925848 0.31115 5 4 
INCE T213 Q9NQS7  INCE T 1.18931 -0.48989 2 1 ISL2 S154 Q96A47  ISL2 S 0.81961 -0.51072 4 6 ISL2 S157 Q96A47  ISL2 S 0.689412 -0.51072 4 6 JCAD S755 Q9P266  JCAD S 0.616973 0.57522 2 4 
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Table 4.1 ETAA1-dependent phosphosites.  
Phosphosite Uniprot ATR Motif (SQ/TQ) CHK1 Motif (R-X-X-S) 
Protein 
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ETAA1∆AAD 
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TOPBP1-AID 
JCAD S757 Q9P266 R-X-X-S JCAD S 0.616973 0.57522 2 4 
K1671 S1757 Q9BY89  K1671 S 0.804632 -0.09517 2 5 K1671 S1760 Q9BY89  K1671 S 0.804632 -0.52195 2 1 KCTD3 S612 Q9Y597  KCTD3 S 0.603379 -0.04941 3 3 KCTD3 S711 Q9Y597  KCTD3 S 0.628447 -0.40124 2 1 KCTD3 T608 Q9Y597 R-X-X-S KCTD3 T 0.614757 -0.03336 3 2 
KI21A S1212 Q7Z4S6  KI21A S 1.42444 0.09464 5 1 KI21A S1271 Q7Z4S6  KI21A S 1.38758 0.24727 2 2 
KIF4A S1016 O95239  KIF4A S 0.709291 -1.62847 2 3 KLF4 S254 O43474  KLF4 S 0.819522 0.29151 3 2 LAD1 S121 O00515  LAD1 S 0.914856 -0.1707 4 1 LARP7 S300 Q4G0J3 R-X-X-S LARP7 S 3.00193 -0.31219 5 4 
LEO1 S300 Q8WVC0  LEO1 S 0.861876 -0.08461 3 1 
LIN54 S310 Q6MZP7  LIN54 S 0.778377 -0.63682 4 6 LIN54 S314 Q6MZP7  LIN54 S 0.778377 0.14952 7 6 LMBL3 S608 Q96JM7  LMBL3 S 0.587461 0.14966 7 5 LSR S464 Q86X29  LSR S 0.640417 -0.01364 2 3 LYN S13 P07948  LYN S 1.41133 0.15676 4 2 
M3K2 S153 Q9Y2U5  M3K2 S 0.595408 0.10423 3 2 M3K2 S331 Q9Y2U5 R-X-X-S M3K2 S 0.613826 -0.05969 4 2 
MAGG1 S303 Q96MG7  MAGG1 S 0.612683 0.03309 2 6 MAP1A S526 P78559  MAP1A S 0.981341 0.19954 2 2 MAP1A S527 P78559  MAP1A S 0.981341 0.19954 2 2 MARK2 S486 Q7KZI7  MARK2 S 0.602418 0.27953 3 2 MAST2 S209 Q6P0Q8 R-X-X-S MAST2 S 0.601697 0.54634 3 4 
MCAF1 S477 Q6VMQ6  MCAF1 S 0.882535 -0.26207 3 1 MCAF1 S559 Q6VMQ6 R-X-X-S MCAF1 S 1.22472 0.23045 3 5 
MCRS1 S282 Q96EZ8  MCRS1 S 0.610511 0.17758 3 2 MDC1 S1820 Q14676  MDC1 S 0.633013 -0.28083 5 6 MEX3C S537 Q5U5Q3 R-X-X-S/SQ MEX3C S 0.750864 0.13159 5 6 
MEX3D T510 Q86XN8  MEX3D T 0.780142 0.46957 2 3 MIB2 S309 Q96AX9 R-X-X-S MIB2 S 0.615796 -0.41431 4 5 
MIIP S303 Q5JXC2 R-X-X-S MIIP S 0.613437 0.27882 3 4 
MLL1 S161 Q03164 R-X-X-S MLL1 S 0.617918 -0.43673 3 3 
MLL1 T163 Q03164 R-X-X-S MLL1 T 1.05977 -0.34622 2 3 
MLXPL S614 Q9NP71 R-X-X-S MLXPL S 0.909888 0.22543 3 4 
MTUS1 S1245 Q9ULD2  MTUS1 S 0.799916 0.21711 4 6 
MTUS1 S1266 Q9ULD2  MTUS1 S 0.603027 0.028 2 1 MTUS1 S399 Q9ULD2  MTUS1 S 0.629363 0.24452 2 3 MUS81 S95 Q96NY9  MUS81 S 0.764856 0.33583 2 1 MY15B S1025 Q96JP2  MY15B S 1.64653 -0.89148 3 6 NDRG1 S2 Q92597  NDRG1 S 0.700568 0.21624 4 3 
NDRG1 T366 Q92597 R-X-X-S NDRG1 T 0.683562 0.28284 3 2 
NELFE S51 P18615 R-X-X-S NELFE S 0.782269 -0.06209 2 2 
NHS S530 Q6T4R5  NHS S 0.620458 0.01678 3 4 NOL8 S890 Q76FK4  NOL8 S 0.829812 -0.30879 5 3 NOL8 T888 Q76FK4  NOL8 T 0.829812 -0.30879 5 3 
NOP56 S314 O00567  NOP56 S 0.607358 0.32331 3 4 OFD1 S663 O75665  OFD1 S 0.585443 -1.02248 3 6 OFD1 S669 O75665  OFD1 S 0.625282 -0.63028 5 6 OFD1 S789 O75665  OFD1 S 0.772477 -1.15037 3 1 PA2G4 T11 Q9UQ80  PA2G4 T 0.975703 0.34596 2 2 
PAIRB S328 Q8NC51  PAIRB S 0.718397 0.4631 2 1 PAIRB S330 Q8NC51  PAIRB S 1.16434 0.02304 8 5 
PALLD Y731 Q8WX93  PALLD Y 1.00236 0.17847 2 2 PAPOG S525 Q9BWT3  PAPOG S 0.815739 0.01121 3 1 PARP4 S1335 Q9UKK3 R-X-X-S PARP4 S 0.642748 -0.71734 4 3 
PCY1A T342 P49585  PCY1A T 0.657823 0.43392 2 2 PHF3 S1133 Q92576  PHF3 S 0.885262 -0.1418 4 6 
PHRF1 S5 Q9P1Y6  PHRF1 S 1.05839 -1.34839 3 4 PI4KB S428 Q9UBF8  PI4KB S 1.19178 0.3611 6 4 PKHA6 S777 Q9Y2H5 R-X-X-S PKHA6 S 0.874723 -0.25309 2 4 
PKN2 T958 Q16513  PKN2 T 0.606916 -0.15991 5 5 
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Table 4.1 ETAA1-dependent phosphosites.  
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Ratio 
TOPBP1 
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TOPBP1-AID 
PP16A S418 Q96I34  PP16A S 2.16302 0.26988 2 2 
PP2BB S471 P16298 R-X-X-S PP2BB S 0.911863 0.10621 3 1 
PRR12 S1104 Q9ULL5  PRR12 S 0.649753 -0.27026 2 6 PTN2 S304 P17706  PTN2 S 0.586272 -0.24951 4 3 PTN21 S637 Q16825  PTN21 S 0.604316 0.24895 2 2 PTN3 S372 P26045  PTN3 S 0.824106 -0.16655 2 3 
PTTG1 S165 O95997  PTTG1 S 0.662661 -0.52511 6 5 PUR6 S27 P22234  PUR6 S 0.873863 0.09802 3 1 
PURB S6 Q96QR8  PURB S 1.11986 -0.08317 2 3 R3GEF S168 Q8TBN0  R3GEF S 1.39495 -0.26747 2 5 R3GEF S179 Q8TBN0  R3GEF S 1.39495 0.11488 2 4 R51A1 S120 Q96B01 SQ R51A1 S 1.30141 -0.0994 2 1 
RAB8A S185 P61006  RAB8A S 0.701344 0.50614 2 2 
RAF1 S244 P04049  RAF1 S 0.58665 0.58458 2 1 RANB3 S100 Q9H6Z4  RANB3 S 1.25048 0.36598 3 5 RANB3 S101 Q9H6Z4  RANB3 S 1.33069 0.14287 3 6 RANB9 S485 Q96S59  RANB9 S 0.592445 0.10814 5 3 RAVR1 S17 Q8IY67  RAVR1 S 0.832525 -0.21826 3 4 
RBL1 S749 P28749  RBL1 S 1.66317 -0.37692 5 6 RBL1 S762 P28749  RBL1 S 1.65908 -0.33303 5 6 
RBMX S88 P38159  RBMX S 0.777451 0.25108 4 6 RBP1 S29 Q15311 R-X-X-S RBP1 S 0.682034 0.28387 4 5 
REPS1 S562 Q96D71 R-X-X-S REPS1 S 1.91516 0.28143 2 3 
RERE S1106 Q9P2R6  RERE S 0.790689 0.48553 2 1 RERE S1113 Q9P2R6  RERE S 0.790689 0.48553 2 1 
RERE S1115 Q9P2R6 R-X-X-S RERE S 0.790689 0.48553 2 1 
RERE S142 Q9P2R6  RERE S 0.635025 0.41868 3 1 RERE S642 Q9P2R6  RERE S 0.943434 0.51712 3 4 RERE T599 Q9P2R6  RERE T 0.648097 0.17517 3 3 RFC1 S283 P35251  RFC1 S 0.819567 -0.18082 2 1 
RGL3 S569 Q3MIN7  RGL3 S 0.970854 0.15043 4 4 RGPS2 S329 Q86X27  RGPS2 S 0.608738 -0.01332 3 1 RGPS2 T326 Q86X27  RGPS2 T 0.928351 -0.01332 2 1 RHG17 S575 Q68EM7  RHG17 S 0.801912 0.22318 2 6 RHG17 S674 Q68EM7  RHG17 S 0.598825 0.51995 3 3 
RHG17 S676 Q68EM7 R-X-X-S RHG17 S 0.598825 0.51995 3 3 
RHPN2 S654 Q8IUC4  RHPN2 S 0.708765 -0.63332 2 1 
RIN1 S210 Q13671  RIN1 S 0.74149 0.28286 3 6 RIOK1 S22 Q9BRS2  RIOK1 S 0.747883 0.54815 5 3 RIOK2 S380 Q9BVS4  RIOK2 S 1.49567 0.04768 2 1 RIOK2 S382 Q9BVS4  RIOK2 S 1.49567 0.04768 2 1 RLF S632 Q13129  RLF S 1.00382 0.40545 3 4 
RN219 S210 Q5W0B1  RN219 S 0.666393 0.45954 2 4 ROA2 S85 P22626 R-X-X-S ROA2 S 0.697685 -0.56175 3 3 
RPIA T107 P49247  RPIA T 0.987088 0.07382 2 1 RS2 S264 P15880  RS2 S 0.593367 -0.08135 2 1 RTKN S106 Q9BST9 R-X-X-S RTKN S 0.869003 0.0404 2 5 
RUNX2 S28 Q13950 R-X-X-S RUNX2 S 1.27417 -0.46023 3 6 
SAC31 S402 A6NKF1 R-X-X-S SAC31 S 0.694122 -0.28847 2 1 
SAMH1 T592 Q9Y3Z3  SAMH1 T 0.694476 -0.29963 5 5 SARG T456 Q9BW04  SARG T 1.23351 0.39164 4 5 SC16A S1178 O15027  SC16A S 0.738033 -0.50173 3 1 
SCRIB S1486 Q14160 R-X-X-S SCRIB S 0.597221 0.11849 2 1 
SDS3 S32 Q9H7L9  SDS3 S 0.674551 -0.25402 3 4 
SETD2 S754 Q9BYW2  SETD2 S 0.686523 0.15924 2 1 SH319 S150 Q5HYK7  SH319 S 1.27047 0.30252 2 2 SH3R1 S735 Q7Z6J0  SH3R1 S 1.04921 -0.13903 2 2 SIN1 S510 Q9BPZ7 R-X-X-S SIN1 S 0.657731 0.14496 3 2 
SKA3 S155 Q8IX90  SKA3 S 0.60046 0.06757 4 4 
SNPC4 S599 Q5SXM2  SNPC4 S 0.647987 -0.09808 2 2 SOX4 S354 Q06945  SOX4 S 0.971295 -0.65203 2 2 SQSTM S332 Q13501  SQSTM S 0.746657 -0.0037 5 4 SRCAP S568 Q6ZRS2  SRCAP S 0.615322 0.47051 2 2 
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TOPBP1-AID 
SRGP1 S1005 Q7Z6B7  SRGP1 S 0.71642 -0.62211 2 3 
SRRM1 S310 Q8IYB3  SRRM1 S 0.775093 0.16993 2 5 SRRM1 S657 Q8IYB3  SRRM1 S 0.726134 0.08298 3 4 SSFA2 S352 P28290  SSFA2 S 0.916629 0.51299 3 1 SSFA2 S746 P28290  SSFA2 S 0.660992 0.58306 6 5 STMN1 S38 P16949  STMN1 S 0.718029 -0.10961 7 6 
STRN3 S229 Q13033  STRN3 S 0.747578 0.09221 4 3 TACC2 S2072 O95359 R-X-X-S TACC2 S 1.02899 0.33743 2 6 
TACC2 S2226 O95359  TACC2 S 1.24329 0.29619 3 6 TACC2 S2317 O95359  TACC2 S 0.898406 0.39408 4 6 TACC2 S2321 O95359  TACC2 S 0.898406 0.39408 4 6 TACC3 S250 Q9Y6A5  TACC3 S 0.722379 0.40991 3 6 TACC3 T249 Q9Y6A5  TACC3 T 0.703758 0.47931 4 5 
TB10B S707 Q4KMP7  TB10B S 1.64966 0.1296 2 5 TFE2 S379 P15923  TFE2 S 0.64612 0.47384 6 6 TNC18 S1038 O15417  TNC18 S 0.993928 -0.27075 3 4 TPIS S58 P60174 R-X-X-S TPIS S 0.683066 -0.8347 8 6 
TPRN S241 Q4KMQ1  TPRN S 0.727528 -0.4088 2 2 
TR150 S55 Q9Y2W1 R-X-X-S TR150 S 0.677441 -0.0212 5 6 
TR150 S575 Q9Y2W1 R-X-X-S TR150 S 0.86769 0.22462 5 5 
UB2J1 S266 Q9Y385 R-X-X-S UB2J1 S 1.02655 0.49088 5 6 
UBP36 S667 Q9P275  UBP36 S 0.603027 -0.41588 3 5 US6NL S680 Q92738  US6NL S 1.05949 0.20727 3 5 VCIP1 S998 Q96JH7 R-X-X-S VCIP1 S 1.61655 0.17486 3 4 
VGLL4 S101 Q14135 R-X-X-S VGLL4 S 1.43328 -0.35874 3 3 
VGLL4 S103 Q14135 R-X-X-S VGLL4 S 1.43328 -0.07599 3 3 
WNK1 S2011 Q9H4A3  WNK1 S 0.708659 -0.00929 4 3 WNK1 S2012 Q9H4A3  WNK1 S 0.667211 -0.12496 5 4 WNK1 S2027 Q9H4A3  WNK1 S 1.02084 0.17172 3 3 WNK1 S2029 Q9H4A3  WNK1 S 1.15653 0.5175 4 4 
WNK1 S2032 Q9H4A3  WNK1 S 1.15653 0.5175 4 4 Y103 (blank)  (blank) Y 0.722029 0.41175 2 1 YTDC1 T148 Q96MU7  YTDC1 T 1.21851 0.21325 3 6 Z3H7B T240 Q9UGR2  Z3H7B T 0.67229 -0.13324 2 2 ZBED4 S609 O75132 R-X-X-S ZBED4 S 0.685097 -0.6405 2 1 
ZC3HD S64 Q5T200  ZC3HD S 1.33297 -0.12265 4 5 ZFAN5 S48 O76080  ZFAN5 S 0.709291 0.35539 3 4 
ZN318 S1856 Q5VUA4  ZN318 S 0.672561 -0.11486 5 5 ZN318 S40 Q5VUA4 R-X-X-S ZN318 S 1.69681 -0.24734 4 1 
ZO1 S1617 Q07157  ZO1 S 0.61995 0.18663 6 5 ZO1 S912 Q07157 R-X-X-S ZO1 S 0.961884 -0.85664 3 3 
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Table 4.2 TOPBP1-dependent phosphosites. TOPBP1-dependent phosphosites are given 
below along with the Uniprot ID, modified residue, presence of ATR or CHK1 motif, and the 
number of experiments in which that peptide was observed. The ratio value is the log2 
transformed ratio of WT /ETAA1 or TOPBP1 cells. Therefore, a higher value (darker green) is 
more dependent on ETAA1 or TOPBP1.   
Table 4.2 TOPBP1-dependent phosphosites 
Phosphosite Uniprot 
ATR Motif (SQ/TQ) 
CHK1 Motif (R-X-X-S) 
Protein 
Name 
Amino 
acid 
ETAA1 
Ratio 
TOPBP1 
Ratio 
Count 
ETAA1∆AAD 
Count 
TOPBP1-AID 
4EBP1 S65 Q13541 
 
4EBP1 S 0.018774 1.42573 6 6 
4EBP1 T46 Q13541 
 
4EBP1 T -0.07551 0.702899 3 3 
4EBP1 T68 Q13541 
 
4EBP1 T 0.08134 0.961179 4 2 
4EBP1 T70 Q13541 
 
4EBP1 T 0.094308 1.01085 7 6 
AAPK1 S356 Q13131 
 
AAPK1 S 0.17479 0.635801 6 6 
ABI1 S222 Q8IZP0 R-X-X-S/SQ ABI1 S 0.445409 2.19374 1 3 
ABI2 Y213 Q9NYB9 
 
ABI2 Y 0.24306 0.902503 5 4 
ACOD S198 O00767 
 
ACOD S 0.579663 0.668426 1 2 
ADAM9 S752 Q13443 
 
ADAM9 S 0.052972 0.674896 1 2 
ADDA S355 P35611 
 
ADDA S 0.212881 0.81052 2 3 
ADNP S709 Q9H2P0 
 
ADNP S -0.06309 1.26879 2 4 
AEBP2 S24 Q6ZN18 
 
AEBP2 S 0.342678 1.26022 7 5 
AF9 S483 P42568 
 
AF9 S 0.474254 0.836828 1 2 
AFAD S1172 P55196 
 
AFAD S 0.128058 0.838508 4 6 
AFAD S1182 P55196 
 
AFAD S 0.10528 0.838508 7 6 
AHNK S2397 Q09666 
 
AHNK S 0.156745 1.199 3 2 
AHNK S5077 Q09666 
 
AHNK S 0.303568 0.930245 4 6 
AHNK S93 Q09666 
 
AHNK S 0.430927 0.621524 7 6 
AKA11 S433 Q9UKA4 
 
AKA11 S -0.15701 1.53725 1 3 
AKA11 T1100 Q9UKA4 
 
AKA11 T 0.186078 1.00806 4 2 
AKA12 S1328 Q02952 
 
AKA12 S 0.425411 1.27638 4 4 
AKA12 S1331 Q02952 
 
AKA12 S 0.297337 0.626112 7 6 
AKA12 S371 Q02952 
 
AKA12 S 0.313151 0.652601 6 3 
AKA12 S483 Q02952 
 
AKA12 S 0.506399 0.685716 5 3 
AKA12 S598 Q02952 
 
AKA12 S 0.31734 0.724738 8 6 
AKA12 S644 Q02952 
 
AKA12 S 0.511639 0.60046 7 6 
AKA12 S645 Q02952 
 
AKA12 S 0.511639 0.60046 7 6 
AKA12 T642 Q02952 
 
AKA12 T 0.133492 0.799087 4 4 
AKA12 T646 Q02952 
 
AKA12 T 0.251204 0.992177 5 4 
AKTS1 S183 Q96B36 
 
AKTS1 S 0.413756 1.12428 2 2 
AKTS1 S203 Q96B36 
 
AKTS1 S 0.017067 0.733084 5 4 
ALG3 S13 Q92685 R-X-X-S ALG3 S -0.23601 1.02883 2 2 
AMD S918 P19021 
 
AMD S 0.480369 1.37095 4 5 
AN32A S17 P39687 R-X-X-S AN32A S 0.4755 1.17376 1 3 
ANK3 S1459 Q12955 R-X-X-S ANK3 S -0.2947 0.742955 3 3 
ANR11 S1878 Q6UB99 
 
ANR11 S -0.05872 0.779218 6 4 
ANR17 S2045 O75179 
 
ANR17 S 0.369006 1.09228 4 6 
ANR17 S2047 O75179 
 
ANR17 S 0.131589 0.957543 6 5 
ANR17 S2067 O75179 
 
ANR17 S 0.438399 1.73202 1 2 
ANR32 S159 Q9BQI6 
 
ANR32 S -0.52701 0.654619 1 2 
ANS1A Y834 Q92625 
 
ANS1A Y 0.153902 1.06516 2 2 
APC1 S377 Q9H1A4 
 
APC1 S 0.050606 2.83946 4 4 
ARHGG S174 Q5VV41 
 
ARHGG S 0.195222 0.654985 6 5 
ARHGI S1101 Q6ZSZ5 
 
ARHGI S 0.280979 1.10969 4 5 
ARHGI S1103 Q6ZSZ5 R-X-X-S ARHGI S -0.03159 0.702746 7 5 
ARI1A S715 O14497 
 
ARI1A S 0.53047 0.762142 1 3 
ARI1A S769 O14497 
 
ARI1A S 0.005525 0.769179 3 3 
ARI4B S666 Q4LE39 R-X-X-S ARI4B S -0.45003 0.862511 3 2 
ARI4B S675 Q4LE39 
 
ARI4B S -0.03614 0.938399 6 6 
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Table 4.2 TOPBP1-dependent phosphosites 
Phosphosite Uniprot 
ATR Motif (SQ/TQ) 
CHK1 Motif (R-X-X-S) 
Protein 
Name 
Amino 
acid 
ETAA1 
Ratio 
TOPBP1 
Ratio 
Count 
ETAA1∆AAD 
Count 
TOPBP1-AID 
ARL3 S5 P36405 
 
ARL3 S 0.312954 0.631337 4 4 
ARRB1 S412 P49407 
 
ARRB1 S 0.039279 0.732194 3 2 
ASAP2 S822 O43150 R-X-X-S ASAP2 S 0.241474 0.955462 2 2 
ATAD2 S342 Q6PL18 
 
ATAD2 S 0.348799 0.673737 4 3 
ATG9A S656 Q7Z3C6 R-X-X-S ATG9A S 0.231678 1.29154 2 3 
ATG9A S828 Q7Z3C6 
 
ATG9A S 0.443552 1.43018 5 4 
ATR S436 Q13535 R-X-X-S ATR S -0.16411 1.00076 4 2 
ATRX S1352 P46100 
 
ATRX S -0.08358 1.60189 4 3 
ATRX S634 P46100 
 
ATRX S 0.068723 0.765704 4 2 
BAG3 S194 O95817 
 
BAG3 S 0.185993 2.20571 2 4 
BAG3 S195 O95817 
 
BAG3 S 0.212693 1.39678 4 5 
BAP18 S96 Q8IXM2 
 
BAP18 S 0.239727 1.03168 5 5 
BAZ1A S1417 Q9NRL2 
 
BAZ1A S 0.297837 0.731369 3 3 
BAZ1B S1342 Q9UIG0 R-X-X-S BAZ1B S 0.367483 0.644779 6 5 
BAZ1B S160 Q9UIG0 
 
BAZ1B S 0.01455 0.652326 4 4 
BBX S478 Q8WY36 
 
BBX S -0.54294 0.783262 7 4 
BBX S479 Q8WY36 R-X-X-S BBX S -0.5161 0.783262 7 4 
BBX S481 Q8WY36 
 
BBX S -0.55618 0.783262 7 3 
BBX S844 Q8WY36 
 
BBX S 0.182057 0.618333 7 4 
BCAS3 S480 Q9H6U6 
 
BCAS3 S 0.578697 1.97311 5 4 
BCAS3 S488 Q9H6U6 
 
BCAS3 S 0.578118 0.893893 1 2 
BCL7C S126 Q8WUZ0 R-X-X-S BCL7C S 0.042784 0.690998 7 6 
BCLF1 S183 Q9NYF8 SQ BCLF1 S 0.037031 0.665666 5 3 
BIG2 S218 Q9Y6D5 
 
BIG2 S 0.157303 0.940881 6 6 
BORG4 S174 Q9H3Q1 
 
BORG4 S -0.04796 0.885106 4 2 
BRM1L S197 Q5PSV4 
 
BRM1L S 0.011353 0.942909 1 4 
BRMS1 S237 Q9HCU9 
 
BRMS1 S -0.08896 0.69073 2 3 
BRWD1 S2018 Q9NSI6 
 
BRWD1 S -0.25096 0.665817 1 2 
BRWD1 S2020 Q9NSI6 
 
BRWD1 S -0.25096 0.665817 1 2 
BRWD1 S696 Q9NSI6 R-X-X-S BRWD1 S -0.22482 0.894294 3 4 
BUD13 S239 Q9BRD0 
 
BUD13 S 0.108491 0.675013 1 4 
BUD13 S240 Q9BRD0 
 
BUD13 S 0.243547 0.675013 2 4 
BUD13 T123 Q9BRD0 R-X-X-S BUD13 T 0.039974 0.587941 3 4 
CA144 S107 Q7Z422 
 
CA144 S 0.001298 1.47303 6 2 
CA144 S37 Q7Z422 
 
CA144 S 0.312009 0.642378 7 6 
CA226 S222 A1L170 R-X-X-S CA226 S -0.30185 1.71664 2 2 
CA226 S223 A1L170 R-X-X-S CA226 S -0.30185 1.71664 2 2 
CAF1A S203 Q13111 
 
CAF1A S 0.143524 0.822263 4 5 
CAF1B S429 Q13112 
 
CAF1B S 0.003537 0.831521 5 5 
CAMP2 S1019 Q08AD1 R-X-X-S CAMP2 S 0.09842 0.706287 2 4 
CAP1 S308 Q01518 
 
CAP1 S 0.068126 1.19333 6 4 
CAP1 S310 Q01518 
 
CAP1 S 0.09692 1.19333 6 4 
CAPON S266 O75052 
 
CAPON S 0.204767 1.25743 3 3 
CB044 S468 Q9H6R7 
 
CB044 S 0.356031 0.681404 4 3 
CBX5 S11 P45973 
 
CBX5 S 0.245374 0.810222 4 3 
CBX5 S12 P45973 
 
CBX5 S 0.245374 0.810222 4 3 
CBX5 S13 P45973 
 
CBX5 S 0.245374 0.810222 4 3 
CBX5 S14 P45973 
 
CBX5 S 0.245374 0.810222 4 3 
CBX8 S311 Q9HC52 R-X-X-S CBX8 S 0.107822 0.838451 4 5 
CC165 S1812 Q9Y4B5 R-X-X-S CC165 S 0.109026 1.86492 1 2 
CC165 S1814 Q9Y4B5 R-X-X-S CC165 S 0.109026 1.86492 1 2 
CC85C S246 A6NKD9 
 
CC85C S 0.030265 0.606158 7 6 
CCDC6 S52 Q16204 
 
CCDC6 S 0.361655 0.74028 3 2 
CCDC9 S202 Q9Y3X0 R-X-X-S CCDC9 S -0.1555 0.627887 1 3 
CCNL1 S342 Q9UK58 
 
CCNL1 S 0.011066 0.800165 6 6 
CDA7L S108 Q96GN5 
 
CDA7L S 0.294077 0.939753 2 2 
CDC23 T562 Q9UJX2 
 
CDC23 T 0.019346 0.698396 1 5 
CDK17 S9 Q00537 R-X-X-S CDK17 S 0.144958 0.79703 2 4 
CDYL1 S201 Q9Y232 
 
CDYL1 S -0.05567 0.603787 6 6 
CE170 S1521 Q5SW79 
 
CE170 S -0.0573 0.849185 5 4 
CE170 S1522 Q5SW79 
 
CE170 S -0.0573 0.781752 5 5 
CE170 S838 Q5SW79 R-X-X-S CE170 S 0.013049 0.61899 3 4 
CG043 S495 Q8WVR3 R-X-X-S CG043 S 0.484491 1.36474 4 3 
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Table 4.2 TOPBP1-dependent phosphosites 
Phosphosite Uniprot 
ATR Motif (SQ/TQ) 
CHK1 Motif (R-X-X-S) 
Protein 
Name 
Amino 
acid 
ETAA1 
Ratio 
TOPBP1 
Ratio 
Count 
ETAA1∆AAD 
Count 
TOPBP1-AID 
CHAP1 S204 Q96JM3 
 
CHAP1 S -0.15999 0.705934 7 6 
CHAP1 S286 Q96JM3 
 
CHAP1 S 0.16337 0.610428 7 5 
CHAP1 S445 Q96JM3 
 
CHAP1 S 0.087887 0.753605 5 3 
CHAP1 S651 Q96JM3 
 
CHAP1 S -0.09463 0.808615 5 3 
CHAP1 S652 Q96JM3 
 
CHAP1 S -0.09463 0.834567 5 3 
CHAP1 S653 Q96JM3 
 
CHAP1 S -0.09463 0.808615 5 3 
CI078 Y147 Q9NZ63 
 
CI078 Y 0.250719 0.605335 4 2 
CIZ1 S838 Q9ULV3 
 
CIZ1 S 0.20964 0.653519 6 5 
CLK3 S280 P49761 
 
CLK3 S 0.273237 1.33777 2 3 
CLK3 S281 P49761 
 
CLK3 S 0.273237 1.33777 3 3 
CLK3 S283 P49761 
 
CLK3 S 0.257888 0.63006 3 5 
COPA S173 P53621 
 
COPA S 0.117296 0.638793 4 3 
CPSF1 S765 Q10570 
 
CPSF1 S 0.079429 1.54775 5 2 
CPSF1 S766 Q10570 R-X-X-S/SQ CPSF1 S 0.108313 1.38156 6 5 
CQ096 S173 A6NHQ4 
 
CQ096 S 0.000636 0.645794 4 2 
CQ096 S184 A6NHQ4 R-X-X-S CQ096 S 0.002936 0.608809 4 2 
CR025 S67 Q96B23 R-X-X-S CR025 S 0.287354 0.6277 3 2 
CRKL S184 P46109 
 
CRKL S -0.08183 0.601411 1 2 
CRKL S185 P46109 
 
CRKL S -0.08183 0.601411 1 3 
CTU2 S435 Q2VPK5 
 
CTU2 S 0.253958 0.782583 2 2 
CUED2 Y275 Q9H467 
 
CUED2 Y -0.20015 0.703559 1 2 
DAB2P S978 Q5VWQ8 
 
DAB2P S 0.313478 2.02801 2 3 
DAP1 S3 P51397 
 
DAP1 S 0.162597 0.984271 3 2 
DBNL S283 Q9UJU6 
 
DBNL S 0.228247 0.710261 2 5 
DCP1A S62 Q9NPI6 R-X-X-S DCP1A S 0.293875 1.5996 3 2 
DDX24 S82 Q9GZR7 
 
DDX24 S 0.061882 0.591679 8 6 
DHX16 S160 O60231 
 
DHX16 S 0.00173 1.49214 2 4 
DHX29 S200 Q7Z478 
 
DHX29 S 0.327457 0.841732 7 6 
DKC1 S21 O60832 
 
DKC1 S -0.10895 1.03017 7 5 
DMAP1 T445 Q9NPF5 
 
DMAP1 T 0.0397 0.592035 5 2 
DNJC5 T11 Q9H3Z4 
 
DNJC5 T 0.125244 0.637253 2 2 
DNM3A S105 Q9Y6K1 
 
DNM3A S 0.077516 1.52421 3 3 
DOCK7 S1383 Q96N67 R-X-X-S DOCK7 S 0.239398 0.940174 3 4 
DOCK7 S2129 Q96N67 
 
DOCK7 S 0.048097 0.678523 3 3 
DOCK7 S452 Q96N67 R-X-X-S DOCK7 S 0.176706 1.02233 5 5 
DOCK7 S888 Q96N67 R-X-X-S DOCK7 S 0.136454 1.90115 1 2 
DOCK7 S900 Q96N67 
 
DOCK7 S 0.224739 0.722204 4 4 
DOT1L S447 Q8TEK3 
 
DOT1L S 0.191548 0.601316 4 2 
DOT1L S902 Q8TEK3 
 
DOT1L S 0.116764 0.982967 5 3 
DPYL3 S522 Q14195 
 
DPYL3 S -0.10815 4.46284 6 4 
DSG2 Y1013 Q14126 
 
DSG2 Y 0.331934 0.665257 1 2 
DYHC1 S4368 Q14204 R-X-X-S DYHC1 S 0.259544 0.752749 3 2 
EHBP1 S428 Q8NDI1 
 
EHBP1 S 0.046701 0.711407 6 5 
EIF3B S81 P55884 
 
EIF3B S -0.07885 0.66339 1 3 
EIF3B S85 P55884 
 
EIF3B S 0.090989 0.71721 2 4 
EIF3G T41 O75821 
 
EIF3G T 0.069702 0.601031 7 4 
ELL S319 P55199 R-X-X-S ELL S -0.08841 1.23691 1 2 
ELOA1 S251 Q14241 SQ ELOA1 S -0.04493 1.38072 1 2 
EMAL4 S144 Q9HC35 
 
EMAL4 S 0.172876 0.968718 5 5 
ENAH T489 Q8N8S7 
 
ENAH T -0.11134 0.85814 1 2 
EP15R S108 Q9UBC2 
 
EP15R S 0.123549 0.662015 3 2 
EPHA2 T898 P29317 
 
EPHA2 T -0.94878 0.822894 1 2 
EPN1 S454 Q9Y6I3 
 
EPN1 S -0.38517 0.880646 4 3 
EPN1 T470 Q9Y6I3 
 
EPN1 T -0.34452 0.773743 7 3 
ERBB3 S982 P21860 
 
ERBB3 S -0.42239 0.665211 1 3 
ERCC5 T338 P28715 
 
ERCC5 T 0.370611 1.10213 1 2 
ERRFI S249 Q9UJM3 
 
ERRFI S 0.114135 2.42089 2 4 
ERRFI S251 Q9UJM3 R-X-X-S ERRFI S 0.277271 2.42089 5 4 
ERRFI S273 Q9UJM3 
 
ERRFI S 0.09031 1.32949 4 2 
ERRFI S334 Q9UJM3 R-X-X-S ERRFI S 0.582845 1.52751 3 2 
ERRFI S461 Q9UJM3 
 
ERRFI S 0.570269 1.50927 1 2 
F122B S115 Q7Z309 
 
F122B S 0.454808 1.46869 7 6 
F122B S119 Q7Z309 
 
F122B S 0.356369 1.45854 7 6 
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Table 4.2 TOPBP1-dependent phosphosites 
Phosphosite Uniprot 
ATR Motif (SQ/TQ) 
CHK1 Motif (R-X-X-S) 
Protein 
Name 
Amino 
acid 
ETAA1 
Ratio 
TOPBP1 
Ratio 
Count 
ETAA1∆AAD 
Count 
TOPBP1-AID 
F122B S137 Q7Z309 
 
F122B S 0.023242 1.32608 4 2 
F122B S24 Q7Z309 R-X-X-S F122B S 0.01985 1.6673 3 4 
F122B S25 Q7Z309 R-X-X-S F122B S 0.2949 1.88491 7 4 
F122B S50 Q7Z309 R-X-X-S F122B S 0.361053 1.42542 5 4 
F169A S635 Q9Y6X4 
 
F169A S -0.09766 3.26616 4 3 
F169A S636 Q9Y6X4 
 
F169A S -0.09766 3.26616 4 3 
F208A S927 Q9UK61 
 
F208A S -0.00225 1.92227 3 5 
F208B S2037 Q5VWN6 R-X-X-S F208B S 0.101582 0.589668 6 6 
FA53B S178 Q14153 
 
FA53B S 0.241352 1.28607 2 2 
FA53B S179 Q14153 
 
FA53B S 0.242389 1.69171 4 4 
FA53C S273 Q9NYF3 R-X-X-S/SQ FA53C S 0.236952 0.801821 1 2 
FAF1 S582 Q9UNN5 R-X-X-S FAF1 S 0.481712 0.769913 2 4 
FAK1 S910 Q05397 
 
FAK1 S -0.10558 0.755229 6 4 
FARP1 S427 Q9Y4F1 
 
FARP1 S -0.28611 0.668755 1 5 
FAS S2236 P49327 R-X-X-S FAS S 0.406646 1.10064 1 4 
FAT1 S4272 Q14517 
 
FAT1 S -0.49498 0.731936 6 5 
FAT1 S4276 Q14517 
 
FAT1 S -0.41876 0.909658 3 3 
FBX42 S488 Q6P3S6 R-X-X-S FBX42 S 0.184979 3.21053 1 3 
FBX42 S552 Q6P3S6 
 
FBX42 S 0.390448 0.775926 1 2 
FCHO1 S583 O14526 
 
FCHO1 S -0.15224 0.602485 1 2 
FCHO1 S585 O14526 R-X-X-S FCHO1 S -0.15224 0.69682 1 2 
FCHO2 S403 Q0JRZ9 R-X-X-S FCHO2 S 0.291721 1.14809 1 2 
FCHO2 S488 Q0JRZ9 R-X-X-S FCHO2 S 0.504757 1.338 5 6 
FCHO2 S496 Q0JRZ9 
 
FCHO2 S 0.503383 1.32642 5 6 
FCHO2 T495 Q0JRZ9 
 
FCHO2 T 0.418892 1.50357 3 3 
FGD1 S48 P98174 R-X-X-S FGD1 S -0.2238 1.93428 4 3 
FGD1 S50 P98174 
 
FGD1 S -0.24623 1.67645 4 4 
FKBP3 S36 Q00688 
 
FKBP3 S -0.08628 1.70189 1 2 
FND3A S213 Q9Y2H6 
 
FND3A S 0.01591 0.647821 2 3 
FOSL1 S101 P15407 
 
FOSL1 S 0.357721 1.99816 3 2 
FOXK2 S398 Q01167 R-X-X-S FOXK2 S 0.003746 0.629846 7 6 
FUBP2 S125 Q92945 SQ FUBP2 S -0.09718 0.994798 1 2 
FUBP2 S129 Q92945 
 
FUBP2 S -0.09718 0.994798 1 2 
FXR2 S601 P51116 
 
FXR2 S 0.304978 0.811774 6 5 
FXR2 S603 P51116 
 
FXR2 S 0.038155 0.811774 6 5 
FYV1 S23 Q9Y2I7 
 
FYV1 S -0.00855 0.857742 1 2 
GCP60 S43 Q9H3P7 
 
GCP60 S 0.307545 0.919988 1 2 
GEPH S188 Q9NQX3 
 
GEPH S -0.00432 0.601316 5 6 
GEPH S194 Q9NQX3 
 
GEPH S -0.00347 0.601316 5 6 
GIPC1 S232 O14908 R-X-X-S GIPC1 S 0.507508 0.767824 4 6 
GLYR1 S130 Q49A26 R-X-X-S GLYR1 S -0.10388 4.19912 5 5 
GLYR1 S158 Q49A26 
 
GLYR1 S 0.35242 4.40061 3 5 
GON4L S206 Q3T8J9 
 
GON4L S 0.116365 2.6762 3 3 
GRIN1 S73 Q7Z2K8 R-X-X-S GRIN1 S -0.10914 1.03682 1 3 
GRIN1 S850 Q7Z2K8 R-X-X-S GRIN1 S -0.37771 0.602362 2 3 
GSK3A S278 P49840 
 
GSK3A S 0.104104 1.74084 2 3 
GULP1 S211 Q9UBP9 
 
GULP1 S 0.285256 1.0267 4 3 
H12 S2 P16403 
 
H12 S 0.041673 0.853517 2 4 
HCFC1 S2019 P51610 R-X-X-S HCFC1 S 0.12366 6.93605 3 2 
HDAC4 S467 P56524 R-X-X-S HDAC4 S 0.296545 1.1944 3 4 
HDAC4 S632 P56524 R-X-X-S HDAC4 S 0.207034 2.03091 6 5 
HDC S264 Q9UBI9 
 
HDC S 0.269742 0.660262 3 4 
HDC S268 Q9UBI9 
 
HDC S 0.269742 0.660262 3 4 
HDC S272 Q9UBI9 
 
HDC S 0.220454 0.74676 2 2 
HEAT6 S395 Q6AI08 
 
HEAT6 S 0.322446 1.02531 2 2 
HEAT6 S396 Q6AI08 R-X-X-S HEAT6 S 0.322446 1.02531 2 2 
HECD1 S1772 Q9ULT8 R-X-X-S HECD1 S 0.309448 1.53824 4 3 
HECD1 S357 Q9ULT8 R-X-X-S HECD1 S 0.235482 0.968883 1 2 
HLTF S397 Q14527 
 
HLTF S 0.144177 1.02704 3 5 
HLTF S398 Q14527 
 
HLTF S 0.144177 1.02704 3 5 
HLTF S400 Q14527 
 
HLTF S 0.144177 1.02704 3 5 
HMGA1 S9 P17096 SQ HMGA1 S -0.50092 1.35561 2 2 
HMGA1 T53 P17096 
 
HMGA1 T 0.152768 1.02843 1 4 
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Ratio 
Count 
ETAA1∆AAD 
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TOPBP1-AID 
HMGA2 S2 P52926 
 
HMGA2 S 0.479541 1.04782 1 5 
HMGX4 S497 Q9UGU5 
 
HMGX4 S 0.37829 0.622462 4 5 
HMGX4 S502 Q9UGU5 
 
HMGX4 S 0.407625 0.776357 3 2 
HMGX4 S512 Q9UGU5 
 
HMGX4 S -0.02191 0.704252 4 2 
HNF1B S279 P35680 R-X-X-S HNF1B S -0.08337 5.09733 3 2 
HNRPM Y64 P52272 
 
HNRPM Y -0.41629 0.693324 1 5 
HOMEZ T451 Q8IX15 R-X-X-S HOMEZ T 0.153546 0.704075 4 3 
HTSF1 S702 O43719 
 
HTSF1 S -0.0286 0.864209 2 2 
I2BP1 S436 Q8IU81 
 
I2BP1 S 0.127765 0.707914 4 3 
ID2 S14 Q02363 R-X-X-S ID2 S 0.378051 0.794686 5 6 
IF2B2 S162 Q9Y6M1 
 
IF2B2 S 0.034259 1.22113 4 3 
IF4G2 S395 P78344 
 
IF4G2 S 0.349026 0.678072 4 4 
IF4G2 T385 P78344 
 
IF4G2 T 0.058663 0.87887 1 3 
IF4G2 T508 P78344 R-X-X-S IF4G2 T 0.174406 0.927669 5 6 
ILF3 T592 Q12906 
 
ILF3 T 0.191942 0.641911 1 2 
IRS1 S527 P35568 R-X-X-S IRS1 S 0.213254 0.685378 4 3 
IRS2 S388 Q9Y4H2 
 
IRS2 S -0.0978 0.8383 1 2 
IRS2 S391 Q9Y4H2 
 
IRS2 S -0.32408 0.88144 1 2 
ITPR3 S1832 Q14573 R-X-X-S ITPR3 S 0.144219 1.35377 2 3 
ITPR3 S916 Q14573 
 
ITPR3 S -0.35916 1.01028 2 3 
ITSN1 S904 Q15811 
 
ITSN1 S -0.29163 0.605589 4 2 
JHD2C T505 Q15652 R-X-X-S JHD2C T 0.256045 0.598937 1 3 
JIP4 S183 O60271 
 
JIP4 S 0.301002 0.910963 3 3 
JMY S888 Q8N9B5 R-X-X-S JMY S -0.13248 1.23915 4 4 
JMY S889 Q8N9B5 R-X-X-S JMY S -0.10919 1.43087 5 3 
JUNB T255 P17275 
 
JUNB T 0.353662 0.844627 4 3 
JUND S255 P17535 
 
JUND S -0.09439 0.650489 7 5 
K0284 S829 Q9Y4F5 
 
K0284 S 0.249705 0.596554 5 6 
K0284 S972 Q9Y4F5 
 
K0284 S 0.318651 0.718565 3 4 
K0913 S567 A7E2V4 R-X-X-S K0913 S -0.62728 1.00166 2 4 
K0930 S304 Q6ICG6 
 
K0930 S -0.01232 1.04872 5 4 
K0930 S351 Q6ICG6 R-X-X-S K0930 S -0.00835 0.608921 1 2 
K0930 S353 Q6ICG6 R-X-X-S K0930 S -0.00835 0.608921 1 2 
K0930 T293 Q6ICG6 
 
K0930 T -0.04862 0.700091 1 2 
K1211 S873 Q6ZU35 
 
K1211 S -0.03139 0.58807 1 3 
K1211 S874 Q6ZU35 R-X-X-S K1211 S 0.525468 0.58807 3 3 
K1211 T875 Q6ZU35 
 
K1211 T -0.03139 0.58807 1 3 
K6PF S667 P08237 
 
K6PF S 0.22404 0.89933 5 4 
KANL1 S268 Q7Z3B3 
 
KANL1 S 0.035591 1.08488 3 2 
KANL3 S515 Q9P2N6 R-X-X-S KANL3 S -0.05754 1.19812 1 4 
KAT5 S86 Q92993 
 
KAT5 S -0.03514 0.647453 2 2 
KAT6A S1113 Q92794 
 
KAT6A S -0.75638 0.681494 3 4 
KHDR1 Y440 Q07666 
 
KHDR1 Y -0.27114 0.826104 2 2 
KI67 S3042 P46013 
 
KI67 S -0.48459 0.738552 1 3 
KI67 S584 P46013 
 
KI67 S 0.028286 0.766807 4 4 
KI67 Y340 P46013 
 
KI67 Y -0.33841 1.21033 2 2 
KIF15 S1141 Q9NS87 
 
KIF15 S 0.441739 0.913939 3 4 
KIF15 T1144 Q9NS87 
 
KIF15 T 0.441739 0.913939 3 4 
KIF23 S18 Q02241 SQ KIF23 S 0.467737 1.46077 3 3 
KITH S231 P04183 
 
KITH S -0.95691 0.974815 1 2 
KLDC4 S407 Q8TBB5 
 
KLDC4 S 0.03196 0.728312 3 3 
KLDC4 S413 Q8TBB5 
 
KLDC4 S -0.05901 0.905351 6 6 
KLDC4 T403 Q8TBB5 
 
KLDC4 T 0.082975 0.728312 1 3 
KLF3 S250 P57682 
 
KLF3 S 0.095047 1.24888 5 4 
KLF3 S71 P57682 
 
KLF3 S 0.341303 0.832363 2 5 
KPCD S299 Q05655 
 
KPCD S 0.044553 1.09535 2 4 
KPCD S645 Q05655 
 
KPCD S -0.03657 0.675635 4 3 
KPCD T295 Q05655 TQ KPCD T -0.0106 0.884168 2 3 
KPYM S37 P14618 
 
KPYM S 0.203106 0.696928 3 4 
KS6A1 S363 Q15418 
 
KS6A1 S -0.14877 1.11522 5 5 
KS6A1 T359 Q15418 
 
KS6A1 T -0.14877 1.29977 5 4 
KS6A3 S369 P51812 
 
KS6A3 S 0.070735 0.853117 4 4 
KS6B1 S441 P23443 
 
KS6B1 S -0.0523 1.27131 1 2 
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KS6B1 T444 P23443 
 
KS6B1 T 0.020564 1.27131 2 3 
KTNB1 Y337 Q9BVA0 R-X-X-S KTNB1 Y -0.19362 0.60005 2 2 
LAP2A S424 P42166 
 
LAP2A S 0.012211 0.664091 1 4 
LAP2A S433 P42166 
 
LAP2A S 0.328837 0.719697 1 2 
LAP2A T74 P42166 R-X-X-S LAP2A T 0.350837 0.644502 3 2 
LAR1B S340 Q659C4 R-X-X-S LAR1B S 0.396598 0.611267 5 6 
LARP1 T782 Q6PKG0 
 
LARP1 T 0.163987 1.80117 2 2 
LARP1 T785 Q6PKG0 
 
LARP1 T 0.077808 1.82204 2 3 
LARP1 T788 Q6PKG0 
 
LARP1 T 0.083384 1.30184 3 3 
LIMA1 S132 Q9UHB6 R-X-X-S LIMA1 S -0.03937 0.660016 7 6 
LIMA1 S374 Q9UHB6 
 
LIMA1 S -0.12047 1.13402 2 5 
LIMA1 S490 Q9UHB6 
 
LIMA1 S 0.037874 0.738811 7 6 
LIMA1 S609 Q9UHB6 
 
LIMA1 S -0.00399 0.75232 7 6 
LIMA1 S686 Q9UHB6 
 
LIMA1 S -0.09923 0.589571 6 5 
LIMA1 S698 Q9UHB6 
 
LIMA1 S -0.40471 0.630512 1 2 
LIPA1 S239 Q13136 
 
LIPA1 S 0.17463 0.966395 6 5 
LMNB1 S393 P20700 
 
LMNB1 S 0.055612 0.894061 4 4 
LRC8B S184 Q6P9F7 
 
LRC8B S 0.214318 0.629639 2 2 
LSR T501 Q86X29 
 
LSR T 0.151209 0.59182 1 2 
MAP2 S1795 P11137 R-X-X-S MAP2 S 0.528552 0.702479 2 4 
MAP2 S1798 P11137 
 
MAP2 S 0.315798 0.665936 1 4 
MAP2 S1799 P11137 
 
MAP2 S 0.315798 0.702479 1 4 
MAPK5 T368 Q8IW41 
 
MAPK5 T -0.3673 0.67912 1 2 
MARCS S167 P29966 
 
MARCS S 0.136848 1.56896 1 2 
MARK2 S40 Q7KZI7 
 
MARK2 S 0.524164 1.04984 3 3 
MBB1A S1243 Q9BQG0 R-X-X-S MBB1A S -0.79912 0.849199 1 2 
MBB1A T1244 Q9BQG0 
 
MBB1A T -0.32649 0.849199 2 2 
MCAF1 S557 Q6VMQ6 R-X-X-S MCAF1 S -0.37409 1.3027 1 2 
MCM3 T722 P25205 
 
MCM3 T 0.148642 0.65378 4 2 
MD13L S2083 Q71F56 R-X-X-S MD13L S -0.2062 0.802317 2 3 
MDC1 S1399 Q14676 
 
MDC1 S -0.3384 0.658518 3 2 
MDC1 S1400 Q14676 
 
MDC1 S -0.40517 0.714228 2 2 
MDC1 S168 Q14676 
 
MDC1 S -0.22183 0.686523 7 3 
MDC1 S1775 Q14676 
 
MDC1 S -0.67394 0.592062 6 3 
MDC1 S990 Q14676 
 
MDC1 S -0.05499 1.16999 2 3 
MDC1 S995 Q14676 
 
MDC1 S -0.1617 1.28744 3 4 
MDC1 T1608 Q14676 
 
MDC1 T 0.256048 0.829038 6 6 
MDC1 T378 Q14676 
 
MDC1 T -0.32287 0.710614 3 4 
MDHC S241 P40925 R-X-X-S MDHC S 0.118493 1.02829 1 3 
MED14 S1136 O60244 
 
MED14 S -0.11202 0.617424 4 3 
MED14 S1142 O60244 
 
MED14 S -0.01995 0.668185 3 4 
MED14 S617 O60244 R-X-X-S MED14 S 0.099109 0.626673 5 5 
MED24 S862 O75448 R-X-X-S MED24 S 0.012354 1.7746 3 2 
MGAP S534 Q8IWI9 R-X-X-S MGAP S 0.02148 0.66239 4 5 
MICA3 S1221 Q7RTP6 
 
MICA3 S 0.579373 4.17249 2 2 
MILK2 S247 Q8IY33 
 
MILK2 S 0.421587 0.751207 1 3 
MILK2 S649 Q8IY33 R-X-X-S MILK2 S 0.27739 0.948526 4 6 
MILK2 S658 Q8IY33 
 
MILK2 S 0.299077 0.587077 3 6 
MK01 T185 P28482 
 
MK01 T 0.104529 1.72459 2 2 
MK01 Y187 P28482 
 
MK01 Y 0.314759 2.11589 6 4 
MK03 T202 P27361 
 
MK03 T -0.19174 0.798337 2 2 
MK03 Y204 P27361 
 
MK03 Y -0.19174 0.857901 4 3 
MK14 S2 Q16539 SQ MK14 S 0.379177 1.21785 5 4 
MKL2 S66 Q9ULH7 
 
MKL2 S 0.209391 1.66407 1 2 
MLL1 S2201 Q03164 
 
MLL1 S -0.21364 1.4727 1 2 
MLL1 T1845 Q03164 
 
MLL1 T 0.093121 0.728051 5 4 
MOT1 S467 P53985 
 
MOT1 S 0.064469 0.78626 1 2 
MPP8 S392 Q99549 R-X-X-S MPP8 S -0.01957 0.874948 2 5 
MPP8 S85 Q99549 
 
MPP8 S 0.331591 0.591581 3 2 
MRCKA S1719 Q5VT25 
 
MRCKA S 0.555914 1.14444 1 2 
MRCKG S1482 Q6DT37 R-X-X-S MRCKG S 0.027432 0.596554 2 5 
MRE11 S688 P49959 
 
MRE11 S 0.100465 0.621149 6 4 
MRE11 S689 P49959 
 
MRE11 S 0.100465 0.621149 6 4 
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MTA1 S449 Q13330 
 
MTA1 S -0.11594 1.21176 7 6 
MVD1 S96 P53602 R-X-X-S MVD1 S 0.027951 1.00741 4 5 
MYCB2 S2751 O75592 R-X-X-S MYCB2 S 0.023468 0.83293 7 6 
MYCB2 S3467 O75592 R-X-X-S MYCB2 S -0.07491 0.794187 2 2 
MYO9B S1935 Q13459 
 
MYO9B S 0.104049 0.686419 3 3 
NAA10 S186 P41227 
 
NAA10 S 0.558855 1.30624 2 4 
NAB1 S183 Q13506 
 
NAB1 S 0.345623 0.928973 4 2 
NAB1 S395 Q13506 R-X-X-S NAB1 S 0.294706 0.812868 3 5 
NAB2 S159 Q15742 R-X-X-S NAB2 S 0.374956 1.56584 3 3 
NAB2 S162 Q15742 
 
NAB2 S 0.374956 1.56584 3 3 
NAB2 S171 Q15742 
 
NAB2 S 0.55768 1.56584 2 2 
NBN S432 O60934 
 
NBN S 0.32262 0.688675 2 2 
NCOAT S364 O60502 
 
NCOAT S 0.17594 0.899635 4 2 
NEK1 S1008 Q96PY6 
 
NEK1 S 0.381283 0.619674 2 2 
NEK4 S563 P51957 
 
NEK4 S -0.30351 0.78031 1 4 
NEK9 S868 Q8TD19 
 
NEK9 S 0.172487 1.51783 7 6 
NEK9 S869 Q8TD19 
 
NEK9 S 0.166683 1.48037 7 6 
NEUL4 S502 Q96JN8 R-X-X-S NEUL4 S -0.05589 0.920674 1 3 
NEUL4 S902 Q96JN8 
 
NEUL4 S 0.120352 0.615322 3 3 
NEUL4 S907 Q96JN8 
 
NEUL4 S 0.120352 0.615322 3 3 
NFAT5 S145 O94916 
 
NFAT5 S -0.4454 1.09565 3 3 
NIPA S359 Q86WB0 
 
NIPA S -0.09564 0.626039 1 4 
NIPBL S274 Q6KC79 
 
NIPBL S -0.03226 0.609824 3 4 
NIPBL S280 Q6KC79 
 
NIPBL S -0.56923 0.721946 2 2 
NKTR S463 P30414 
 
NKTR S -0.32976 0.690551 1 3 
NOLC1 S508 Q14978 
 
NOLC1 S 0.073957 1.43621 2 4 
NOLC1 S622 Q14978 
 
NOLC1 S 0.04675 1.71145 3 4 
NOLC1 S698 Q14978 
 
NOLC1 S -0.12207 0.60521 8 6 
NOLC1 T607 Q14978 
 
NOLC1 T 0.376718 1.37443 5 5 
NOLC1 T610 Q14978 
 
NOLC1 T 0.376718 1.00562 4 3 
NOP56 S591 O00567 SQ NOP56 S 0.062536 0.964635 1 2 
NPAT S1151 Q14207 
 
NPAT S -0.53138 0.597984 5 4 
NPM S139 P06748 
 
NPM S -0.1489 0.640158 3 3 
NPM S227 P06748 
 
NPM S -0.78496 0.896233 1 3 
NPM S254 P06748 
 
NPM S 0.162057 0.670931 2 3 
NRIP1 S564 P48552 
 
NRIP1 S 0.035979 2.47171 4 2 
NSN5C T141 Q63ZY6 
 
NSN5C T 0.333996 0.662205 1 3 
NTR1 S401 P30989 
 
NTR1 S -0.0345 1.10131 6 5 
NTR1 S403 P30989 
 
NTR1 S 0.347439 1.10143 1 3 
NTR1 S404 P30989 
 
NTR1 S -0.17428 1.04838 3 3 
NU133 S45 Q8WUM0 
 
NU133 S -0.18203 0.934277 2 4 
NU133 S50 Q8WUM0 
 
NU133 S -0.05347 0.945863 2 4 
NU188 S1709 Q5SRE5 
 
NU188 S 0.103934 0.790601 5 5 
NUCL T121 P19338 
 
NUCL T -1.01911 1.36793 1 2 
NUMA1 S1862 Q14980 R-X-X-S NUMA1 S -0.36186 0.784202 5 5 
NUP53 S73 Q8NFH5 
 
NUP53 S -0.24219 0.87688 2 2 
ORC6 T195 Q9Y5N6 
 
ORC6 T 0.422188 0.611833 2 3 
OSB10 S188 Q9BXB5 R-X-X-S OSB10 S -0.01537 0.674044 2 3 
OSB10 T190 Q9BXB5 R-X-X-S OSB10 T -0.13946 1.02531 2 2 
P121C S165 A8CG34 
 
P121C S -0.29226 4.38488 3 2 
P5CR1 S301 P32322 
 
P5CR1 S 0.031532 0.59388 2 3 
P66B S129 Q8WXI9 
 
P66B S 0.2529 0.761966 7 3 
PA1B2 S2 P68402 SQ PA1B2 S -0.05715 1.06523 7 3 
PAF S72 Q15004 
 
PAF S 0.345208 0.80091 7 6 
PAIRB S234 Q8NC51 
 
PAIRB S 0.163112 0.625501 5 5 
PAIRB T232 Q8NC51 
 
PAIRB T 0.287354 0.637935 3 4 
PAK4 S181 O96013 R-X-X-S PAK4 S 0.220949 0.688315 6 6 
PARP1 T368 P09874 
 
PARP1 T 0.073683 0.902421 4 3 
PATL1 S184 Q86TB9 
 
PATL1 S 0.274888 1.10766 4 4 
PAXI Y88 P49023 
 
PAXI Y 0.056136 0.597019 5 4 
PB1 S10 Q86U86 R-X-X-S PB1 S -0.22383 0.607579 6 6 
PB1 S39 Q86U86 R-X-X-S PB1 S -0.13373 0.847756 7 6 
PB1 T9 Q86U86 R-X-X-S PB1 T 0.023043 0.654985 3 3 
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PCDH1 S962 Q08174 
 
PCDH1 S 0.316531 0.892988 2 5 
PCM1 S1494 Q15154 
 
PCM1 S -0.02584 0.79362 1 2 
PDD2L S20 Q9BRP1 
 
PDD2L S 0.482332 2.03859 1 2 
PDZD8 S530 Q8NEN9 
 
PDZD8 S 0.375362 1.28179 2 2 
PDZD8 S538 Q8NEN9 
 
PDZD8 S -0.25046 1.1273 4 3 
PDZD8 T527 Q8NEN9 
 
PDZD8 T 0.375362 1.28179 2 2 
PDZD8 T528 Q8NEN9 
 
PDZD8 T 0.375362 1.28179 2 2 
PERQ2 S593 Q6Y7W6 
 
PERQ2 S -0.00878 0.597499 2 2 
PF21A T350 Q96BD5 R-X-X-S PF21A T 0.199625 0.716899 2 2 
PHC1 S862 P78364 R-X-X-S PHC1 S -0.14076 0.626673 2 2 
PHC1 T922 P78364 
 
PHC1 T 0.156341 0.867979 4 2 
PHF12 S662 Q96QT6 
 
PHF12 S -0.03156 1.00973 3 3 
PHF2 S539 O75151 
 
PHF2 S 0.125998 0.941343 4 2 
PHF2 S899 O75151 R-X-X-S PHF2 S -0.2612 0.772815 4 6 
PHF3 S1925 Q92576 R-X-X-S PHF3 S -0.08139 0.777283 2 3 
PHLA2 S141 Q53GA4 
 
PHLA2 S 0.092653 0.922462 4 5 
PHLA2 S144 Q53GA4 
 
PHLA2 S 0.248221 0.630405 4 2 
PHLA2 S42 Q53GA4 
 
PHLA2 S 0.375401 0.603611 4 2 
PIAS1 S485 O75925 
 
PIAS1 S 0.035342 0.748093 1 5 
PIEZ1 S1646 Q92508 R-X-X-S PIEZ1 S -0.33119 0.613207 1 2 
PININ S100 Q9H307 R-X-X-S PININ S 0.088305 0.876095 7 4 
PKCB1 S406 Q9ULU4 
 
PKCB1 S 0.128598 0.842399 3 2 
PKCB1 S444 Q9ULU4 
 
PKCB1 S -0.28557 0.894837 1 2 
PKCB1 S488 Q9ULU4 
 
PKCB1 S -0.37462 0.839797 5 4 
PKCB1 S490 Q9ULU4 
 
PKCB1 S -0.27097 0.858061 7 6 
PKCB1 S737 Q9ULU4 
 
PKCB1 S -0.55457 0.775935 3 2 
PKCB1 S754 Q9ULU4 
 
PKCB1 S -0.17762 1.06874 2 2 
PKCB1 S756 Q9ULU4 
 
PKCB1 S -0.34874 0.65104 7 6 
PKHG5 S907 O94827 R-X-X-S PKHG5 S 0.077927 0.946881 2 2 
PKP4 S273 Q99569 R-X-X-S PKP4 S 0.258388 1.08415 2 2 
PLEC S4396 Q15149 
 
PLEC S 0.107152 1.29213 1 2 
PLPL6 S353 Q8IY17 
 
PLPL6 S 0.089634 0.702978 1 2 
PO210 S1848 Q8TEM1 
 
PO210 S -0.04423 0.833752 1 2 
PO210 S1852 Q8TEM1 
 
PO210 S -0.04423 0.833752 1 2 
PO210 S1874 Q8TEM1 R-X-X-S PO210 S -0.19553 0.625364 3 3 
PP4R2 S226 Q9NY27 
 
PP4R2 S 0.406537 0.610314 4 2 
PP6R1 S759 Q9UPN7 
 
PP6R1 S 0.031113 0.950767 2 3 
PPIG S696 Q13427 SQ PPIG S -0.01156 0.726831 3 3 
PR40A S34 O75400 R-X-X-S PR40A S 0.124857 0.668143 5 4 
PRC2A S1690 P48634 
 
PRC2A S 0.260628 0.675329 2 3 
PRC2C S1246 Q9Y520 
 
PRC2C S 0.249385 0.93757 1 2 
PRDM2 S739 Q13029 R-X-X-S PRDM2 S 0.530806 1.4418 2 3 
PRDM2 S742 Q13029 
 
PRDM2 S 0.25214 1.55179 2 3 
PRKDC S893 P78527 
 
PRKDC S 0.325847 0.617393 2 3 
PRP4B S23 Q13523 
 
PRP4B S -0.04043 0.88534 4 3 
PRP4B S568 Q13523 
 
PRP4B S -0.19883 1.9062 2 2 
PRP4B S569 Q13523 
 
PRP4B S -0.19883 0.600705 1 3 
PSD3 T1019 Q9NYI0 
 
PSD3 T 0.122607 0.833173 3 2 
PTRF S300 Q6NZI2 
 
PTRF S 0.168849 0.656277 2 2 
PUR6 S107 P22234 
 
PUR6 S 0.298658 0.633385 1 3 
PYGO2 T302 Q9BRQ0 
 
PYGO2 T 0.498864 0.694894 4 2 
PYR1 S1859 P27708 
 
PYR1 S 0.292233 0.787934 7 6 
QCR1 S23 P31930 
 
QCR1 S -0.1761 0.606754 2 5 
RAD50 T690 Q92878 
 
RAD50 T -0.20512 1.25898 4 2 
RAF1 S621 P04049 
 
RAF1 S 0.048366 1.156 6 3 
RAI1 S1374 Q7Z5J4 
 
RAI1 S -0.10434 0.716877 3 4 
RALY S135 Q9UKM9 
 
RALY S -0.13951 0.765195 5 6 
RANB9 S482 Q96S59 R-X-X-S RANB9 S 0.521955 0.613154 1 2 
RB12B S250 Q8IXT5 
 
RB12B S 0.524665 0.941407 7 4 
RB12B S375 Q8IXT5 
 
RB12B S -0.02984 1.55208 2 3 
RBBP6 S516 Q7Z6E9 
 
RBBP6 S 0.274379 0.700529 3 3 
RBM10 S733 P98175 
 
RBM10 S 0.003026 0.821439 3 4 
RBM15 Y546 Q96T37 
 
RBM15 Y -0.00703 0.774619 2 2 
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RBM25 S703 P49756 
 
RBM25 S 0.157936 0.785843 5 3 
RBNS5 S215 Q9H1K0 
 
RBNS5 S 0.045443 1.46085 1 3 
RBNS5 S219 Q9H1K0 
 
RBNS5 S 0.285605 0.602086 2 2 
RBP1 S34 Q15311 
 
RBP1 S -0.21841 1.56565 1 3 
RBP2 S1400 P49792 
 
RBP2 S -0.08319 1.02008 1 4 
RBP2 S786 P49792 
 
RBP2 S -0.61633 0.660506 1 3 
RECQ5 S727 O94762 
 
RECQ5 S 0.141534 1.46944 6 5 
REQU T248 Q92785 
 
REQU T 0.017352 0.722553 3 3 
RFC1 T161 P35251 
 
RFC1 T 0.253747 1.29531 7 6 
RHG21 S856 Q5T5U3 R-X-X-S RHG21 S 0.328262 0.647913 2 5 
RHG29 S1029 Q52LW3 
 
RHG29 S -0.18784 3.95233 5 2 
RHG29 S949 Q52LW3 R-X-X-S RHG29 S -0.33169 0.839557 5 4 
RING1 T238 Q06587 R-X-X-S RING1 T 0.163756 0.729096 1 2 
RING1 T243 Q06587 
 
RING1 T -0.33712 0.838901 1 3 
RL14 S139 P50914 
 
RL14 S -0.53264 1.03621 6 5 
RPA43 S316 Q3B726 R-X-X-S RPA43 S -0.06136 0.587941 8 6 
RPC5 S161 Q9NVU0 
 
RPC5 S -0.15654 0.664665 2 3 
RPC5 S162 Q9NVU0 SQ RPC5 S -0.3715 0.664665 2 3 
RPC5 S522 Q9NVU0 
 
RPC5 S 0.05339 0.593828 2 2 
RPRD2 S1099 Q5VT52 R-X-X-S RPRD2 S -0.0478 1.21207 7 5 
RPTOR S863 Q8N122 
 
RPTOR S 0.047107 0.621993 5 4 
RS6 S236 P62753 R-X-X-S RS6 S 0.135535 0.852398 6 6 
RS6 S240 P62753 
 
RS6 S 0.393313 1.69681 5 3 
RS6 S244 P62753 
 
RS6 S -0.77482 1.9201 1 2 
RTN3 S30 O95197 
 
RTN3 S 0.302332 1.1688 2 2 
RTN4 S15 Q9NQC3 
 
RTN4 S 0.489603 0.669571 8 6 
RTN4 S7 Q9NQC3 
 
RTN4 S 0.237808 0.74122 5 4 
S26A6 S752 Q9BXS9 
 
S26A6 S -0.31262 1.18516 1 2 
S4A7 S556 Q9Y6M7 
 
S4A7 S 0.040192 0.692338 2 3 
S4A7 T557 Q9Y6M7 
 
S4A7 T 0.013749 0.692338 2 3 
SAC2 S1103 Q9Y2H2 
 
SAC2 S -0.0949 0.820889 3 3 
SAC2 S935 Q9Y2H2 
 
SAC2 S 0.101064 0.763242 5 4 
SAC2 S940 Q9Y2H2 
 
SAC2 S 0.2221 0.899485 5 3 
SAP30 S131 O75446 R-X-X-S SAP30 S -0.02477 1.13069 8 4 
SAP30 S138 O75446 
 
SAP30 S 0.219779 1.17233 8 4 
SCAPE S85 Q9BY12 
 
SCAPE S 0.521352 1.04875 2 4 
SCML2 S499 Q9UQR0 
 
SCML2 S -0.27 0.723877 6 3 
SDS3 S234 Q9H7L9 R-X-X-S SDS3 S -0.09696 0.924328 7 6 
SENP3 S169 Q9H4L4 
 
SENP3 S -0.16093 0.640898 7 6 
SENP3 S181 Q9H4L4 
 
SENP3 S -0.26856 1.0355 6 5 
SET1A S1169 O15047 
 
SET1A S -0.42167 1.3452 3 2 
SET1A T1167 O15047 R-X-X-S SET1A T -0.49745 1.35249 3 2 
SF3B1 T434 O75533 
 
SF3B1 T 0.094371 0.748805 5 4 
SFR19 S239 Q9H7N4 
 
SFR19 S 0.011554 1.22367 4 2 
SFR19 S500 Q9H7N4 R-X-X-S SFR19 S -0.06708 1.02411 6 6 
SFR19 S612 Q9H7N4 R-X-X-S SFR19 S 0.238665 3.34554 3 3 
SFR19 S614 Q9H7N4 R-X-X-S SFR19 S 0.238665 4.00978 3 2 
SFR19 S724 Q9H7N4 
 
SFR19 S -0.27299 0.931105 4 4 
SFR19 S725 Q9H7N4 
 
SFR19 S -0.06965 0.931105 6 4 
SFR19 T976 Q9H7N4 
 
SFR19 T 0.079975 1.02817 3 4 
SH24A S315 Q9H788 R-X-X-S SH24A S 0.190736 0.762987 4 3 
SHAN2 S1330 Q9UPX8 R-X-X-S SHAN2 S -0.06401 0.647078 1 2 
SHAN2 S67 Q9UPX8 R-X-X-S SHAN2 S 0.12032 1.6999 2 3 
SHC1 S426 P29353 
 
SHC1 S 0.012211 0.960512 1 2 
SHRM2 S1036 Q13796 R-X-X-S SHRM2 S 0.019061 0.63911 7 5 
SHRM2 S456 Q13796 
 
SHRM2 S -0.21073 0.977744 3 3 
SI1L1 S1433 O43166 
 
SI1L1 S -0.15613 0.744075 1 2 
SIN3A S1108 Q96ST3 
 
SIN3A S -0.13976 0.862432 3 5 
SIN3A S1112 Q96ST3 
 
SIN3A S -0.21481 0.915253 3 6 
SIN3A S277 Q96ST3 
 
SIN3A S -0.46977 1.2649 4 2 
SIN3A S832 Q96ST3 
 
SIN3A S 0.215865 0.842778 7 6 
SIN3A S940 Q96ST3 
 
SIN3A S -0.07666 0.587845 4 4 
SIN3A T1111 Q96ST3 
 
SIN3A T 0.15549 0.651758 1 2 
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Table 4.2 TOPBP1-dependent phosphosites 
Phosphosite Uniprot 
ATR Motif (SQ/TQ) 
CHK1 Motif (R-X-X-S) 
Protein 
Name 
Amino 
acid 
ETAA1 
Ratio 
TOPBP1 
Ratio 
Count 
ETAA1∆AAD 
Count 
TOPBP1-AID 
SIR1 S14 Q96EB6 
 
SIR1 S 0.405217 0.737254 6 6 
SIR1 S47 Q96EB6 
 
SIR1 S 0.307846 0.70186 7 4 
SLBP S7 Q14493 R-X-X-S SLBP S -0.01486 0.750676 2 2 
SMBT1 S765 Q9UHJ3 R-X-X-S SMBT1 S 0.399538 0.739589 5 2 
SMRC2 S347 Q8TAQ2 
 
SMRC2 S 0.074518 1.05596 6 3 
SMRCD S132 Q9H4L7 SQ SMRCD S 0.10916 0.844546 1 2 
SP130 S442 Q9H0E3 
 
SP130 S 0.32458 0.902549 3 5 
SP130 S855 Q9H0E3 
 
SP130 S -0.01197 0.716433 3 4 
SP130 T856 Q9H0E3 
 
SP130 T -0.01197 0.716433 3 4 
SP6 S20 Q3SY56 
 
SP6 S 0.104888 1.98645 3 2 
SPAG1 S418 Q07617 
 
SPAG1 S 0.54336 0.72657 3 4 
SPE39 S121 Q9H9C1 R-X-X-S SPE39 S 0.446044 0.930018 1 2 
SPHK2 S484 Q9NRA0 
 
SPHK2 S 0.327228 3.77442 1 2 
SPN90 S122 Q9NZQ3 
 
SPN90 S 0.158854 0.856081 1 2 
SPY4 S125 Q9C004 
 
SPY4 S 0.118963 0.891541 3 2 
SRCAP S1940 Q6ZRS2 
 
SRCAP S -0.06956 0.736215 3 4 
SRP72 S621 O76094 
 
SRP72 S -0.11546 0.609188 8 6 
SRP72 T624 O76094 
 
SRP72 T -0.10084 0.616734 8 6 
SRRM1 S393 Q8IYB3 
 
SRRM1 S -0.0874 1.56267 8 6 
SRRM1 S756 Q8IYB3 
 
SRRM1 S 0.189831 0.922655 5 6 
SRRM2 S1008 Q9UQ35 
 
SRRM2 S 0.008774 0.762902 1 2 
SRRM2 S1012 Q9UQ35 
 
SRRM2 S 0.059217 0.71308 4 5 
SRRM2 S1014 Q9UQ35 
 
SRRM2 S -0.04091 0.663846 7 6 
SRRM2 S1233 Q9UQ35 SQ SRRM2 S 0.111842 0.714487 4 3 
SRRM2 S1421 Q9UQ35 R-X-X-S SRRM2 S -0.03548 0.701682 2 3 
SRRM2 S1441 Q9UQ35 R-X-X-S SRRM2 S 0.160676 0.647821 5 6 
SRRM2 S1458 Q9UQ35 
 
SRRM2 S 0.087882 0.760956 4 4 
SRRM2 S1497 Q9UQ35 R-X-X-S SRRM2 S 0.524118 1.11783 5 5 
SRRM2 S1502 Q9UQ35 
 
SRRM2 S -0.26096 0.618896 3 2 
SRRM2 S1517 Q9UQ35 R-X-X-S SRRM2 S -0.04167 1.02 1 4 
SRRM2 S1542 Q9UQ35 SQ SRRM2 S 0.067363 0.606904 3 3 
SRRM2 S783 Q9UQ35 
 
SRRM2 S 0.296193 1.94223 3 5 
SRRM2 S950 Q9UQ35 
 
SRRM2 S 0.100709 0.649294 7 6 
SRRM2 S968 Q9UQ35 
 
SRRM2 S 0.266397 0.776305 2 3 
SRRM2 S972 Q9UQ35 
 
SRRM2 S 0.256528 0.689389 2 2 
SRRM2 S973 Q9UQ35 
 
SRRM2 S 0.256528 0.689389 2 2 
SRRM2 S974 Q9UQ35 
 
SRRM2 S 0.256528 0.689389 2 2 
SRRM2 T829 Q9UQ35 
 
SRRM2 T -0.05481 0.882925 1 2 
SSFA2 S591 P28290 
 
SSFA2 S 0.248656 0.676635 1 2 
SSFA2 S668 P28290 
 
SSFA2 S 0.082566 0.612022 1 2 
STK39 S385 Q9UEW8 
 
STK39 S 0.016068 0.683921 5 4 
STK39 T354 Q9UEW8 
 
STK39 T -0.25106 0.794437 2 3 
SVIL S245 O95425 
 
SVIL S 0.287584 0.615895 4 3 
SYMPK S1173 Q92797 
 
SYMPK S -0.0687 0.614757 2 2 
SYNE2 S6389 Q8WXH0 
 
SYNE2 S -0.78519 0.90273 2 3 
SYNRG S1075 Q9UMZ2 R-X-X-S SYNRG S -0.20655 2.41973 3 2 
SYTC S8 P26639 
 
SYTC S 0.285295 0.664392 2 2 
TAF9B S147 Q9HBM6 
 
TAF9B S -0.00036 0.934108 1 2 
TAF9B S153 Q9HBM6 
 
TAF9B S -0.05846 0.910039 2 2 
TAOK1 S965 Q7L7X3 
 
TAOK1 S 0.134615 0.845232 1 3 
TAU S411 P10636 
 
TAU S 0.154842 0.683023 1 4 
TAU S519 P10636 
 
TAU S 0.132884 0.795684 2 4 
TB10B S687 Q4KMP7 R-X-X-S TB10B S -0.92276 0.679694 2 5 
TB182 S1029 Q9C0C2 
 
TB182 S 0.174998 1.02304 4 2 
TB182 S1385 Q9C0C2 
 
TB182 S 0.373899 0.683641 4 3 
TB182 S836 Q9C0C2 SQ TB182 S 0.086506 0.874915 3 2 
TCF20 Y1632 Q9UGU0 
 
TCF20 Y 0.209066 0.684741 2 2 
TDIF2 S381 Q5QJE6 
 
TDIF2 S 0.081985 0.726395 2 4 
TENC1 S1003 Q63HR2 
 
TENC1 S -0.0719 1.47611 2 2 
TF3C4 S611 Q9UKN8 
 
TF3C4 S -0.22805 0.718707 3 3 
THOC1 S2 Q96FV9 
 
THOC1 S 0.128029 0.968008 3 3 
TIF1A S1042 O15164 R-X-X-S TIF1A S -0.16766 0.891108 2 2 
TIF1A S667 O15164 
 
TIF1A S -0.15161 0.771209 2 3 
	 	
	
133	
	
Table 4.2 TOPBP1-dependent phosphosites 
Phosphosite Uniprot 
ATR Motif (SQ/TQ) 
CHK1 Motif (R-X-X-S) 
Protein 
Name 
Amino 
acid 
ETAA1 
Ratio 
TOPBP1 
Ratio 
Count 
ETAA1∆AAD 
Count 
TOPBP1-AID 
TIF1B S19 Q13263 
 
TIF1B S -0.06486 1.08644 8 6 
TIF1B S473 Q13263 R-X-X-S TIF1B S -0.0009 1.08706 8 6 
TIF1B Y458 Q13263 
 
TIF1B Y -0.27593 0.628767 2 2 
TISD S125 P47974 R-X-X-S TISD S 0.058524 0.660837 3 3 
TISD S490 P47974 
 
TISD S 0.233888 0.878498 1 2 
TNC18 S995 O15417 
 
TNC18 S 0.521855 0.633013 4 3 
TOB1 S205 P50616 
 
TOB1 S 0.253505 0.851682 3 4 
TOB1 T204 P50616 
 
TOB1 T 0.253505 0.851682 3 4 
TOP2B S1424 Q02880 
 
TOP2B S -0.11167 0.621431 4 3 
TOP2B S1522 Q02880 
 
TOP2B S -0.00428 0.592828 7 6 
TOP2B S1524 Q02880 
 
TOP2B S -0.03667 0.594644 7 6 
TOP2B S1550 Q02880 R-X-X-S TOP2B S -0.4645 0.624215 2 3 
TOP2B S1552 Q02880 
 
TOP2B S -0.4645 0.624215 2 3 
TOPB1 S860 Q92547 R-X-X-S TOPB1 S 0.287354 4.09071 2 3 
TP53B S1068 Q12888 SQ TP53B S -0.1639 0.820622 3 3 
TP53B S1317 Q12888 R-X-X-S TP53B S -0.28309 1.12188 2 3 
TP53B S1320 Q12888 
 
TP53B S -0.09979 1.30561 1 2 
TP53B T919 Q12888 
 
TP53B T 0.0297 0.913186 4 3 
TP53B T922 Q12888 
 
TP53B T -0.03184 1.08706 5 4 
TRAF2 S11 Q12933 
 
TRAF2 S 0.004897 2.23285 5 4 
TRAF2 T7 Q12933 
 
TRAF2 T 0.196229 2.23285 7 4 
TREF1 S715 Q96PN7 
 
TREF1 S -0.48825 1.07211 3 3 
TRIO S2455 O75962 
 
TRIO S -0.21177 0.655077 2 3 
TRMB S27 Q9UBP6 R-X-X-S TRMB S 0.559149 0.736935 3 3 
TRPM4 S1103 Q8TD43 
 
TRPM4 S -1.01034 0.941282 1 2 
TSSC4 S143 Q9Y5U2 
 
TSSC4 S 0.04698 0.744333 1 3 
TSYL2 S17 Q9H2G4 R-X-X-S TSYL2 S -0.89648 0.857172 3 5 
TSYL2 S18 Q9H2G4 
 
TSYL2 S -1.25389 0.857172 3 5 
TSYL2 S20 Q9H2G4 
 
TSYL2 S -0.97761 1.32941 2 2 
TTYH2 S504 Q9BSA4 
 
TTYH2 S -0.24257 1.83491 1 2 
U5S1 S19 Q15029 
 
U5S1 S 0.561898 0.845912 6 6 
UBA1 S21 P22314 
 
UBA1 S -0.01165 0.861003 5 2 
UBE2O S87 Q9C0C9 
 
UBE2O S 0.239642 0.719052 5 4 
UBE2O S89 Q9C0C9 
 
UBE2O S 0.239642 0.719052 5 4 
UBN2 S11 Q6ZU65 
 
UBN2 S -0.48655 0.760945 2 2 
UBP10 S576 Q14694 
 
UBP10 S 0.110388 0.681317 7 4 
UBP20 S132 Q9Y2K6 
 
UBP20 S 0.195675 1.6568 2 2 
UBP20 S134 Q9Y2K6 
 
UBP20 S 0.195675 1.6568 2 2 
UCK1 S253 Q9HA47 R-X-X-S UCK1 S 0.342782 1.52677 3 3 
ULK1 S477 O75385 
 
ULK1 S 0.475707 1.16053 4 3 
ULK1 S479 O75385 
 
ULK1 S 0.475707 1.16053 4 3 
ULK1 S758 O75385 
 
ULK1 S 0.199751 1.11463 1 2 
ULK1 T625 O75385 
 
ULK1 T 0.407826 0.96303 6 3 
UNG S23 P13051 
 
UNG S -0.25343 0.733962 7 6 
UNG S63 P13051 
 
UNG S -0.00139 0.741057 5 2 
UNG T60 P13051 
 
UNG T -0.10933 0.829301 5 3 
UT14A S29 Q9BVJ6 
 
UT14A S -0.22336 0.642008 3 3 
UT14A S445 Q9BVJ6 SQ UT14A S 0.28629 1.855 3 2 
VEZF1 S197 Q14119 
 
VEZF1 S 0.320311 1.1648 1 2 
VIP2 S1108 O43314 
 
VIP2 S 0.274769 0.658006 1 3 
VP26B S304 Q4G0F5 
 
VP26B S 0.207143 0.815389 1 2 
VRK3 S59 Q8IV63 
 
VRK3 S 0.475085 0.591584 5 6 
WAP53 S491 Q9BUR4 
 
WAP53 S 0.272579 2.13806 2 5 
WDR11 S626 Q9BZH6 
 
WDR11 S -0.09086 1.0277 1 2 
WDR7 S1456 Q9Y4E6 
 
WDR7 S 0.182184 0.681881 1 3 
WIZ S983 O95785 
 
WIZ S 0.141825 0.598175 1 3 
XPO4 S521 Q9C0E2 
 
XPO4 S 0.364372 0.721504 4 3 
XRN1 S1656 Q8IZH2 
 
XRN1 S 0.016639 0.665379 1 2 
XRN1 S1657 Q8IZH2 
 
XRN1 S 0.016639 0.665379 1 2 
XRN2 S487 Q9H0D6 
 
XRN2 S -0.15748 0.728628 1 2 
Y272 (blank) 
 
(blank) Y 0.301471 0.789187 1 4 
YBOX1 S165 P67809 
 
YBOX1 S 0.265832 0.592541 2 2 
YBOX1 S174 P67809 
 
YBOX1 S 0.262433 0.592541 1 2 
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Table 4.2 TOPBP1-dependent phosphosites 
Phosphosite Uniprot 
ATR Motif (SQ/TQ) 
CHK1 Motif (R-X-X-S) 
Protein 
Name 
Amino 
acid 
ETAA1 
Ratio 
TOPBP1 
Ratio 
Count 
ETAA1∆AAD 
Count 
TOPBP1-AID 
YBOX1 S2 P67809 
 
YBOX1 S 0.030265 0.595122 2 2 
YETS2 S575 Q9ULM3 
 
YETS2 S -0.11691 0.648356 4 5 
YRDC S60 Q86U90 
 
YRDC S 0.339935 1.03837 3 3 
YTDC2 S1279 Q9H6S0 
 
YTDC2 S 0.315163 1.24803 4 5 
Z280C S80 Q8ND82 
 
Z280C S -0.09516 0.990249 3 5 
Z280C T540 Q8ND82 
 
Z280C T 0.229219 1.38637 2 2 
Z280D S545 Q6N043 
 
Z280D S 0.25084 1.39709 5 4 
ZBT7A S511 O95365 
 
ZBT7A S -0.00045 0.779872 4 5 
ZBTB3 S549 Q9H5J0 
 
ZBTB3 S -0.07282 0.652693 3 2 
ZC3H4 S1104 Q9UPT8 
 
ZC3H4 S 0.238 1.00712 5 5 
ZC3HD S1010 Q5T200 R-X-X-S ZC3HD S -1.50703 0.772795 2 2 
ZC3HD S1210 Q5T200 R-X-X-S ZC3HD S 0.042504 0.98675 5 5 
ZC3HD S198 Q5T200 
 
ZC3HD S -0.00404 0.588325 5 6 
ZC3HD S316 Q5T200 
 
ZC3HD S 0.321618 0.667756 4 6 
ZC3HD S318 Q5T200 R-X-X-S ZC3HD S -0.06596 0.657091 6 6 
ZC3HD S325 Q5T200 
 
ZC3HD S 0.007913 0.616358 6 6 
ZC3HD S333 Q5T200 R-X-X-S ZC3HD S 0.11405 0.718088 3 4 
ZC3HD S387 Q5T200 R-X-X-S ZC3HD S 0.182819 0.749062 2 3 
ZC3HD S833 Q5T200 
 
ZC3HD S 0.123401 0.995521 1 5 
ZC3HD S837 Q5T200 
 
ZC3HD S 0.496207 0.676492 3 5 
ZC3HD S845 Q5T200 R-X-X-S ZC3HD S 0.021906 0.797612 1 3 
ZC3HD S848 Q5T200 
 
ZC3HD S 0.021906 0.797612 1 2 
ZC3HD S853 Q5T200 
 
ZC3HD S 0.021906 0.797612 1 3 
ZC3HD T1033 Q5T200 
 
ZC3HD T -0.00845 0.700351 4 5 
ZC3HD T317 Q5T200 
 
ZC3HD T 0.208392 0.694657 6 6 
ZC3HE S515 Q6PJT7 
 
ZC3HE S 0.039138 0.793688 6 6 
ZCH18 S67 Q86VM9 
 
ZCH18 S 0.497068 0.701211 4 4 
ZDHC5 S529 Q9C0B5 R-X-X-S ZDHC5 S 0.514905 0.876273 1 3 
ZDHC5 Y533 Q9C0B5 
 
ZDHC5 Y 0.514905 0.904917 1 3 
ZMYM4 S1181 Q5VZL5 R-X-X-S ZMYM4 S 0.118493 0.708231 3 6 
ZMYM4 S122 Q5VZL5 
 
ZMYM4 S 0.145774 1.1306 2 4 
ZN316 S10 A6NFI3 
 
ZN316 S -0.18355 0.741578 7 4 
ZN318 S501 Q5VUA4 SQ ZN318 S 0.040542 1.99105 1 2 
ZN444 S235 Q8N0Y2 
 
ZN444 S 0.202136 0.887805 1 2 
ZN507 S195 Q8TCN5 
 
ZN507 S 0.53067 1.4031 1 2 
ZN592 S334 Q92610 
 
ZN592 S -0.47593 0.679784 3 3 
ZN592 S573 Q92610 
 
ZN592 S 0.124228 0.600175 5 6 
ZN592 S74 Q92610 
 
ZN592 S -0.03716 0.650941 1 2 
ZN592 S78 Q92610 R-X-X-S ZN592 S 0.050049 0.764346 5 3 
ZN687 S1057 Q8N1G0 
 
ZN687 S -0.44099 1.03471 7 6 
ZN687 S1106 Q8N1G0 
 
ZN687 S -0.0216 1.43629 2 5 
ZN687 S251 Q8N1G0 
 
ZN687 S -0.06367 0.657457 3 2 
ZN768 S97 Q9H5H4 
 
ZN768 S 0.152146 0.828225 4 2 
ZNRF2 S82 Q8NHG8 R-X-X-S ZNRF2 S 0.217851 0.737841 1 4 
ZYX S281 Q15942 
 
ZYX S 0.404819 0.931154 2 3 
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Table 4.3 ETAA1 and TOPBP1-dependent phosphosites. ETAA1 and TOPBP1-dependent 
phosphosites are given below along with the Uniprot ID, modified residue, presence of ATR or 
CHK1 motif, and the number of experiments in which that peptide was observed. The ratio value 
is the log2 transformed ratio of WT /ETAA1 or TOPBP1 cells. Therefore, a higher value (darker 
green) is more dependent on ETAA1 or TOPBP1.   
Table 4.3 ETAA1 and TOPBP1-dependent phosphosites 
Phosphosite Uniprot 
ATR Motif (SQ/TQ) 
CHK1 Motif (R-X-X-S) 
Protein 
Name 
Amino 
acid 
ETAA1 
Ratio 
TOPBP1 
Ratio 
Count 
ETAA1∆AAD 
Count 
TOPBP1-AID 
ADA19 S802 Q9H013 R-X-X-S ADA19 S 1.55292 0.600437 1 2 
AHNK T490 Q09666  AHNK T 0.741316 0.662844 4 6 AKA12 S283 Q02952  AKA12 S 0.716684 1.29731 5 5 AKA12 S648 Q02952  AKA12 S 0.645898 0.615785 2 2 
AKA12 S697 Q02952 R-X-X-S AKA12 S 0.719052 0.699907 1 3 
AKA12 S698 Q02952  AKA12 S 0.719052 0.699907 1 3 AKA12 T597 Q02952  AKA12 T 0.591967 0.687777 4 4 AKTS1 S202 Q96B36  AKTS1 S 0.623118 0.733084 5 3 ANXA1 S37 P04083  ANXA1 S 0.589284 0.857583 1 2 
AT2C2 S7 O75185  AT2C2 S 2.5815 5.08286 1 2 ATRIP S239 Q8WXE1  ATRIP S 0.641638 0.636915 4 3 
BAIP2 S325 Q9UQB8  BAIP2 S 1.10554 0.7582 4 5 BCL9L S25 Q86UU0  BCL9L S 0.714224 0.618509 1 4 BCR S459 P11274  BCR S 0.892449 0.847359 4 4 
BRD1 S128 O95696  BRD1 S 1.44679 0.89476 3 6 BRD9 S566 Q9H8M2  BRD9 S 0.681 1.96614 5 3 
CAMP1 S575 Q5T5Y3  CAMP1 S 0.71352 1.10735 2 2 CCNT2 S480 O60583  CCNT2 S 0.930397 1.13297 3 3 CHAP1 S297 Q96JM3  CHAP1 S 0.714487 0.853203 5 4 CHAP1 S386 Q96JM3  CHAP1 S 0.692606 1.55699 1 2 CHD8 S2046 Q9HCK8  CHD8 S 0.7019 0.618161 6 5 
CLASR S335 Q8N2M8  CLASR S 2.41943 0.971737 1 4 CND1 S1333 Q15021  CND1 S 0.591201 0.688225 1 2 DC1L1 T513 Q9Y6G9  DC1L1 T 0.692017 1.33405 2 2 DCP1A S525 Q9NPI6  DCP1A S 0.772646 1.03069 3 5 EHBP1 S436 Q8NDI1  EHBP1 S 0.662661 0.58938 6 6 
ELYS S1160 Q8WYP5  ELYS S 0.721063 0.632827 5 6 ERCC5 S563 P28715  ERCC5 S 2.87389 0.883621 4 2 
F101B S26 Q8N5W9  F101B S 0.594071 0.763836 3 3 F10A1 S75 P50502  F10A1 S 0.855432 1.71233 4 4 F10A1 S76 P50502  F10A1 S 0.724476 1.71233 4 4 F10A1 S79 P50502  F10A1 S 0.789938 1.71233 4 4 F18B2 S6 Q96ET8  F18B2 S 1.37268 1.35075 2 2 
FAS Y45 P49327  FAS Y 0.678162 0.678029 1 2 GCFC2 S19 P16383  GCFC2 S 1.04013 0.938329 2 2 GORS1 S220 Q9BQQ3  GORS1 S 1.11297 1.37751 5 4 GORS1 T237 Q9BQQ3  GORS1 T 0.603027 1.13534 5 4 HMGA2 S101 P52926  HMGA2 S 0.601031 0.626392 7 3 
HMGA2 S102 P52926 SQ HMGA2 S 0.587269 1.15023 3 2 
HMGA2 S105 P52926  HMGA2 S 0.737193 0.906572 7 4 HMGA2 T100 P52926  HMGA2 T 0.587269 0.60421 1 2 HMGX4 S197 Q9UGU5  HMGX4 S 0.601401 1.17709 2 3 HUWE1 S3373 Q7Z6Z7  HUWE1 S 1.41967 0.673513 3 3 
IMA2 S62 P52292  IMA2 S 0.700795 0.636355 5 2 IMA2 T61 P52292  IMA2 T 0.860367 0.719402 1 2 
K0284 S969 Q9Y4F5  K0284 S 0.902267 0.718565 2 2 KHDR1 S18 Q07666  KHDR1 S 1.28321 0.707878 2 3 KI18B S434 Q86Y91 SQ KI18B S 0.880646 0.831796 1 3 
KI21A S1239 Q7Z4S6  KI21A S 1.33629 0.669662 5 6 KLH36 S17 Q8N4N3  KLH36 S 0.856086 1.50141 2 2 
KPCD Y313 Q05655  KPCD Y 0.882213 0.702622 3 2 LIPS S950 Q05469  LIPS S 0.739848 1.85667 2 2 LRCH3 S415 Q96II8 R-X-X-S LRCH3 S 0.674641 0.656542 3 3 
M3K1 S250 Q13233  M3K1 S 1.27472 0.653707 2 2 M3K1 S252 Q13233 R-X-X-S M3K1 S 1.27472 0.653707 2 2 
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Table 4.3 ETAA1 and TOPBP1-dependent phosphosites 
Phosphosite Uniprot 
ATR Motif (SQ/TQ) 
CHK1 Motif (R-X-X-S) 
Protein 
Name 
Amino 
acid 
ETAA1 
Ratio 
TOPBP1 
Ratio 
Count 
ETAA1∆AAD 
Count 
TOPBP1-AID 
MAP1A S1069 P78559  MAP1A S 0.645077 0.741111 2 2 
MAP2 S1782 P11137  MAP2 S 1.16941 0.735435 1 2 MRCKA S1721 Q5VT25  MRCKA S 0.663481 1.14444 1 2 MX2 S385 P20592  MX2 S 6.095 4.69346 1 2 MYD88 S244 Q99836  MYD88 S 0.760264 1.79628 2 2 NHRF1 S290 O14745 R-X-X-S NHRF1 S 0.719227 0.750991 3 2 
NO40 S114 Q9NP64 R-X-X-S NO40 S 1.47975 0.749384 3 5 
OAS3 T365 Q9Y6K5  OAS3 T 0.725436 1.5864 1 2 
PALLD S1104 Q8WX93  PALLD S 0.825224 2.59477 4 5 PALLD S1116 Q8WX93 R-X-X-S PALLD S 1.5479 2.46968 5 5 
PALLD S1118 Q8WX93 R-X-X-S PALLD S 1.41548 2.01314 5 5 
PALLD S1121 Q8WX93  PALLD S 1.40757 2.46121 4 6 PALLD S641 Q8WX93  PALLD S 1.22621 4.91476 4 3 
PALLD S688 Q8WX93  PALLD S 1.51035 3.68549 3 6 PALLD S766 Q8WX93  PALLD S 1.79327 2.48962 2 3 PALLD S893 Q8WX93 R-X-X-S PALLD S 1.40387 2.73645 5 5 
PALLD T704 Q8WX93  PALLD T 1.25222 2.07165 2 3 PATL1 S177 Q86TB9  PATL1 S 0.632933 1.36783 3 4 
PATL1 T178 Q86TB9 R-X-X-S PATL1 T 0.643487 1.3881 5 5 
PDE7A S84 Q13946 R-X-X-S PDE7A S 0.865048 0.873999 3 2 
PHF12 S131 Q96QT6 R-X-X-S PHF12 S 1.54898 1.17082 4 2 
PHIP S1315 Q8WWQ0 R-X-X-S PHIP S 3.81517 1.2926 1 2 
PIAS1 S483 O75925  PIAS1 S 0.633571 0.748093 1 2 PKP3 S314 Q9Y446 R-X-X-S PKP3 S 0.678613 2.33322 3 2 
PRC2C T2673 Q9Y520  PRC2C T 0.847917 0.594644 4 6 
PRDX3 S237 P30048  PRDX3 S 3.26158 1.97263 1 2 PTRF T302 Q6NZI2  PTRF T 0.933827 0.656277 2 2 PTSS1 S439 P48651  PTSS1 S 0.889242 2.11866 2 3 PURB S8 Q96QR8  PURB S 1.11986 2.06856 2 2 PYRG1 S571 P17812  PYRG1 S 0.609254 0.70779 5 3 
RANG S14 P43487  RANG S 0.586531 1.08678 2 4 RANG T13 P43487  RANG T 0.641912 0.770618 3 2 RANG T15 P43487  RANG T 0.598556 0.995797 1 2 RGAP1 T580 Q9H0H5  RGAP1 T 0.663026 0.60046 6 3 RIN1 S258 Q13671  RIN1 S 0.762902 1.01778 1 2 
RIR2 S20 P31350  RIR2 S 1.48192 1.25574 5 4 RNF8 S157 O76064 R-X-X-S RNF8 S 0.829021 2.81486 5 5 
SCRIB S1140 Q14160  SCRIB S 3.70117 2.62919 3 5 SEPT7 S334 Q16181  SEPT7 S 0.607701 0.965987 5 3 SKP2 S64 Q13309  SKP2 S 0.844948 0.919988 2 3 SLMAP S148 Q14BN4  SLMAP S 1.1163 0.732052 1 3 SOS1 S1275 Q07889  SOS1 S 0.615981 1.27965 1 4 
SPDLY S515 Q96EA4  SPDLY S 1.05693 2.28735 2 2 SRRM2 S1539 Q9UQ35 R-X-X-S SRRM2 S 1.40218 0.591967 2 2 
STIM2 S609 Q9P246 R-X-X-S STIM2 S 0.691579 0.773701 3 2 
STIM2 S613 Q9P246  STIM2 S 0.742997 0.680909 2 2 STMN1 S16 P16949  STMN1 S 0.588905 0.603027 7 6 
TBC30 S713 Q9Y2I9  TBC30 S 3.85659 1.16742 2 2 TJAP1 T422 Q5JTD0  TJAP1 T 0.808856 0.872001 6 4 TOB2 S222 Q14106  TOB2 S 0.711054 0.701999 1 5 TOM34 S186 Q15785 R-X-X-S TOM34 S 0.962162 0.833416 5 4 
UBP10 S547 Q14694  UBP10 S 0.59684 0.880646 2 4 
ULK1 S544 O75385  ULK1 S 1.13895 2.13767 1 2 ULK1 S623 O75385  ULK1 S 0.647268 0.96303 5 5 
YBOX1 S167 P67809  YBOX1 S 0.599935 0.592541 2 2 ZC3H1 S28 O60293  ZC3H1 S 0.898789 1.25564 2 3 ZCCHV S378 Q7Z2W4  ZCCHV S 1.01557 0.587799 2 2 ZN576 S23 Q9H609  ZN576 S 0.960254 1.65019 4 5 ZN608 S627 Q9ULD9  ZN608 S 0.767655 3.11686 1 3 
ZN609 S413 O15014 R-X-X-S/SQ ZN609 S 0.64589 1.25978 4 4 
ZN609 S491 O15014  ZN609 S 0.726243 1.02857 6 6 ZN609 S576 O15014  ZN609 S 0.887915 0.892663 7 6 ZN609 S578 O15014  ZN609 S 0.947105 0.612777 7 6 
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Table 4.4 ETAA1-dependent GO terms. Gene ontology analysis of ETAA1-dependent 
phosphoproteins was completed using ClueGO.  Similar GO terms were grouped into functional 
GO Groups. The GO term, p-value for each term, GO Group, and p-value for each GO group 
are provided. The number of genes and % of genes associated with each GO term are also 
provided.  
Table 4.4 ETAA1-dependent GO terms 
GO Term Term p-value 
Group p-
value GO Groups 
% Associated 
Genes # Genes 
mitotic cell cycle 6.70E-13 9.47E-17 Group01 5.19 54.00 
mitotic cell cycle process 3.09E-09 9.47E-17 Group01 4.97 43.00 
chromosome organization 1.76E-08 9.47E-17 Group01 4.17 51.00 
regulation of cell cycle 8.08E-08 9.47E-17 Group01 4.05 50.00 
cell cycle process 1.84E-07 9.47E-17 Group01 3.84 53.00 
mitotic sister chromatid segregation 4.44E-07 9.47E-17 Group01 10.60 16.00 
mitotic cell cycle phase transition 1.64E-06 9.47E-17 Group01 5.23 30.00 
regulation of mitotic cell cycle 1.88E-06 9.47E-17 Group01 4.83 33.00 
nuclear chromosome segregation 4.47E-06 9.47E-17 Group01 6.77 21.00 
spindle checkpoint 3.15E-05 9.47E-17 Group01 20.51 8.00 
chromosome separation 1.10E-04 9.47E-17 Group01 12.50 10.00 
regulation of mitotic sister chromatid 
segregation 
1.50E-04 9.47E-17 Group01 14.06 9.00 
regulation of cell cycle process 1.67E-04 9.47E-17 Group01 4.14 31.00 
organelle fission 2.13E-04 9.47E-17 Group01 5.01 23.00 
cell cycle checkpoint 4.33E-04 9.47E-17 Group01 6.45 16.00 
regulation of mitotic nuclear division 5.25E-04 9.47E-17 Group01 7.78 13.00 
regulation of chromosome segregation 8.56E-04 9.47E-17 Group01 10.00 10.00 
negative regulation of cell cycle 9.73E-04 9.47E-17 Group01 4.12 27.00 
microtubule cytoskeleton organization 1.32E-03 9.47E-17 Group01 4.48 23.00 
negative regulation of mitotic cell cycle 1.92E-03 9.47E-17 Group01 5.45 17.00 
mitotic spindle assembly checkpoint 2.91E-03 9.47E-17 Group01 17.65 6.00 
regulation of organelle organization 6.45E-03 9.47E-17 Group01 3.12 40.00 
regulation of mitotic cell cycle phase 
transition 
8.20E-03 9.47E-17 Group01 4.49 19.00 
mitotic cell cycle checkpoint 1.87E-02 9.47E-17 Group01 6.36 11.00 
negative regulation of cell cycle process 2.00E-02 9.47E-17 Group01 4.69 16.00 
positive regulation of cell cycle 3.21E-02 9.47E-17 Group01 4.31 17.00 
positive regulation of cell cycle process 3.38E-02 9.47E-17 Group01 4.90 14.00 
attachment of spindle microtubules to 
kinetochore 
3.52E-02 9.47E-17 Group01 14.71 5.00 
regulation of chromosome organization 3.62E-02 9.47E-17 Group01 4.63 15.00 
protein localization to kinetochore 3.81E-02 9.47E-17 Group01 21.05 4.00 
negative regulation of chromosome 
organization 
3.83E-02 9.47E-17 Group01 6.98 9.00 
negative regulation of mitotic cell cycle 
phase transition 
4.57E-02 9.47E-17 Group01 5.31 12.00 
chromosome organization 1.76E-08 2.80E-10 Group02 4.17 51.00 
mitotic sister chromatid segregation 4.44E-07 2.80E-10 Group02 10.60 16.00 
nuclear chromosome segregation 4.47E-06 2.80E-10 Group02 6.77 21.00 
covalent chromatin modification 1.01E-03 2.80E-10 Group02 4.32 25.00 
chromatin organization 6.77E-03 2.80E-10 Group02 3.65 28.00 
negative regulation of mRNA metabolic 
process 
1.10E-04 5.12E-08 Group03 12.50 10.00 
regulation of mRNA metabolic process 1.27E-04 5.12E-08 Group03 6.34 18.00 
mRNA metabolic process 1.01E-03 5.12E-08 Group03 3.79 32.00 
RNA processing 6.08E-03 5.12E-08 Group03 3.36 33.00 
mRNA processing 1.07E-02 5.12E-08 Group03 4.13 21.00 
regulation of transcription elongation from 
RNA polymerase II promoter 
1.20E-02 5.12E-08 Group03 18.52 5.00 
transcription elongation from RNA 
polymerase II promoter 
1.22E-02 5.12E-08 Group03 8.18 9.00 
regulation of mRNA processing 1.84E-02 5.12E-08 Group03 7.76 9.00 
negative regulation of mRNA catabolic 
process 
2.06E-02 5.12E-08 Group03 12.50 6.00 
regulation of mRNA catabolic process 2.24E-02 5.12E-08 Group03 6.21 11.00 
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Table 4.4 ETAA1-dependent GO terms 
GO Term Term p-value 
Group p-
value GO Groups 
% Associated 
Genes # Genes 
RNA splicing 4.42E-02 5.12E-08 Group03 4.04 18.00 
mRNA splicing, via spliceosome 4.58E-02 5.12E-08 Group03 4.52 15.00 
cytoskeleton organization 9.25E-05 1.38E-07 Group04 3.48 44.00 
organelle fission 2.13E-04 1.38E-07 Group04 5.01 23.00 
microtubule cytoskeleton organization 1.32E-03 1.38E-07 Group04 4.48 23.00 
negative regulation of nucleobase-
containing compound metabolic process 
7.53E-04 1.83E-05 Group05 3.13 47.00 
negative regulation of nucleic acid-
templated transcription 
1.01E-03 1.83E-05 Group05 3.29 41.00 
negative regulation of transcription from 
RNA polymerase II promoter 
2.29E-03 1.83E-05 Group05 3.66 31.00 
negative regulation of transcription, DNA-
templated 
3.45E-03 1.83E-05 Group05 3.25 39.00 
DNA metabolic process 1.22E-03 2.55E-05 Group06 3.51 36.00 
DNA biosynthetic process 5.64E-03 2.55E-05 Group06 5.83 14.00 
regulation of DNA metabolic process 1.99E-02 2.55E-05 Group06 4.34 18.00 
cytokinesis 4.13E-03 7.06E-05 Group07 7.53 11.00 
mitotic cytokinesis 3.82E-02 7.06E-05 Group07 11.11 6.00 
regulation of transferase activity 2.10E-02 9.60E-05 Group08 3.16 34.00 
regulation of small GTPase mediated 
signal transduction 
1.17E-03 1.39E-04 Group09 5.41 18.00 
regulation of GTPase activity 7.62E-03 1.39E-04 Group09 4.23 21.00 
small GTPase mediated signal 
transduction 
2.73E-02 1.39E-04 Group09 3.85 21.00 
nuclear export 2.13E-02 1.52E-04 Group10 5.80 12.00 
nucleocytoplasmic transport 2.29E-02 1.52E-04 Group10 4.02 20.00 
RNA localization 2.87E-02 1.52E-04 Group10 5.26 13.00 
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Table 4.5 TOPBP1-dependent GO terms. Gene ontology analysis of ETAA1-dependent 
phosphoproteins was completed using ClueGO.  Similar GO terms were grouped into functional 
GO Groups. The GO term, p-value for each term, GO Group, and p-value for each GO Group 
are provided. The number of genes and % of genes associated with each GO term are also 
provided.  
Table 4.5 TOPBP1-dependent GO terms 
GO Term Term p-value 
Group p-
value GO Groups 
% Associated 
Genes # Genes 
regulation of cell cycle 2.45E-09 1.58E-20 Group01 6.32 78.00 
mitotic cell cycle 2.51E-09 1.58E-20 Group01 7.12 74.00 
cell cycle process 3.64E-08 1.58E-20 Group01 5.87 81.00 
mitotic cell cycle process 6.37E-07 1.58E-20 Group01 6.58 57.00 
cellular response to DNA damage 
stimulus 1.08E-05 1.58E-20 Group01 6.33 53.00 
positive regulation of cell cycle 3.94E-05 1.58E-20 Group01 8.12 32.00 
DNA repair 2.25E-04 1.58E-20 Group01 6.90 37.00 
positive regulation of cell cycle process 3.05E-04 1.58E-20 Group01 8.74 25.00 
regulation of mitotic cell cycle 3.76E-04 1.58E-20 Group01 6.30 43.00 
negative regulation of cell cycle 1.81E-03 1.58E-20 Group01 6.11 40.00 
sister chromatid segregation 3.12E-03 1.58E-20 Group01 8.64 21.00 
response to ionizing radiation 3.52E-03 1.58E-20 Group01 10.06 17.00 
regulation of cell cycle process 8.59E-03 1.58E-20 Group01 5.61 42.00 
DNA integrity checkpoint 8.75E-03 1.58E-20 Group01 9.39 17.00 
DNA biosynthetic process 9.00E-03 1.58E-20 Group01 8.33 20.00 
regulation of signal transduction by p53 
class mediator 1.07E-02 1.58E-20 Group01 8.87 18.00 
cell cycle checkpoint 1.44E-02 1.58E-20 Group01 8.06 20.00 
signal transduction by p53 class 
mediator 2.40E-02 1.58E-20 Group01 7.33 22.00 
G1/S transition of mitotic cell cycle 3.28E-02 1.58E-20 Group01 7.60 20.00 
chromosome organization 7.88E-21 2.13E-20 Group02 8.18 100.00 
chromatin organization 1.40E-15 2.13E-20 Group02 9.00 69.00 
organelle organization 2.82E-15 2.13E-20 Group02 4.92 187.00 
covalent chromatin modification 7.41E-15 2.13E-20 Group02 10.02 58.00 
histone modification 3.76E-11 2.13E-20 Group02 9.89 46.00 
DNA metabolic process 3.19E-09 2.13E-20 Group02 6.72 69.00 
peptidyl-lysine modification 1.84E-08 2.13E-20 Group02 9.57 38.00 
peptidyl-amino acid modification 1.94E-08 2.13E-20 Group02 6.04 79.00 
cytoskeleton organization 1.28E-07 2.13E-20 Group02 5.94 75.00 
negative regulation of nucleic acid-
templated transcription 1.77E-07 2.13E-20 Group02 5.94 74.00 
negative regulation of transcription, DNA-
templated 3.27E-06 2.13E-20 Group02 5.75 69.00 
regulation of cellular component 
organization 4.11E-05 2.13E-20 Group02 4.53 111.00 
internal protein amino acid acetylation 4.78E-04 2.13E-20 Group02 11.04 18.00 
histone acetylation 8.20E-04 2.13E-20 Group02 11.18 17.00 
histone deacetylation 1.12E-03 2.13E-20 Group02 14.13 13.00 
negative regulation of transcription from 
RNA polymerase II promoter 1.84E-03 2.13E-20 Group02 5.67 48.00 
protein sumoylation 2.31E-03 2.13E-20 Group02 13.27 13.00 
protein acylation 4.22E-03 2.13E-20 Group02 8.77 20.00 
cellular macromolecule metabolic 
process 3.86E-16 2.67E-18 Group03 3.82 333.00 
histone modification 3.76E-11 2.67E-18 Group03 9.89 46.00 
peptidyl-lysine modification 1.84E-08 2.67E-18 Group03 9.57 38.00 
peptidyl-amino acid modification 1.94E-08 2.67E-18 Group03 6.04 79.00 
macromolecule modification 5.12E-06 2.67E-18 Group03 4.00 180.00 
cellular protein modification process 6.42E-04 2.67E-18 Group03 3.85 163.00 
cellular protein metabolic process 2.02E-02 2.67E-18 Group03 3.55 186.00 
peptidyl-serine modification 4.77E-02 2.67E-18 Group03 6.82 23.00 
peptidyl-lysine modification 1.84E-08 4.86E-18 Group04 9.57 38.00 
regulation of gene expression, epigenetic 5.73E-05 4.86E-18 Group04 9.00 27.00 
nuclear transport 1.44E-04 4.86E-18 Group04 7.14 36.00 
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Table 4.5 TOPBP1-dependent GO terms 
GO Term Term p-value 
Group p-
value GO Groups 
% Associated 
Genes # Genes 
RNA localization 1.12E-03 4.86E-18 Group04 8.91 22.00 
establishment of RNA localization 1.50E-03 4.86E-18 Group04 9.39 20.00 
protein sumoylation 2.31E-03 4.86E-18 Group04 13.27 13.00 
mRNA transport 7.81E-03 4.86E-18 Group04 9.94 16.00 
RNA export from nucleus 9.09E-03 4.86E-18 Group04 10.34 15.00 
nuclear export 1.38E-02 4.86E-18 Group04 8.70 18.00 
negative regulation of cellular amide 
metabolic process 1.87E-02 4.86E-18 Group04 8.19 19.00 
response to heat 2.02E-02 4.86E-18 Group04 9.20 16.00 
regulation of chromatin silencing 2.33E-02 4.86E-18 Group04 26.09 6.00 
regulation of gene silencing 3.95E-02 4.86E-18 Group04 10.91 12.00 
mRNA export from nucleus 4.69E-02 4.86E-18 Group04 10.71 12.00 
organelle organization 2.82E-15 4.01E-17 Group05 4.92 187.00 
cytoskeleton organization 1.28E-07 4.01E-17 Group05 5.94 75.00 
actin cytoskeleton organization 1.09E-02 4.01E-17 Group05 5.95 37.00 
chromosome organization 7.88E-21 1.87E-13 Group06 8.18 100.00 
organelle organization 2.82E-15 1.87E-13 Group06 4.92 187.00 
DNA metabolic process 3.19E-09 1.87E-13 Group06 6.72 69.00 
regulation of DNA metabolic process 3.44E-06 1.87E-13 Group06 8.43 35.00 
cellular response to DNA damage 
stimulus 1.08E-05 1.87E-13 Group06 6.33 53.00 
cellular response to stress 1.55E-05 1.87E-13 Group06 4.86 96.00 
regulation of chromosome organization 2.10E-05 1.87E-13 Group06 8.95 29.00 
regulation of cellular component 
organization 4.11E-05 1.87E-13 Group06 4.53 111.00 
DNA replication 5.19E-05 1.87E-13 Group06 8.81 28.00 
DNA repair 2.25E-04 1.87E-13 Group06 6.90 37.00 
regulation of organelle organization 2.47E-04 1.87E-13 Group06 5.22 67.00 
positive regulation of DNA metabolic 
process 4.20E-04 1.87E-13 Group06 9.44 22.00 
positive regulation of chromosome 
organization 9.63E-04 1.87E-13 Group06 10.53 18.00 
telomere maintenance via telomere 
lengthening 3.26E-03 1.87E-13 Group06 13.95 12.00 
response to ionizing radiation 3.52E-03 1.87E-13 Group06 10.06 17.00 
regulation of cellular response to stress 3.81E-03 1.87E-13 Group06 5.99 40.00 
cell aging 5.01E-03 1.87E-13 Group06 12.38 13.00 
protein complex assembly 5.26E-03 1.87E-13 Group06 4.71 70.00 
regulation of response to DNA damage 
stimulus 5.35E-03 1.87E-13 Group06 9.33 18.00 
DNA conformation change 6.00E-03 1.87E-13 Group06 8.03 22.00 
telomere organization 7.81E-03 1.87E-13 Group06 9.94 16.00 
DNA integrity checkpoint 8.75E-03 1.87E-13 Group06 9.39 17.00 
DNA biosynthetic process 9.00E-03 1.87E-13 Group06 8.33 20.00 
positive regulation of telomere 
maintenance 1.22E-02 1.87E-13 Group06 16.67 9.00 
macromolecular complex subunit 
organization 1.42E-02 1.87E-13 Group06 4.22 92.00 
macromolecular complex assembly 1.43E-02 1.87E-13 Group06 4.37 82.00 
cell cycle checkpoint 1.44E-02 1.87E-13 Group06 8.06 20.00 
protein complex subunit organization 1.51E-02 1.87E-13 Group06 4.43 77.00 
regulation of telomere maintenance 1.87E-02 1.87E-13 Group06 12.79 11.00 
regulation of protein complex assembly 1.96E-02 1.87E-13 Group06 6.62 28.00 
response to heat 2.02E-02 1.87E-13 Group06 9.20 16.00 
signal transduction by p53 class 
mediator 2.40E-02 1.87E-13 Group06 7.33 22.00 
positive regulation of cellular component 
organization 2.59E-02 1.87E-13 Group06 4.75 60.00 
positive regulation of organelle 
organization 4.21E-02 1.87E-13 Group06 5.52 37.00 
regulation of cellular component 
biogenesis 4.35E-02 1.87E-13 Group06 5.11 46.00 
peptidyl-amino acid modification 1.94E-08 4.75E-11 Group07 6.04 79.00 
activation of protein kinase activity 8.70E-03 4.75E-11 Group07 7.25 25.00 
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Table 4.5 TOPBP1-dependent GO terms 
GO Term Term p-value 
Group p-
value GO Groups 
% Associated 
Genes # Genes 
peptidyl-serine modification 4.77E-02 4.75E-11 Group07 6.82 23.00 
posttranscriptional regulation of gene 
expression 4.30E-05 3.21E-10 Group08 7.14 39.00 
mRNA metabolic process 3.04E-04 3.21E-10 Group08 5.92 50.00 
regulation of cellular amide metabolic 
process 3.05E-04 3.21E-10 Group08 7.28 33.00 
regulation of translation 9.02E-04 3.21E-10 Group08 7.33 30.00 
regulation of mRNA catabolic process 6.52E-03 3.21E-10 Group08 9.60 17.00 
mRNA transport 7.81E-03 3.21E-10 Group08 9.94 16.00 
regulation of catabolic process 1.22E-02 3.21E-10 Group08 5.20 50.00 
RNA splicing 1.62E-02 3.21E-10 Group08 6.52 29.00 
negative regulation of cellular amide 
metabolic process 1.87E-02 3.21E-10 Group08 8.19 19.00 
regulation of mRNA metabolic process 3.19E-02 3.21E-10 Group08 7.39 21.00 
RNA processing 3.76E-02 3.21E-10 Group08 4.99 49.00 
regulation of RNA stability 4.36E-02 3.21E-10 Group08 9.04 15.00 
cellular senescence 5.20E-04 6.07E-09 Group09 18.33 11.00 
cell aging 5.01E-03 6.07E-09 Group09 12.38 13.00 
regulation of response to DNA damage 
stimulus 5.35E-03 6.07E-09 Group09 9.33 18.00 
DNA integrity checkpoint 8.75E-03 6.07E-09 Group09 9.39 17.00 
regulation of signal transduction by p53 
class mediator 1.07E-02 6.07E-09 Group09 8.87 18.00 
signal transduction by p53 class 
mediator 2.40E-02 6.07E-09 Group09 7.33 22.00 
nucleic acid metabolic process 3.70E-23 3.25E-08 Group10 4.79 255.00 
heterocycle metabolic process 3.88E-20 3.25E-08 Group10 4.42 274.00 
cellular aromatic compound metabolic 
process 3.36E-19 3.25E-08 Group10 4.38 273.00 
organic cyclic compound metabolic 
process 4.39E-19 3.25E-08 Group10 4.32 279.00 
RNA metabolic process 7.71E-19 3.25E-08 Group10 4.76 229.00 
cellular nitrogen compound metabolic 
process 6.35E-18 3.25E-08 Group10 4.22 283.00 
regulation of nucleobase-containing 
compound metabolic process 2.99E-17 3.25E-08 Group10 4.81 211.00 
gene expression 1.15E-16 3.25E-08 Group10 4.43 247.00 
regulation of cellular metabolic process 2.40E-16 3.25E-08 Group10 4.24 268.00 
cellular macromolecule metabolic 
process 3.86E-16 3.25E-08 Group10 3.82 333.00 
regulation of cellular macromolecule 
biosynthetic process 8.92E-16 3.25E-08 Group10 4.79 201.00 
chromatin organization 1.40E-15 3.25E-08 Group10 9.00 69.00 
regulation of macromolecule biosynthetic 
process 1.69E-15 3.25E-08 Group10 4.74 204.00 
regulation of biosynthetic process 5.69E-15 3.25E-08 Group10 4.61 212.00 
regulation of RNA metabolic process 6.69E-15 3.25E-08 Group10 4.82 192.00 
covalent chromatin modification 7.41E-15 3.25E-08 Group10 10.02 58.00 
regulation of cellular biosynthetic process 1.02E-14 3.25E-08 Group10 4.62 209.00 
regulation of metabolic process 2.69E-14 3.25E-08 Group10 4.05 277.00 
regulation of gene expression 3.00E-14 3.25E-08 Group10 4.53 214.00 
regulation of primary metabolic process 4.04E-14 3.25E-08 Group10 4.16 260.00 
cellular nitrogen compound biosynthetic 
process 5.27E-14 3.25E-08 Group10 4.40 226.00 
regulation of macromolecule metabolic 
process 6.74E-14 3.25E-08 Group10 4.14 260.00 
heterocycle biosynthetic process 1.12E-13 3.25E-08 Group10 4.55 206.00 
cellular macromolecule biosynthetic 
process 1.19E-13 3.25E-08 Group10 4.35 228.00 
regulation of nitrogen compound 
metabolic process 1.50E-13 3.25E-08 Group10 4.16 253.00 
organic cyclic compound biosynthetic 
process 2.63E-13 3.25E-08 Group10 4.48 210.00 
macromolecule biosynthetic process 3.31E-13 3.25E-08 Group10 4.29 231.00 
	 	
	
142	
	
Table 4.5 TOPBP1-dependent GO terms 
GO Term Term p-value 
Group p-
value GO Groups 
% Associated 
Genes # Genes 
aromatic compound biosynthetic process 7.42E-13 3.25E-08 Group10 4.50 204.00 
nucleic acid-templated transcription 1.73E-12 3.25E-08 Group10 4.67 184.00 
regulation of nucleic acid-templated 
transcription 1.17E-11 3.25E-08 Group10 4.65 176.00 
macromolecule metabolic process 4.99E-11 3.25E-08 Group10 3.57 338.00 
negative regulation of cellular 
macromolecule biosynthetic process 6.91E-11 3.25E-08 Group10 6.20 91.00 
negative regulation of cellular 
biosynthetic process 1.71E-10 3.25E-08 Group10 5.93 97.00 
negative regulation of cellular process 2.76E-10 3.25E-08 Group10 4.28 202.00 
cellular biosynthetic process 8.00E-10 3.25E-08 Group10 3.91 251.00 
negative regulation of nucleobase-
containing compound metabolic process 1.80E-09 3.25E-08 Group10 5.93 89.00 
organic substance biosynthetic process 1.86E-09 3.25E-08 Group10 3.88 253.00 
negative regulation of gene expression 2.50E-09 3.25E-08 Group10 5.52 102.00 
negative regulation of macromolecule 
metabolic process 2.99E-09 3.25E-08 Group10 4.92 133.00 
negative regulation of biological process 4.30E-09 3.25E-08 Group10 4.08 213.00 
positive regulation of nucleobase-
containing compound metabolic process 4.70E-09 3.25E-08 Group10 5.48 102.00 
negative regulation of cellular metabolic 
process 6.85E-09 3.25E-08 Group10 4.88 131.00 
negative regulation of RNA metabolic 
process 8.04E-09 3.25E-08 Group10 6.07 81.00 
regulation of cellular process 9.01E-09 3.25E-08 Group10 3.36 365.00 
negative regulation of nitrogen 
compound metabolic process 9.41E-09 3.25E-08 Group10 4.97 124.00 
negative regulation of metabolic process 2.18E-08 3.25E-08 Group10 4.69 140.00 
positive regulation of macromolecule 
metabolic process 4.34E-08 3.25E-08 Group10 4.57 145.00 
positive regulation of metabolic process 7.30E-08 3.25E-08 Group10 4.46 153.00 
positive regulation of cellular metabolic 
process 8.06E-08 3.25E-08 Group10 4.53 145.00 
negative regulation of nucleic acid-
templated transcription 1.77E-07 3.25E-08 Group10 5.94 74.00 
transcription from RNA polymerase II 
promoter 2.76E-07 3.25E-08 Group10 4.93 112.00 
positive regulation of biosynthetic 
process 5.19E-07 3.25E-08 Group10 5.10 100.00 
positive regulation of cellular biosynthetic 
process 1.05E-06 3.25E-08 Group10 5.08 98.00 
positive regulation of RNA metabolic 
process 1.11E-06 3.25E-08 Group10 5.36 85.00 
positive regulation of macromolecule 
biosynthetic process 1.16E-06 3.25E-08 Group10 5.18 92.00 
regulation of transcription from RNA 
polymerase II promoter 2.25E-06 3.25E-08 Group10 4.92 102.00 
positive regulation of gene expression 2.37E-06 3.25E-08 Group10 5.03 96.00 
positive regulation of cellular process 2.49E-06 3.25E-08 Group10 3.90 202.00 
negative regulation of transcription, DNA-
templated 3.27E-06 3.25E-08 Group10 5.75 69.00 
positive regulation of nitrogen compound 
metabolic process 4.83E-06 3.25E-08 Group10 4.38 135.00 
positive regulation of transcription, DNA-
templated 7.43E-06 3.25E-08 Group10 5.28 80.00 
positive regulation of biological process 2.48E-05 3.25E-08 Group10 3.73 217.00 
negative regulation of transcription from 
RNA polymerase II promoter 1.84E-03 3.25E-08 Group10 5.67 48.00 
positive regulation of transcription from 
RNA polymerase II promoter 1.46E-02 3.25E-08 Group10 4.90 58.00 
cellular protein metabolic process 2.02E-02 3.25E-08 Group10 3.55 186.00 
positive regulation of molecular function 1.85E-05 6.66E-08 Group11 4.90 92.00 
regulation of apoptotic process 2.13E-04 6.66E-08 Group11 4.95 78.00 
regulation of cell death 2.71E-04 6.66E-08 Group11 4.82 83.00 
	 	
	
143	
	
Table 4.5 TOPBP1-dependent GO terms 
GO Term Term p-value 
Group p-
value GO Groups 
% Associated 
Genes # Genes 
apoptotic process 3.05E-04 6.66E-08 Group11 4.64 92.00 
programmed cell death 4.49E-04 6.66E-08 Group11 4.53 96.00 
intracellular signal transduction 4.41E-02 6.66E-08 Group11 3.91 111.00 
positive regulation of molecular function 1.85E-05 1.62E-06 Group12 4.90 92.00 
positive regulation of kinase activity 4.12E-04 1.62E-06 Group12 6.58 39.00 
positive regulation of catalytic activity 5.18E-04 1.62E-06 Group12 4.92 75.00 
positive regulation of transferase activity 5.56E-04 1.62E-06 Group12 6.11 45.00 
activation of protein kinase activity 8.70E-03 1.62E-06 Group12 7.25 25.00 
positive regulation of protein kinase 
activity 2.43E-02 1.62E-06 Group12 5.95 33.00 
regulation of transferase activity 2.43E-02 1.62E-06 Group12 4.92 53.00 
regulation of kinase activity 2.85E-02 1.62E-06 Group12 5.15 46.00 
intracellular signal transduction 4.41E-02 1.62E-06 Group12 3.91 111.00 
peptidyl-serine modification 4.77E-02 1.62E-06 Group12 6.82 23.00 
regulation of cellular response to stress 3.81E-03 6.56E-06 Group13 5.99 40.00 
response to heat 2.02E-02 6.56E-06 Group13 9.20 16.00 
regulation of gene silencing 3.95E-02 6.56E-06 Group13 10.91 12.00 
mRNA export from nucleus 4.69E-02 6.56E-06 Group13 10.71 12.00 
symbiosis, encompassing mutualism 
through parasitism 1.17E-03 6.56E-06 Group14 5.62 50.00 
viral process 1.37E-03 6.56E-06 Group14 5.73 47.00 
chromatin remodeling 1.06E-02 4.89E-05 Group15 9.70 16.00 
protein localization 4.79E-02 5.76E-05 Group16 3.93 109.00 
Ras protein signal transduction 3.59E-03 6.49E-05 Group17 7.28 27.00 
small GTPase mediated signal 
transduction 1.85E-02 6.49E-05 Group17 6.06 33.00 
response to epidermal growth factor 3.05E-02 7.24E-05 Group17 17.02 8.00 
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CHAPTER V 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
Summary 
ATR is an apical DNA damage response (DDR) kinase that promotes genome stability 
by regulating the cell division cycle and cellular stress responses (Saldivar et al., 2017). ATR 
signaling coordinates the DNA replication stress response, controls the S/G2 and G2/M 
transitions to ensure completion of DNA replication before mitosis, and ensures proper 
chromosome separation during mitosis (Cimprich and Cortez, 2008; Saldivar et al., 2018; 
Kabeche et al., 2017; Zachos et al., 2007). ATR can phosphorylate hundreds of proteins in 
response to replication stress regulating a wide range of biological processes including DNA 
metabolism, cell cycle regulation, protein metabolism, and gene expression (Matsuoka et al., 
2007). Emphasizing the critical functions of ATR as a master regulator of genome maintenance, 
loss of ATR is incompatible with life, and mutations in ATR result in the disease Seckel 
syndrome (O’Driscoll et al., 2003).  
The essential function of ATR is to coordinate cellular responses to RS (Nam et al., 
2011a). ATR and its obligate binding partner ATRIP, localize to sites of RS through an 
interaction with RPA on ssDNA (Zou and Elledge, 2003). However, ATR localization to sites of 
RS is not sufficient for its activation, ATR requires an activating protein to stimulate its kinase 
activity. Vertebrate cells utilize two ATR-activating proteins to regulate ATR activity, TOPBP1 
and ETAA1 (Bass et al., 2016; Haahr et al., 2016; Feng et al., 2016; Kumagai et al., 2006). 
Once activated, ATR initiates a signaling cascade that results in decreased origin firing, 
stabilization of stalled replication forks, and halts cell cycle progression.  
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During my graduate studies I have identified a new ATR activator, ETAA1, and 
examined how both ETAA1 and TOPBP1 direct ATR signaling. Chapter III describes the 
identification of ETAA1 as a novel ATR activator and its functions to promote genome stability 
during RS. Chapter IV describes how I utilize quantitative phosphoproteomics to identify ETAA1 
and TOPBP1 substrates and the discovery of a unique function of ETAA1 to regulate mitotic 
ATR signaling at centromeric regions. 
Discussion 
Defining ATR/Mec1 activators 
In my thesis work I identified ETAA1 as a second ATR activating protein in vertebrate 
cells, ten years after the identification of the first ATR activating protein, TOPBP1. Although 
studies during the past decade have expanded our knowledge of how ATR and Mec1 are 
regulated by activating proteins, some questions remain outstanding. First, are there additional 
ATR/Mec1 activators? Second, how do these activators stimulate ATR/Mec1 kinase activity? 
Lastly, how do these different activators direct ATR/Mec1 toward specific substrates?   
In yeast, three proteins can activate Mec1ATR: Dpb11TOPBP1 , Ddc1Rad9, and Dna2 (Mordes 
et al., 2008b; Navadgi-Patil and Burgers, 2009, 2008a; Kumar and Burgers, 2013). However, 
only the TOPBP1/DPB11 activation pathway of ATR/Mec1 appears to be conserved throughout 
eukaryotes.  While Rad9 and Ddc1Rad9 are both part of checkpoint clamps required to recruit 
TOPBP1/Dpb11, Rad9 cannot activate ATR on its own, unlike its yeast counterpart DDC1. 
Similarly, human DNA2 cannot stimulate ATR kinase activity. Conversely, yeast do not contain 
an obvious ETAA1 homolog. Although the human orthologues of Ddc1Rad9, DNA2, do not 
activate ATR, these Mec1 activators and ETAA1 may be functional orthologues based on how 
they direct ATR/Mec1 signaling, a process described later. 
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At least two papers suggest that there may be additionally Mec1 activators in yeast, and 
the recent discovery of proteins that regulate ATR signaling may hint at the presence of 
additional ATR activators (Bandhu et al., 2014; Bastos de Oliveira et al., 2015; Reynolds et al., 
2017).  Although direct evolutionary conservation does not seem a promising method of 
identifying new ATR/Mec1 activators, defining the characteristics of an ATR/Mec1 activation 
domain may assist with identification of novel activators. Extensive work from the Peter Burgers 
lab has identified common features in Mec1 activators and ongoing work by Vaughn Thada in 
our laboratory is expanding the definition of an ATR activating domain. The only common 
structural or sequence feature of ATR and Mec1 activators is the presence of two aromatic 
residues contained within an intrinsically disordered region.  Although this is a loose biochemical 
definition of an AAD/MAD, potential ATR activating proteins that have lacked obvious aromatic 
residues have failed to stimulate ATR in our kinase assays. Therefore, a biochemical definition 
of what defines an AAD/MAD combined with genetic and/or proteomic screening for ATR 
signaling pathway defects may reveal additional activators. 
Characterizing how ATR/Mec1 activators work 
  Exactly how ATR and Mec1 are stimulated by activating-proteins has not been 
described but likely involves conformation changes of the kinase upon binding by the activating 
protein (Mordes and Cortez, 2008). ATR-activating proteins utilize the same surface of ATR for 
activation, as a point mutant that disrupted the ability of TOPBP1 to activate ATR also 
prevented activation by ETAA1 (Bass et al., 2016). Additionally, interchanging of the of Dpb11 
and Dna2 MADs still promotes Mec1 activation, suggesting a common mechanism of Mec1 
activation (Kumar and Burgers, 2013).  
Structures of the Mec1ATR-Ddc2ATRIP complex reveal that they form a dimer of 
heterodimers with butterfly-like architecture, similar to the dimeric architecture of Tel1, the ATM 
orthologue (Wang et al., 2017; Deshpande et al., 2017; Rao et al., 2018).  Heterodimerization is 
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mediated using interactions between the PRD and FAT domains of Mec1ATR and the coiled-coil 
of Ddc2ATRIP (Ball and Cortez, 2005; Itakura et al., 2005; Wang et al., 2017). The PRD keeps the 
Mec1 activation pocket in a closed conformation, which is likely opened after binding of a 
Mec1/ATR activator. Although ATR/Mec1 forms a dimeric complex, it is not known if two 
activating proteins are required for activation of both ATR molecules. The activation domain lies 
at the dimerization interface and therefore a single ATR/Mec1 activating protein may be able to 
activate both molecules. Future structural studies incorporating AAD/MADs into the ATR/Mec1 
complex are required to obtain a detailed understanding of ATR/Mec1 activation.  
Benefits of having multiple ATR/Mec1 activators 
Another remaining question is if ATR/Mec1 activators stimulate ATR/Mec1 kinase 
activity though the same mechanism, why do cells require multiple activators? Having multiple 
activators appears to account for more than just a contingency plan in case one activation 
pathway fails, as ATR and Mec1 activators have some non-redundant functions in cells. Below, 
I will detail the possible benefits of utilizing multiple ATR activators, including temporal 
regulation of ATR, separation of ATR signaling pathways, and promoting response to more 
diverse DNA lesions (Fig 5.1)   
Temporal regulation of ATR signaling 
The utilization of multiple ATR activators may be a conserved regulatory mechanism for 
checkpoint activation throughout eukaryotes. Although the unique functions of each Mec1ATR 
activator have not been fully defined, there are several common themes between Mec1ATR and 
ATR activation that may explain why multiple activators are used for checkpoint signaling. First, 
the cell-cycle-specific utilization of each Mec1ATR activator allows for temporal regulation of 
Mec1ATR throughout the process of cell division (Navadgi-Patil and Burgers, 2011). Ddc1Rad9 
activates Mec1ATR during G1, while both Ddc1Rad9 and Dpb11TOPBP1 activate Mec1ATR during G2  
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(Navadgi-Patil et al., 2011; Navadgi-Patil and Burgers, 2009). During S-phase, all three 
Mec1ATR activators contribute to Mec1ATR activation with partial redundancy. 
 I have observed a similar cell-cycle specific usage of ETAA1 and TOPBP1 (Fig. 5.1A).  
Both activators are utilized during S-phase when ATR signaling is highest. However, during 
mitosis only ETAA1 is required to promote ATR signaling at centromeric regions.  Previous 
studies indicate that TOPBP1 does function during mitosis at sites of under-replication but that it 
is independent of ATR signaling (Pedersen et al., 2015). Additionally, TOPBP1 localizes to ultra-
fine anaphase bridges and promotes their resolution through direct recruitment of 
topoisomerase IIα. (Germann et al., 2014; Broderick et al., 2015). Therefore, while TOPBP1 is 
active during mitosis, its functions do not appear tied to ATR activation. Utilizing certain 
activators at specific times during cell cycle progression may direct ATR signaling to substrates 
required for that specific stage of the cell cycle.   
Separation of ATR signaling pathways 
Another potential benefit of having multiple ATR/Mec1 activators is that they may keep 
different signaling pathways distinct (Fig 5.1B). ATR functions throughout the cell cycle to 
coordinate responses to genotoxic stress and regulate cell cycle transitions. Using cells 
deficient for ETAA1 or TOPBP1, we were able to separate the functions of ATR during 
replication stress and a normal cell cycle. We found that ETAA1-dependent ATR activity 
controlled the anaphase to metaphase transition through regulation of the SAC. These findings 
expand the requirement for ETAA1 to enforce normal cell cycle progression as ETAA1 activates 
ATR during an unperturbed S-phase to control the S/G2 transition (Saldivar et al., 2018). 
Conversely, we identified TOPBP1 as the primary activator of ATR in response to replication 
stress. These findings suggest each activator may regulate a separate ATR pathway, ETAA1 
regulating ATR signaling to promote optimal cell cycle progression and TOPBP1 promoting 
cellular responses to replication stress. This separation of function parallels how different 
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Mec1ATR activators work in yeast where Dpb11TOPBP1 activates Mec1ATR-Rad53CHK1 signaling 
during replication stress while the other Mec1ATR activators, Dna2 and Ddc1Rad9, activate Mec1 
during an unperturbed cell cycle (Bastos de Oliveira et al., 2015). Therefore, although there is 
no apparent yeast homolog of ETAA1, Dna2 and Ddc1 may be functional orthologs.  Utilizing 
different activators may ensure separation of ATR/Mec1 signaling pathways, keeping responses 
to RS distinct from signaling during a normal, unperturbed cell cycle.  
ATR activators may respond to unique DNA lesions 
In all of these models of ATR/Mec1 activation, the advantage of having multiple 
activating proteins is to direct ATR to specific and potentially distinct substrates. But how do 
these ATR/Mec1 activators direct ATR activity toward specific substrates?  In yeast, Mec1ATR 
activators direct Mec1ATR to phosphorylate substrates proximal to the activator, promoting 
localization-dependent Mec1 signaling (Lanz et al., 2018).   Localization of ETAA1 or TOPBP1 
may similarly regulate ATR. Indeed, one of the distinguishing differences between ETAA1 and 
TOPBP1 is their mode of recruitment to sites of RS. ETAA1 is localized through two RPA-
interaction motifs that are both sufficient for its binding to RPA (Haahr et al., 2016; Lee et al., 
2016; Bass et al., 2016; Feng et al., 2016). TOPBP1 recruitment to 5’ ss/dsDNA junctions is 
dependent on MRN, RHINO, and a direct interaction with the phosphorylated C-terminal tail of 
RAD9 of the 9-1-1 (Cotta-Ramusino et al., 2011; Lee et al., 2007a; Duursma et al., 2013). 
These different modes of recruitment may ensure ATR can be activated at a wide range of DNA 
lesions and influence which ATR substrates get phosphorylated (Fig 5.1C).  
Although 5’ junctions limit TOPBP1 localization, it is the primary activator of ATR during 
RS. Therefore, most stalled forks must naturally generate a 5’ junction or be processed by fork 
remodeling proteins to contain a junction. Following uncoupling of the helicase and polymerase 
activities, DNA polymerase α (Pol α) forms 5’ junctions as it continues to synthesize primers 
ahead of the stalled polymerase, promoting checkpoint activation (Fig. 5.2 A).  
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Figure 5.2 Generation of 5’ ss/dsDNA junctions for TOPBP1 activation. (A) Lesions on the lagging 
strand can causes helicase and polymerase uncoupling generating ssDNA, but may not have a 5‘ junction. 
DNA polymerase α forms 5’ junctions as it continues to synthesize primers ahead of the stalled polymerase, 
promoting TOPBP1 recruitment. (B) A stalled lagging strand naturally forms 5’ junctions due to 
discontinuous synthesis of Okazaki fragments from RNA-DNA primers. (C) For DNA lesions that do not 
generate ssDNA, the stalled fork can be reversed to generate a 5’ junction to promote TOPBP1 recruitment. 
If the leading strand is longer than the lagging strand, the regressed arm would have to be resected by an 
exonuclease such as DNA2 to generate a 5’ junction.
BA
C
	 	
	
152	
	
(Van et al., 2010; Michael et al., 2000). A stalled lagging strand also naturally forms 5’ junctions 
due to the discontinuous synthesis of Okazaki fragments from RNA-DNA primers (Fig. 5.2 B). 
Therefore, continued DNA primer synthesis is one mechanism ensuring TOPBP1 recruitment to 
stalled forks.  
For DNA lesions that do not generate ssDNA a potential mechanism to protect forks and 
recruit ATR and TOPBP1 is fork reversal (Fig. 5.2 C). When forks stall, fork remodeling 
enzymes can regress the replication fork protruding the regressed arm consisting of annealed 
nascent DNA. If the nascent lagging strand is shorter than the nascent leading strand, then fork 
reversal would have sufficiently generated a 5’ junction. However, if the leading strand was 
longer than the lagging strand, the regressed arm must be resected by 5’-to-3’ exonucleases 
such as DNA2 to generate a 5’ ss/dsDNA junction.  Similarly, lesions such as DSBs can activate 
ATR but require processing by exonucleases such as Exo1 to generate ssDNA to localize 
ATR/ATRIP and a 5’ junction to recruit TOPBP1 (Fig. 5.3 A).  
While TOPBP1 is the primary activator of ATR during S-phase, ETAA1 does contribute 
to ATR signaling to a lesser extent. While most DNA lesions can generate a 5’ junction to 
localize TOPBP1, ETAA1 may be required for DNA lesions that lack a 5’ ss/dsDNA junction but 
contain RPA-coated ssDNA. One such common DNA structure is a R-loop, a three stranded 
nucleic acid structure composed of a DNA:RNA hybrid and the displaced ssDNA loop (Skourti-
Stathaki and Proudfoot, 2014). R-loops impede DNA replication causing genome instability 
(Gan et al., 2011). R-loops form naturally when a nascent RNA transcript behind an elongating 
Polymerase II (Pol II) duplexes with the DNA template strand, displacing the non-template 
strand (Fig. 5.3B). RPA can bind the displaced ssDNA strand and can elicit checkpoint 
response through recruitment of ATR/ATRIP.    
Activation of ATR at R-loops may require ETAA1 which can be recruited by RPA on the 
displaced strand, while lack of a 5’ junction should preclude TOPBP1 localization to R-loops  
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(Fig. 5.3 B). Although this hypothesis has not yet been directly tested, my studies outlined in this 
dissertation in combination with findings from the Zou lab suggest ATR signaling at R-loops is 
dependent on ETAA1.  The Zou lab discovered that ATR recruitment to centromeres during 
mitosis is dependent on centromeric R-loop formation (Kabeche et al., 2017). Additionally, work 
described in Chapter IV demonstrated that ETAA1 but not TOPBP1 is required for mitotic ATR 
signaling at centromeric regions. Therefore, the dependence on ETAA1 but not TOPBP1 for 
ATR signaling at centromeric regions may reflect an inability of TOPBP1 to localize to R-loops, 
requiring ETAA1 activation of ATR.  
 Studies have shown that increasing the amount of ssDNA increases ATR signaling, 
even if the number of 5’ ss/dsDNA junctions are kept constant (MacDougall et al., 2007; 
Shiotani et al., 2013). Therefore, cells may utilize ETAA1 following extensive DNA resection to 
bolster ATR signaling by activation of ATR molecules localized too far away from a junction to 
interact with TOPBP1 (Fig. 5.4 A). Following formation of a DSB, MRN and CtIP initiate 
resection, processing the ends of the DNA breaks by short range resection.  MRN then recruits 
and stimulates EXO1 and/or DNA2/BLM to promote long-range resection (Nimonkar et al., 
2011; Zhu et al., 2008). As resection becomes more extensive, localized ATR signaling away 
from the junction may become more ETAA1-dependent.  
Topoisomerase poisons such as CPT and ETOP can induce double strand breaks that 
are extensively resected promoting ATR activation (Gobbini et al., 2013).  Hyperphosphorylation 
of RPA is used as a common readout for long-range resection (Cruz-García et al., 2014). 
Interestingly, loss of ETAA1 reduces RPA phosphorylation after treatment with CPT, despite an 
increase in ssDNA and RPA accumulation at sites of replication (Bass et al., 2016). These 
results show that even though resection is still occurring, RPA is not getting phosphorylated 
supporting a model for ETAA1 activation of ATR on long stretches of ssDNA. 
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 While loss of ETAA1 decreased RPA phosphorylation during RS, other ATR substrates 
such as CHK1 and MCM2 are more dependent on TOPBP1. CHK1 phosphorylation requires 
the replisome component CLASPIN (Kumagai and Dunphy, 2000), and MCM2 is part of the 
replicative helicase. Thus, it is possible that the proximity to the replisome where it may be more 
likely to have a 5’ DNA junction to load 9-1-1/TOPBP1 could determine ETAA1 versus TOPBP1 
dependency.  
 
Regulation of ETAA1  
Checkpoint initiation requires concentrating ATR and its activators at sites of RS to 
promote an interaction.  By requiring independent recruitment of two protein complexes to sites 
of RS, cells prevent spurious activation of ATR. TOPBP1 localization to sites of RS is very 
distinct from ATR, relying on a different DNA substrate, a 5’ ss/dsDNA junction, and different 
recruiting proteins: 9-1-1, MRN, and RHINO. In contrast, ETAA1 and ATR recruitment is 
mediated by the same substrate, RPA-coated ssDNA. Surprisingly, although ETAA1 appears to 
have fewer requirements to colocalize with ATR, it is not the primary activator during RS. 
Therefore, I hypothesize that cells employ additional mechanisms that regulate ETAA1 ability to 
activate ATR during RS. 
ETAA1 is phosphorylated during replication stress 
 In support of this hypothesis, I have observed that after addition of RS-inducing agents 
ETAA1 becomes more difficult to detect by western blotting in many different cell types 
suggesting either a decrease in ETAA1 levels or a change in its electrophoretic mobility due to 
post-translational modifications (PTMs) (Fig. 3.11E; Fig. 5.4 A). Alteration of protein levels or 
modification of ETAA1 by PTMs may serve as mechanisms to regulate ETAA1 activity during  
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Figure 5.4 ETAA1 is phosphorylated during replication stress. (A)  HeLA cells were treated with 100 nM 
CPT or 2 mM HU for four hours following a 1.5 hour pretreatment with DMSO or MG132. Cell were 
harvested, lysed proteins examined by western blotting following  separation by SDS-PAGE. (B) Hela cells 
were left untreated or treated for four hours with 100 nM CPT. Cells were collected, lysed, and treated with 
lambda phosphatase for 20 min. (C) HeLa cells were pretreated with the indicated kinase inhibitors prior to 
a four hour treatment with 100 nM CPT. Asterisk denotes a non-specific band. (D) HCT116 Wild type and 
ΔAAD cells were treated with 100 nM CPT for 4 hrs before separation separation by SDS-PAGE and 
detection of proteins by western blotting. (E)  ETAA1 PTM sites and frequency they are referenced. Diagram 
was exported from Phosphosite Plus. 
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RS. To test if RS induces ETAA1 degradation, cells were pretreated with the proteasome 
inhibitor MG132 before addition of CPT. Although MG132 treatment prevented proteasomal 
degradation of p53, it did not stabilize ETAA1 levels suggesting the inability to detect ETAA1 is 
not due to degradation by the proteasome (Fig. 5.4 A).  
ETAA1 has been identified as an ATR substrate in two phosphoproteomic screens and 
is phosphorylated by ATR in our kinase assays (Matsuoka et al., 2007; Haahr et al., 2016). To  
examine if the difficulties in detecting ETAA1 during RS is due to phosphorylation, cell lysates 
were treated with lambda phosphatase before separation by SDS-PAGE.  Treatment with 
phosphatase restored the appearance of ETAA1 to that of an untreated control, demonstrating 
that ETAA1 is phosphorylated during RS (Fig. 5.4B). Since ETAA1 has been identified as an 
ATR substrate and its phosphorylation is induced by RS, I examined if ETAA1 phosphorylation 
could be prevented by treatment with ATR or CHK1 inhibitors. Inhibition of ATR by VE-821 and 
caffeine prevented ETAA1 phosphorylation while inhibition of CHK1 did not affect ETAA1 
modification demonstrating that ETAA1 is phosphorylated by ATR (Fig. 5.4C). ETAA1 
phosphorylation does not appear dependent on its ability to interact and activate ATR as ETAA1 
is still modified in ETAA1ΔAAD cells (Fig. 5.4 D). Many sites on ETAA1 are phosphorylated 
(Fig. 5.4E), some of which are S/TQ sites and therefore likely candidates as sites of 
phosphorylation by ATR.  
  To examine if ETAA1 phosphorylation serves any regulatory functions, I examined 
kinetics of ATR signaling and modification of ETAA1 at different times post treatment with CPT 
(Fig. 5.5 A). An hour post CPT addition, nearly 50% of ETAA1 was modified, measured by 
reduced ETAA1 detection (Fig. 5.5 B). Modification of ETAA1 continued to increase during 24 
hours of CPT treatment. In comparison, I observed no detectable difference in TOPBP1 
throughout the duration of the time course (Fig 5.5 A).   
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In addition to monitoring modifications of ATR activators I also examined phosphorylation of 
ATR substrates previously shown to be dependent on ETAA1 or TOPBP1. Just 15 minutes after 
CPT addition, CHK1 and MCM2 phosphorylation rose to over half their maximum detected 
levels and plateaued around 2 hours (Fig. 5.5 C).  In contrast, RPA phosphorylation was not 
detected until two hours after CPT treatment and continued to increase over the course of 16 
hours (Fig. 5.5 D). Similarly, throughout the 24 hours of CPT treatment I observed a steady 
increase in autophosphorylation of ATR on S1989, a readout of ATR activation (Fig. 5.5 E) 
(Nam et al., 2011b; Liu et al., 2011).  Strikingly, proteins dependent on TOPBP1 activation of 
ATR such as MCM2 and CHK1 are phosphorylated early, well before ETAA1 is modified. 
Meanwhile, RPA phosphorylation is only detectable at later timepoints, after large amounts of 
ETAA1 is modified. Therefore, phosphorylation of ETAA1 may be a prerequisite for its ability to 
stimulate ATR.   
ETAA1 demonstrates delayed localization to sites of replication stress 
To examine if ETAA1 modification might correspond with ETAA1 localization to sites of 
RS, I examined localization of RPA, TOPBP1, and ETAA1 at differing times post treatment with 
CPT (Fig. 5.6 A-D).  Just 30 minutes after addition of CPT, around 20% of cells in an 
asynchronous population begin to form RPA or TOPBP1 foci. Throughout a 16-hour time course 
the percentage of cells with TOPBP1 and RPA foci continued to increase, reaching 40% two 
hours after addition of CPT and ending around 90% after 16 hours.  In comparison, only 10% of 
cells contain ETAA1 foci after 4 hours of CPT treatment and only 20-25% of cells are ETAA1-
foci positive after 16 hours. Although the amount of RPA-coated ssDNA was sufficient to form 
foci at 30 min, ETAA1 recruitment is delayed until four hours (Fig. 5.6 A). Therefore, while an 
interaction with RPA is required for its localization to sites of RS, it may not be solely sufficient. 
The similar kinetics of ETAA1 modification and its localization to foci present a potential model 
for ETAA1 phosphorylation to promote its recruitment to sites of RS.   
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Future directions 
 
Defining mechanism of ETAA1 regulation  
Findings from these initial experiments could direct future studies of ETAA1 and further 
define how ETAA1 and TOPBP1 function through different pathways to regulate ATR signaling. 
One future direction of study could identify important ETAA1 modification sites and identify the 
modifying enzymes. ETAA1 appears to be heavily phosphorylated during RS and is likely an 
ATR substrate, although its ability to activate ATR is not required for its modification. Activation 
of ATR by TOPBP1 may promote an initial, early signaling cascade that results in 
phosphorylation of CHK1 and MCM2 and substrates proximal to the 5’ junction (Fig 5.7A). 
ETAA1 may activate ATR at later time points, following its phosphorylation and subsequent 
recruitment to sites of RS, sustaining the checkpoint signal (Fig 5.7B). This would allow ATR to 
phosphorylate substrates away from the initial site of damage, as extensive resection and DNA 
processing may require ATR localization away from a 5’ ss/dsDNA junction.  Of interest would 
be to identify how phosphorylation of ETAA1 regulates its activity and test if ETAA1 
phosphorylation is required for its recruitment to sites of RS. 
TOPBP1 is regulated at the level of recruitment, requiring formation of additional DNA 
substrates and protein complexes to colocalize with ATR. Since ETAA1 recruitment utilizes the 
same substrate as ATR, PTMs may serve as an additional level of regulation to limit ETAA1 
localization and prevent spurious ATR activation. The use of phosphomimetic and phosphodead 
mutants of ETAA1 may reveal the significance of these PTMs and establish if these 
phosphorylation sites are required for proper ETAA1 recruitment. Furthermore, if localization is 
the main determinant of which activator is utilized and which substrates are phosphorylated, it 
would be interesting to observe how swapping the RAD9-interaction domain of TOPBP1 with  
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the RPA-interaction motifs of ETAA1 would affect ATR signaling. Would this ETAA1-RAD9 
fusion protein be able to promote phosphorylation of substrates that were normally dependent 
on TOPBP1. Would the ETAA1 fusion protein localize to sites of RS earlier like TOPBP1 or later 
like ETAA1? Such experiments would provide needed details about how each ATR activator is 
regulated and the determinants of which activator is utilized.   
Comparing ETAA1 and TOPBP1 substrate specificity 
 An additional route of study would be to examine if ETAA1 is indeed required for DNA 
lesions that lack 5’ junctions. To examine ETAA1 dependency, one could monitor dependence 
on ETAA1 at resected double strand breaks and R-loops. Double strand breaks could be 
induced by CPT treatment or irradiating cells synchronized in S-phase. The extent of resection 
could be modulated by siRNAs to genes that positively or negatively regulate resection such as 
BRCA1 (breast cancer type 1 susceptibility protein) and 53BP1 (p53 binding protein 1) (Cruz-
García et al., 2014; Bunting et al., 2010; Daley and Sung, 2014), and examine ATR signaling in 
cells deficient for ETAA1 or TOPBP1. Overexpression of nucleases may also increase the 
amount of resection, leading to increased ETAA1 dependency for ATR signaling.  
To investigate the requirement for ETAA1 at R-loops, I would examine ETAA1 and 
TOPBP1 localization to R-loops using immunofluorescence, proximity ligation assays, and 
immunoprecipitations. R-loops can be detected by an antibody, S9.6, that specifically 
recognizes DNA:RNA hybrids to facilitate these experiments (Boguslawski et al., 1986).  As 
previously mentioned, ATR recruitment to centromeric regions is dependent on R-loop formation 
and this may explain the dependency for ETAA1 activation during mitosis. I would examine if 
ETAA1 localization to centromeres is also dependent on R-loops, or alternatively, if ETAA1 
utilizes an interaction with one of its mitotic interaction partners for its localization.  
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To determine the DNA substrate specificity of ETAA1, one could also examine ATR 
activation in Xenopus egg extracts after addition of predefined DNA substrates. Different ATR 
activating structures can be produced by annealing oligos to ssDNA plasmids such as M13 
(MacDougall et al., 2007; Duursma et al., 2013). Biotinylation of oligos can block 5’ or 3’ ends 
and oligos can be spaced to alter the amount of ssDNA on the plasmids.  Similar approaches in 
Xenopus extracts have shown that although a 5’ end is required for checkpoint activation, the 
amount of ssDNA adjacent to the junction results in increased CHK1 phosphorylation 
(MacDougall et al., 2007).  I believe this may reflect an initial requirement for TOPBP1-
dependent ATR activation but propagation of signaling as ETAA1 continues to activate ATR 
accumulated along the ssDNA. Immunodepletion of ETAA1 may prevent a further increase in 
CHK1 phosphorylation as the amount of ssDNA next to a primer is extended. Furthermore, if 
ETAA1 regulation by phosphorylation is a conserved mechanism, it would be interesting to 
examine if addition of phosphomimetic ETAA1 would activate structures without a 5’ junction.  
  
Conclusions 
 
 The findings in this dissertation have contributed to the field of replication stress 
signaling and expanded our models for ATR activation. In Chapter III, I identified the previously 
uncharacterized protein, ETAA1 as a novel ATR activator and demonstrated that it functioned in 
a pathway independent from TOPBP1. In Chapter IV, I used quantitative phosphoproteomics to 
examine how ETAA1 and TOPBP1 direct ATR signaling and revealed a unique function of 
ETAA1 to promote mitotic ATR signaling at centromeric regions.  
 Future studies may investigate some of the proposed models for how ETAA1 and 
TOPBP1 differentially regulate ATR signaling. Although these pathways function independently, 
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there may be some crosstalk between pathways regulating ETAA1 function. Additionally, a 
combination of in vivo and in vitro systems may be able to determine if ATR preferentially 
utilizes each activator at different DNA substrates.  
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